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Acute Myeloid Leukaemia refers to the excess proliferation of myeloid progenitor 
cells. Whilst the 5-year survival rate is 40% in younger patients, this falls to 5% in 
patients over 65 and resistance to front-line chemotherapy agents remain a problem. 
We previously identified NRF2, a regulator of anti-oxidant genes, to be 
constitutively activated in AML and this correlated with resistance to 
chemotherapy. Recent studies have also suggested NRF2 also plays a more 
oncogenic role. 
To further understand NRF2’s role in both chemotherapy resistance and 
oncogenesis we looked at its ability to regulate miRNA in AML. Using a miRNA 
array, we identified several miRNAs, including miR-125b and miR-29b, whose 
expression correlated with that of NRF2 in both cell lines and AML patient samples.  
Both miRNAs exist as paralogs, in that they contain the same miRNA sequence but 
exist in different genomic locations and we used qPCR to identify miR-125b1 and 
miR-29b1 as paralogs regulated by NRF2. Using a reporter assay we confirmed the 
activity of putative NRF2-ARE binding sites in both miRNA promoters. To 
understand the function of both in AML we manipulated their expression using 
miRNA “mimics” or antagomIRs. Individual manipulation of either miRNA 
resulted in a slight increase in apoptosis. However, the miRNAs appeared to act 
synergistically as when expressed simultaneously a significant increase in apoptosis 
was seen both in cell lines and patient blasts.  
Manipulation of both miRNA also resulted in the increased sensitivity of AML cells 
to chemotherapy agents. BAK1, STAT3 and AKT2 were shown to be targets of 
both miRNAs providing a novel mechanism by which NRF2 expression can affect 
AML cells. 
To further study the role of NRF2 in AML we used CRISPR-Cas9 to generate 
NRF2-deficient cells. CRISPR guide RNA were designed to target NRF2 Exons 1, 
2 and genome editing validated in HEK293T cells. Leukaemic cell lines (K562 and 
THP-1) were virally transduced with guides targeting Exon 4 of NRF2. Once 
editing was verified clones were derived by growing selected cells in 
Methycellulose-containing medium.  
Putative clones were initially screened using MG-132 (to stabilise NRF2) and 
further confirmed by treatment with the NRF2 inducers CDDO-Me and 
Sulforaphane. Verified clones were characterised by Sanger Sequencing. In 
addition to CRISPR-Cas9 we also validated a number of other gene-editing 
methodologies including CRISPR-Cpf-1 and TALENs. 
Overall these methodologies represent powerful tools to further characterise the 
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Project overview and context 
Chemotherapy resistance remains a prominent issue in Acute Myeloid Leukaemia, 
particularly in patients over the age of 65. Our lab has previously identified the 
transcription factor NRF2 as being constitutively active in AML and this leads to 
resistance to frontline chemotherapy. miRNAs are 20-25 base pair RNA molecules 
that repress their complementary mRNA targets, and therefore play an important 
role in regulating gene expression. Given that NRF2 has previously been shown to 
regulate several miRNAs we wished to investigate whether this played a role in 
resistance in AML. Furthermore, we wished to explore the use of gene editing 
technology to further understand the role of NRF2 in AML. 
1.1 Overview of Leukaemia 
1.1.1 Haematopoiesis 
Haematopoiesis refers to the formation of blood cells, in particular, the generation 
of mature myeloid, lymphoid and erythroid cells from primitive haematopoietic 
cells. The current accepted model suggests all haematopoietic cells are derived from 
Haematopoietic Stem Cells (HSC). HSCs are multipotent and have the ability to 
replicate themselves as well as produce any haematopoietic cells in the human body 
(Baum et al., 1992). One study showed HSC cells derived from murine bone 
marrow have the ability to differentiate into myeloid, B and T cells (Spangrude et 
al., 1988). As the HSCs divide they produce mature daughter cells with a narrower 
differentiation potential. The HSCs can form two lineages, myeloid and lymphoid 
and both are multipotent stem cells with a limited differentiation capacity. The 
myeloid progenitor cells have the ability to differentiate into immune cells such as 
megakaryocytes, erythrocytes, mast cells, basophils, neutrophils, eosinophils, 
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myeloid derived dendritic cells and macrophages.  The lymphoid progenitors can 
differentiate into B and T lymphocytes, lymphoid-derived dendritic cells and 
natural killer cells. The myeloid system, derived from a common myeloid 
progenitor, plays a crucial role in the innate immune response. Dendritic cells 
present antigens to the lymphocytes and the macrophages/neutrophils play an 
important role in phagocytosis. Eosinophils and Mast cells protect cells from 
pathogens. The lymphatic system on the other hand plays a critical role in the 
adaptive immune response. B lymphocytes produce antibodies (through plasma 
cells) and the T lymphocytes can either activate the B lymphocytes/macrophages 
or directly induce cell death in virally infected cells  (Kondo, 2010, Iwasaki and 
Akashi, 2007, Lai and Kondo, 2008). 
 
The haemopoietic system is derived during embryogenesis, initially through 
specialisation of the mesoderm (one of the three germ layers). This process can be 
divided into primitive and definitive haematopoiesis. Primitive haematopoiesis 
occurs during the early stages of foetal development and results in the production 
of primitive haematopoietic cells including macrophages and nucleated 
erythrocytes (Baron, 2003).  This provides oxygen during the early stages of 
embryogenesis (Orkin and Zon, 2008, Jagannathan-Bogdan and Zon, 2013). From 
the yolk sacs, the HSCs migrate towards the liver, before firmly establishing 
themselves in the bone marrow for definitive haematopoiesis. (Jagannathan-
Bogdan and Zon, 2013).  Definitive haematopoiesis produces all haematopoietic 
lineages in the human body. Like its primitive counterpart, definitive 
haematopoiesis initially begins in the yolk sac, before becoming widespread after 
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the formation of the circulatory system. In addition to generating all haematopoietic 
lineages required in the body, all “mature” cells are generated (such as anuclear 
erythrocytes) (Lux et al., 2008). 
 
The origin of HSC cells is the subject of some debate with some evidence 
suggesting they may be derived from the yolk sac. One study isolated haemopoietic 
cells derived from the yolk sac and showed they can differentiate into different 
haematological types (Moore and Metcalf, 1970). However studies in avian models 
contradict these results suggesting the HSC originate from the extra-embryonic 
mesoderm (Tanaka et al., 2012). 
 
There are several models that explore the ability of HSCs (or stem cells in general) 
to divide and populate the haematopoietic system. One such model is asymmetrical 
cell division. According to this model, every division of haematopoietic cells 
produces two daughter cells, one of which will have a more committed fate than the 
other which retains the parental cell’s stem cell characteristics. Asymmetrical 
division has the advantage of the haemopoietic cell population remaining at a 
constant level, keeping numbers of both the multipotent HSC population and the 
differentiated lineage specific cells constant. While this process will maintain cell 
numbers, there are times when the population needs to rapidly expand. Systemic 
division occurs when the HSC, or stem cell, divides with both daughter cells either 
becoming HSC, stem cells or differentiated cells (Måløy et al., 2017). This is 
particularly useful when it is necessary to replenish a certain cell type. 
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1.1.2 Subtypes of Leukaemia 
Haematological malignancies refer to a diverse range of disorders primarily 
affecting the blood forming tissues. More specifically it refers to all leukaemias, 
lymphomas and myelomas. In leukaemias, the malignancy primarily occurs when 
myeloid or lymphocytic cells overcrowd the bone marrow preventing normal 
function. Lymphoma primarily affects the lymphocytic regions (notably the 
thymus, lymph nodes and spleen) and is commonly split into two subcategories 
Hodgkin and non-Hodgkin. Multiple myeloma occurs due to over-division of 
plasma cells in the bone marrow. Leukaemias can arise due to defects in the myeloid 
or lymphocytic progenitor cells and are commonly subdivided into four classes: 
Acute Myeloid Leukaemia (AML), Acute Lymphocytic Leukaemia (ALL), 
Chronic Myeloid Leukaemia (CML) and Chronic Lymphocytic Leukaemia (CLL). 
 
Acute Myeloid leukaemia, (discussed in greater detail in the next section), refers to 
the excess proliferation of myeloid progenitor cells (Grove and Vassiliou, 2014). 
Compared to other haematological malignancies, AML is a heterogeneous disorder 
characterised by a plethora of molecular, genetic and chromosomal abnormalities 
resulting in abnormal myeloid cells (Kumar, 2011). 




Figure 1.1: Schematic of the haematopoiesis process and the derivation of 
myeloid and lymphoid classes of blood cancers. The line thickness represents 
differentiation stage, from least to most differentiated. Adapted with permission 
from Springer Nature: Nature Reviews Cancer (Ramsay and Gonda, 2008) 
 
Acute Lymphocytic Leukaemia (ALL) refers to the over-proliferation of B or T 
cells derived from a lymphoid progenitor. ALL predominately affects children and 
young adults. ALL is underlined by several genetic abnormalities and chromosomal 
translocations, including the BCR-ABL1 fusion or deletions in IKAROS (IKZF1) 
(Collins-Underwood and Mullighan, 2010). The repression or deletion of IKAROS 
is associated with poor prognosis and other chromosomal abnormalities including 
BCR-ABL1 (IKZA1 deletions are identified in approximately 80% of ALL cases 
with the translocation). Furthermore its deficiency in mice inhibits lymphocyte 
differentiation (Payne and Dovat, 2011). 
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Chronic Myeloid Leukaemia (CML) again refers to the over proliferation of 
myeloid progenitor cells, however unlike AML its cytogenetic profile is limited. 
Primarily CML is the result of the translocation of ABL (chromosome 9) and BCR 
(chromosome 11) which forms the Philadelphia chromosome, also known as the 
BCR-ABL fusion gene. This translocation is the primary abnormality in the 
disorder, and results in malignant cell transformation and increased cell 
proliferation (Haririan et al., 2012). CML progresses slower than AML, and can be 
segregated into three distinct phases: chronic, accelerated and blast (Calabretta and 
Perrotti, 2004). The initial chronic phase allows the slow proliferation and 
accumulation of myeloid progenitor cells in sites such as the bone marrow. The 
accelerated phase lasts up to six months and results in an increase of blast cells 
(Calabretta and Perrotti, 2004). The final blast crisis phase results in uncontrolled 
proliferation of the myeloid cells, not dissimilar from that in AML. Until recently, 
blast crisis was deemed fatal (Radich, 2007) but recent prognosis has drastically 
improved thanks to the introduction of tyrosine kinase inhibitors such as imatinib. 
Imatinib inhibits the activity of the BCR-ABL fusion protein and since its 
introduction CML survival rates have significantly increased, with the 8 year 
survival rates increasing from 6% in 1975 to 87% in 2001 (Kantarjian et al., 2012). 
 
The most common leukemic subtype is Chronic Lymphocytic Leukaemia (CLL) 
and this again refers to the over proliferation of lymphocytic cells resulting in 
overcrowding in the lymph nodes and bone marrow. One of the most common 
defects in CLL is the dysregulation of the B cell signalling (BCR) transduction 
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pathway. The BCR pathway plays a crucial role in the growth and development of 
B cells (Shinners et al., 2007). 
 
1.2 Acute Myeloid Leukaemia 
1.2.1 Overview of Acute Myeloid Leukaemia 
Acute Myeloid Leukaemia (AML) is responsible for 80% of acute leukaemias, 
affecting approximately 3-4 people per 100,000 (Almeida and Ramos, 2016). 
Whilst the five-year survival rate post diagnosis is 40% in young patients, it is less 
than 5% in patients aged over 65. Furthermore, 70% of patients over the age of 65 
die within a year of being diagnosed (Meyers et al., 2013). This is of particular 
concern considering the average age of diagnosis of AML is 67. Despite this, the 
efficacy of AML treatment has improved in recent years, the historic 5-10 years 
survival rate of 10% has increased up to 40-50%. The majority of AML cases, 
approximately 97%, are as a result of mutation. One theory proposed to describe 
leukaemogenesis (as well as other cancers) is the “two-hit hypothesis” of 
Knudson’s (Conway O'Brien et al., 2014, Kelly and Gilliland, 2002). This states 
that leukaemia is caused by two main driving mutations which are required for 
oncogenesis. The first mutation (class one) allows cells to uncontrollably 
proliferate. The second mutation (class two) prevents the differentiation of the 
haematopoietic cells thereby allowing the leukaemia to develop (De Kouchkovsky 
and Abdul-Hay, 2016). Examples of a class one mutation include FLT3, c-Kit and 
TP53. Example of class two mutations include Core Binding Factor (CBF) and 
NPM1.  
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There has been criticism of this model, in particular due to a significant number of 
AML patients having epigenetic defects, i.e. in histone modification, DNA 
methylation and CpG hypermethylation (Shih et al., 2012). Some mutations, for 
example PML-RARα, occur at a certain point in myeloid cell development. For 
example, in the case of PML-RARα the translocation must occur at the pre 
myelocytic stage for it to have a prognostic effect (Reilly, 2005, Conway O'Brien 
et al., 2014).  A third class of mutations has therefore been suggested which affect 
epigenetic-related genes, examples of these include IDH-1 and 2 (De Kouchkovsky 
and Abdul-Hay, 2016). 
 
Acute Leukaemia is diagnosed by the presence of 20% (previously 30% before 
2001) or more leukaemic blasts in the peripheral blood or bone marrow (Döhner et 
al., 2010). Myeloid leukaemia is defined by identifying the cell is of myeloid origin, 
through immunophenotyping. The primary symptoms of AML include bone 
marrow failure and leucocytosis. Other symptoms include fatigue, anorexia, 
anaemia and weight loss. Secondary death can occur due to bleeding or infection 
(De Kouchkovsky and Abdul-Hay, 2016). 
 
1.2.2 Classification of AML 
Classifying AML allows clinicians and scientists to group together different AML 
subtypes using either cytogenetics or through the prognostic outlook of patients. 
This allows us to better understand and diagnose similar AML subtypes, allowing 
better targeted treatments based on their characteristics. The French-American-
British classification (FAB) was designed in 1976 and divides AML into eight 
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subtypes (M0-M7) based on immunological characteristics and morphology (Table 
1.1). M0-M3 is primarily of a granulocytic lineage (with M0 being undifferentiated 
myeloblastic leukaemia, M1 refers to myeloblastic leukaemia without maturation, 
M2 refers to myeloblastic with maturation, and M3 refer to promyelocytic 
differentiation). M4 is primarily of both myleoblast and monocytic origin (here both 
the myleoblast and monocytic population are above 20% in the peripheral blood 
and bone marrow), a subtype M4eos is similar but also contains an increased 
eosinophils population. M5 refers to Acute Monocytic Leukaemia and defined by 
an excess monocytic population. M6 is erthyroid leukaemia and M7 refers to Acute 
megakaryoblastic leukaemia (referring to excess erythroid and megakaryoblastic  
cells respectively) (Bennett et al., 1976, Arber et al., 2003).   
 
Table 1.1: FAB classification of AML 
 
This classification has been criticised for not giving enough weight to prognostic 
information. In 2001 the World Health Organisation (WHO) created a classification 
combining morphological, genetic, immunophenotyping and cytochemical 
information (Table 1.2). Since its creation in 2001, the classification has been 
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revised in both 2008 and 2016.  This classification splits AML into several 
categories including “AML with recurrent genetic abnormalities”, “AML with 
myelodysplasia related changes”, “Therapy related myeloid neoplasms”, “Myeloid 
sarcoma” and “AML not categorised”. 
 






AML with myelodysplasia related changes 
Therapy related myeloid neoplasms 
Myeloid sarcoma 
AML not categorised 
AML (minimal differentiation) 
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1.2.3 AML Translocations and Cytogenetics 
As previously mentioned, AML is a highly heterogeneous disorder exhibiting a 
range of mutations and chromosomal abnormalities. Understanding these genetic 
abnormalities is important as they have proven to relate to prognosis and response 
to chemotherapy (Tamamyan et al., 2017). 
 
50-60% of AML patients suffer from chromosomal abnormalities, which result in 
the formation of fusion proteins, many of which cause aberrant transcriptional 
activity. Notable translocations include: t(16;16)(also known as inv (16)(p13q22)); 
as well as t(8;21)(q22;q22); t(1;22)(p13;q13); t(15;17)(q24;q21); 7q loss and 
t(11;19)(q23;p13.1) (Tamamyan et al., 2017, Mrózek et al., 2004). Due to the scope 
of this introduction only a few chromosomal translocations will be discussed in 
further detail. 
 
t(16;16) results in the fusion of CBFB and MYH11 creating the fusion protein 
CBFB-MYH11. CBFB-MYH11 plays a critical role in AML, repressing 
differentiation through binding to CBFA2 (Delaunay et al., 2003, Kundu and Liu, 
2001). Binding to CBFA2 allows it to recruit HDAC, which modifies acetyl groups 
post-translationally, thereby modulating gene expression (Delaunay et al., 2003). 
This alone is insufficient to act as a driving mutation (Kundu and Liu, 2001). 
t(16;16) patients are commonly classified with M4eo (high  eosinophil count) (Le 
Beau et al., 1983). This translocation is associated with a favourable prognosis and 
a high proportion of patients reach complete remission.  Despite this, older patients 
have a high risk of relapse and exhibit a poorer prognosis (Delaunay et al., 2003). 




t(8;21)(q22;q22) involves a translocation between RUNX1 and RUNX1T1 
(chromosomes 8 and 21 respectively), creating the fusion protein RUNX1-
RUNX1T1 (also known as AML1-ETO). This translocation is responsible for 5-
12% new AML cases and is predominately associated with FAB M2 (acute 
myeloblastic leukaemia with maturation), or in rare cases FAB M1 and M4 
(Peterson and Zhang, 2004). RUNX1-RUNX1T1 blocks a myriad of cellular 
processes including myeloid differentiation and apoptosis, thereby allowing the cell 
to escape regulation (Peterson et al., 2007). Remission rates are high among patients 
who suffer from this translocation de novo, in particular in those treated with high 
levels of cytarabine (Bloomfield et al., 1998). However, the remission rates are 
lower in patients who gain this translocation as a response to their chemotherapy 
(known as therapy related AML or t-AML) (Gustafson et al., 2009). 
 
Another translocation t(15;17) (q24;q21) causes a fusion between the 
Promyelocytic Leukaemia Protein (PML) and Retinoic Acid Receptor alpha 
(RARα) creating the PML-RARα fusion protein. This inhibits differentiation and 
increases proliferation (He et al., 1997). Meaning that the AML cells have had the 
“two hits” as discussed above (i.e. uncontrolled proliferation and arrest of 
differentiation) (Grimwade et al., 2000). This translocation is the most common 
molecular abnormality identified in patients suffering from Acute Promyelocytic 
Leukaemia (APL), classified in the French American British system as FAB M3. 
APL is responsible for 5% of all AML cases, and 15-18% of all acute non- 
lymphocytic leukaemia cases. Prior to 1985 patients were treated with daunorubicin 
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and cytarabine. While the complete remission rate were relatively high (up to 80%), 
remission on average only lasted up to 25 months (Wang and Chen, 2008). Patients 
suffered from bleeding diathesis (a defect in blood coagulation) which was 
responsible for a high proportion of deaths in APL patients (as opposed to resistance 
to the given chemotherapy agents), however these chemotherapy agents used did 
increase the severity of the condition (Wang and Chen, 2008, Coombs et al., 2015). 
 
Retinoids have shown to be effective at causing granulocytic differentiation of APL 
cell lines and cultured patient samples, successfully differentiating the 
characteristic promyeloblasts to mature neutrophils (Breitman et al., 1981). This led 
to the development of the drug All-Trans Retinoic Acid (ATRA). ATRA induces 
differentiation by binding and conformationally changing PML-RARα, leading to 
the activation of various genes containing a retinoic response elements (RARE) 
motif in their promoter including C/EBP (critical in the differentiation process in 
neutrophils) (Raelson et al., 1996, Duprez et al., 2003). Furthermore it leads to the 
ubiquitination and degradation of PML-RARA (Zhu et al., 1999). ATRA was first 
used therapeutically in Shanghai, China and since then complete remission has 
increased up to 95%, and the 5 year disease free survival has increased to 74%  
(Huang et al., 1988, Wang and Chen, 2008). More recently arsenic has also been 
used in APL treatment, and has shown to be particularly effective when used either 
as a single agent, or in combination with ATRA (Chen et al., 1996, Tomita et al., 
2013). 
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FMS like tyrosine kinase-3 (FLT-3), FLT-3 is a type III receptor tyrosine kinase 
initially identified on haematopoietic stem cells. It is located on chromosome 13 
(13q2) and spans 100 kb with 24 exons. FLT3 is made up of five external 
immunoglobulin like domains,  a transmembrane domain, and two kinase domains 
(Levis and Small, 2003). Upon binding  FLT3 ligand (FLT3L) causes dimerization 
of the receptor creating a conformational change resulting in the auto-
phosphorylation and a constitutively signalling receptor (Fathi and Chen, 2011). 
 
FLT3 is predominately expressed in CD34+ cells in the bone marrow and FLT3-
deficient mice show a decrease in lymphoid population and a skew to the myeloid 
lineage (Mackarehtschian et al., 1995). FLT3 expression can be found in a high 
proportion of  leukaemic cells, across all four subtypes, in the case of AML FLT3 
expression is found in over 90% of AML cells (Carow et al., 1996). Ectopic 
expression of FLT3L causes leukaemia in mice (Hawley et al., 1998). In AML, a 
number of patients contain activating mutations in FLT3, these are mostly internal 
tandem duplications (ITD), which can be found in 23% of newly presented AML 
cases, and in a smaller subset of patients a point mutation occurs in the kinase 
domain resulting in its activation (Fathi and Chen, 2011). The ITD mutation is most 
commonly found in the vicinity of exon 14 (typically within the region coding for 
amino acids 590-600) but can occasionally span to exon 15. This primarily affects 
the juxtamembrane region (which regulates kinase activity) (Abu-Duhier et al., 
2001). The ITD occurs in multiples of three (maintaining the reading frame) and 
can span from 3-400 bp (Schnittger et al., 2002). The duplication results in the 
constitutive activation of FLT3, which in turn activates downstream pathways 
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including STAT5, AKT and MAP kinase. The dysregulation of these signalling 
pathways in cancer cells can promote cell growth, whilst supressing apoptosis 
(Hayakawa et al., 2000). The most recent drug to be introduced for the treatment of 
AML is midostaurin, that is an inhibitor of FLT3 kinase activity (Stone et al., 2018). 
 
Another crucial mutation is the phosphoprotein nucleophosphin 1 (NPM1), found 
in approximately 35% of AML cases (Falini et al., 2005). NPM1 is made up of 12 
exons and contains nuclear export signals (NES) in its N-terminal, nuclear 
localisation signals (NLS) in the central region, the C-terminal also contains an 
NLS. The C-terminal region is also responsible for DNA binding (Heath et al., 
2017).  NPM1 is primarily located in the nucleolus,  however due to the presence 
of NES and NLS domains, it translocates between the nucleus and cytoplasm 
(Federici and Falini, 2013).   NPM1 has several roles including the regulation of 
genomic stability, promoting apoptosis, inhibiting proliferation, and the biogenesis 
of ribosomes (Heath et al., 2017). In AML, NPM1 can be mutated, predominately 
in exon 12, which creates a frameshift mutation towards the end of the exon (Falini 
et al., 2005). This causes the accumulation of NPM1 in the cytoplasm. These 
mutations are always heterozygous,  with attempts to create murine models with 
homozygous mutated NPM1 being unviable, likely due to it being embryonic lethal 
(Grisendi et al., 2005). In AML, mutated NPM1 is therefore haploinsufficient (i.e. 
only partial production of the wild type protein). Murine models with mutated 
NPM1 showed excess proliferation of haematopoietic cells with a skew towards the 
myeloid lineage. The mutated NPM1 can repress apoptosis (through interfering 
with caspase 6/8 activity) and myeloid differentiation (Leong et al., 2010). 
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Furthermore it activates oncogenes such as Myc, due to the degradation of Fbw7y, 
a key factor in the ubiquitination and subsequent proteasomal degradation of c-Myc 
(Bonetti et al., 2008). 
 
1.2.4 AML Treatment 
AML is commonly treated using either induction or consolidation therapy. Initially 
newly diagnosed patients are treated with induction therapy. Induction therapy is 
underlined by the “7+3” regimen, which indicates seven days of cytosine 
arabinoside (cytarabine or Ara-C), alongside three days of anthracyclines (such as 
daunorubicin or doxycycline) (De Kouchkovsky and Abdul-Hay, 2016). This 
regimen is given to patients with a good or intermediate prognosis, in particular 
younger patients (Estey, 2014). The treatment gives complete remission in up to 
80% of young patients, and 50% of patients above 65 (Seval and Ozcan, 2015, 
Menzin et al., 2002). Consolidation therapy is given to patients post induction 
therapy, with chemotherapy agents given to patients with low or intermediate 
prognosis. Older or less fit patients are considered not as healthy to receive 
combination therapy and are given cytarabine treatment alone.  However, their 
resulting prognosis is poorer than patients deemed robust enough for combination 
therapy. Bone Marrow Stem Cell transplants (SCT) is given to those with severe 
prognosis or who relapse from their chemotherapy (Showel and Levis, 2014). 
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1.3 The redox-sensitive transcription factor - NRF2 
1.3.1 Structure, activation and regulation by KEAP1 
Reactive Oxygen Species (ROS) includes hydroxyl radicals, and superoxide anion, 
are produced from processes such as oxidative phosphorylation, NADPH oxidase 
and cytochrome P450 (Turrens, 2003). Hydroxyl radicals can be produced from 
H2O2through “Fenton-like” reactions catalysed by a transition metal (such as 
Fe(II))”.  ROS play an important role in cellular processes including signal 
transductions. Low levels of ROS can act as intracellular signalling intermediates, 
while high levels can act as anti-microbial protection (Finkel, 2011, Nathan, 2003). 
Altered ROS results in oxidative stress and its dysregulation is present in several 
diseases such as Huntington’s, Atherosclerosis, Alzheimer’s, Rheumatoid Arthritis 
and Parkinson’s (Deshmukh et al., 2017). Oxidative stress can cause DNA damage 
directly through the formation of free radicals, but high levels also result in the 
repression of the DNA mismatch repair gene mutS as well as regulating DNA 
methyltransferases (Bridge et al., 2014, Wu and Ni, 2015). Collectively this can 
cause genomic instability or aberrant cellular proliferation leading to a number of 
malignancies (Visconti and Grieco, 2009). 
 
Oxidative stress is regulated by antioxidants including the phase II cytoprotective 
enzyme Haem Oxygenase 1 (HO-1), NAD(P)H dehydrogenase [quinone] 1 
(NQO1), glutathione-S-transferase (GST) and other redox proteins (Kim and 
Keum, 2016). The transcription factor Nuclear factor (erythroid-derived-2) like 2 
(NFE2L2 or NRF2) is known as the master regulator of antioxidant genes. NRF2 is 
a member of the “Cap n Collar” (CNC) family and contains both a CNC and basic 
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leucine zipper domain (Moi et al., 1994). These domains allow NRF2 to regulate 
gene expression through binding to the “Antioxidant Response Element” (ARE) in 
the promoter region of its target genes. When NRF2 translocates to the nucleus it 
associates with small Maf proteins which aid its binding to AREs (Itoh et al., 1997). 
 
NRF2 is made up of six NEH domains, NEH2 is located at the N-terminal, followed 
by NEH4, 5, 6, 1 and finally 3 (Figure 1.2). NEH 4 and 5 are activation domains 
and NEH 1 contains the CNC domain, as well as the basic leucine zipper region 
DNA binding domain. The NEH2 motif is important for regulation of NRF2 by 
binding to KEAP1 (Kelch-like ECH associated protein 1) (Taguchi et al., 2011). 
Under basal conditions NRF2 is kept in check by its inhibitor KEAP1.  
 
Figure 1.2: Domain structure of NRF2 and KEAP1 
 
KEAP1 is made up of five domains (figure 1.2), the N terminal Region (NTR), 
Broad complex, tramtrack and “bric-a-brac” (BTB), intervening region (IVR), 
Kelch-like domain and C-terminal Region (CTR) (Itoh et al., 2004). KEAP1 
binding to NRF2 is believed to occur as an “hinge and latch model”, a Kelch domain 
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on KEAP1 binds strongly to the ETGE motif “Hinge” on NRF2, whereas a weaker 
interaction is seen between the binding of another Kelch domain to the DLG motif  
“Latch” on NRF2 (Tong et al., 2006). The DLG ensures NRF2s Neh2 domain is in 
the correct orientation to be ubiquitinated by Cul3. Ubiquitination of NRF2 causes 
proteasomal degradation ensuring it remains at low levels under basal conditions 
(Zhang and Hannink, 2003, Cullinan et al., 2004). In addition, NRF2 can be 
ubiquitinated and degraded in a KEAP1-independent manner. Neh6 contains two 
β-TrCP binding sites; DSGIS and DSAPGS, allowing SCF-mediated 
ubiquitination. The DSGIS motif can be phosphorylated by GSK-3 increasing its 
ability to bind to β-TrCP and therefore causing accumulation of NRF2. GSK-3 can 
be repressed by PI3K signalling, which is dysregulated in many malignancies 
(McMahon et al., 2004, Chowdhry et al., 2013). 
 The KEAP1/NRF2 complex is associated with the actin cytoskeleton through 
double glycine (Kelch) repeats on KEAP1, ensuring the complex remains in the 
cytoplasm until activated (Kang et al., 2004). In the presence of ROS, oxidation of 
Cys151 on KEAP1 prevents DLG-mediated binding NRF2 interfering with its 
ubiquitination. NRF2 subsequently becomes stabilised, de-novo synthesised NRF2 
accumulates in the cytoplasm before translocating to the nucleus (Fig 
1.3).(Stępkowski and Kruszewski, 2011).  




Figure 1.3: NRF2 activation in cells following oxidative/chemical stress. The 
figure legend was updated “Figure 1.3: NRF2 activation in cells following 
oxidative/chemical stress. Under basal conditions NRF2 is ubiquitinated by either 
by Cul3 in a KEAP1-dependent mechanism or by β-TcRP leading to its 
degradation. Following oxidative stress, KEAP1 is modified, and de-novo 
synthesised NRF2 accumulates in the cytoplasm before translocating to the nucleus, 
inducing its target genes. Adapted with permission from Elsevier: Trends in 
Pharmacological Sciences (Suzuki et al., 2013a) 
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1.3.2 Pathological roles of NRF2 
The role of NRF2 expression has been indicated in several respiratory diseases. 
Patients with chronic obstructive pulmonary disease (COPD), show lower NRF2 
and its downstream target, HO-1, levels in older patients who smoke than in age-
matched controls. This is significant as low levels of NRF2 increases the risk of 
COPD (Suzuki et al., 2008). A polymorphism (617C/A) in the NRF2 promoter, 
which attenuates NRF2 expression, significantly increases the risk of lung injury 
post trauma (Marzec et al., 2007). 
 
Chronic Kidney Disease (CKD) (caused mainly by chronic disorders such as 
hypertension and diabetes) is underlined by high levels of oxidative stress and 
inflammation. Murine models indicate NRF2 plays a protective role in CKD with 
NRF2-deficient female mice exhibiting glomerulonephritis and a lupus-like 
autoimmune nephritis (Yoh et al., 2001). ROS have previously been shown to 
aggravate immunological conditions and amplify tissue damage (Cooke et al., 
1997). 
 
In cancers, NRF2 has been dubbed as “Janus-faced” as it appears to play a dual role 
acting both as a tumour suppressor and an oncogene. Murine NRF2 knockout 
models appear to be protected against carcinogenesis. When exposed to 
benzo(a)pyrene, NRF2-deficient mice had an increased incidence in gastric 
neoplasia compared to their wild-type littermates. When treated with the 
chemoprotective agent Oltipraz a significant decrease in tumour burden was seen 
in the wild-type mice, with no reciprocal effect observed in NRF2-deficient mice. 
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This is likely due to Oltipraz inhibiting tumour growth through the induction of 
phase II enzymes (which are regulated by NRF2) (Ramos-Gomez et al., 2001). 
 
Another study showed patients containing a SNP (rs6721961) which results in the 
repression of NRF2 expression, having an increased risk to lung cancers 
particularly in patients who smoke (Suzuki et al., 2013b). Furthermore, NRF2-
deficient mice show increased metastasis in a Lewis Lung Carcinoma model with 
these cells exhibiting high levels of ROS. This effect was reversed in KEAP1-
deficient mice (Satoh et al., 2010). 
 
1.3.3 Oncogenic role of NRF2 in cancer 
Upregulated or constitutive activation of NRF2 is found in a range of cancers 
including lung, ovarian, breast and head and neck (Jaramillo and Zhang, 2013). One 
study performing immunohistochemistry on 304 non-small cell lung cancer patients 
(NSCLC), detected high levels of NRF2, particularly in squamous cell carcinomas, 
while low levels of KEAP1 were detected, particularly in adenocarcinomas. High 
levels of NRF2 or low levels of KEAP1 both correlated with poor prognosis (Solis 
et al., 2010). In both of these studies high NRF2 levels were linked to resistance to 
frontline chemotherapy agents. 
 
The role of NRF2 in resistance to chemotherapy has also been observed in primary 
gastric and pancreatic cancer samples and cell lines and this could be reversed by 
reducing NRF2 levels using siRNA (Hong et al., 2010, Hu et al., 2013). In the latter 
study NRF2 appeared to regulate the multidrug resistance genes ABCG2, GCLC, 
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MRP1,2,4 and 5 (Hong et al., 2010). This indicates NRF2’s ability to protect against 
chemotherapy agents appears to go beyond its role in regulating oxidants and 
electrophiles. 
Interestingly, several studies have identified many commonly used chemotherapy 
agents that activate or upregulate NRF2 signalling. The proteasome inhibitor 
Bortezomib, commonly used in MM, has been implicated in repressing Bach1, 
which allows NRF2 to bind to Maf unimpeded, thereby inducing expression of its 
downstream cytoprotective genes (Rushworth et al., 2011a). Histone deacetylase 
inhibitors (HDAC), work by causing histone acetylation, thereby altering gene 
expression which can result in increased differentiation or apoptosis (Wang et al., 
2012, Bai et al., 2016). 
 
In contrast, ATRA, which is commonly used in the AML subtype APL causes 
RARα and NRF2 to complex together, thereby preventing binding to its respective 
ARE sequences (Wang et al., 2007). Contrasting with its role in protecting against 
toxic compounds/insult, recent studies have suggested that NRF2 plays a larger role 
than simply protecting cells from chemotherapy agents and can also directly affect 
tumorigenesis in several cancer types.  For example, in NSCLC high levels of NRF2 
result in increased proliferation and cisplatin resistance, and this appeared to be 
linked indirectly to NRF2 by hyperphosphorylation of the Retinoblastoma (Rb) 
tumour suppressor gene and inhibition of p21CIP1/WAF1 (Homma et al., 2009). 
Moreover, in breast cancer there is a correlation between high levels of NRF2 and 
worse prognosis. This appeared to be linked to the effect of NRF2 on increased 
proliferation in these cells, partly due to stabilisation and elevated expression of 
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RhoA. When NRF2 levels are decreased a significant inhibition of proliferation and 
metastasis is seen (Zhang et al., 2016). The oncogenic function of NRF2 may also 
be due to its regulation of miRNA (discussed in more detail in the next section). 
 
To further understand the role of NRF2 in cancer cell proliferation, one group used 
a range of lung cancer cell lines that were characterised with constitutive activation 
of NRF2 (Mitsuishi et al., 2012b). As expected NRF2 downregulation in these cells 
resulted in the attenuation of proliferation. The group next performed a microarray 
analysis using NRF2 siRNAs and identified a reduction in expression in several 
Pentose Phosphate Pathway (PPP)-related genes including G6PD, TALDO1, TKT, 
and PGD. Genes involved in NADPH production (such as IDH1 and ME1) were 
also reduced. The potential of NRF2 to bind to the promoters of these genes was 
confirmed by ChIP-Seq. This is significant because the PPP pathway is used to 
produce ribose 5-phosphate which is necessary for nucleotide synthesis, a process 
that requires NADPH. Additional experiments indicated that NRF2 was important 
in purine (but not pyrimidine) nucleotide synthesis. NRF2 was also shown to 
promote glutamine synthesis (through positive regulation of GCL) and involved in 
glutaminolysis (through ME1 regulation). In terms of NRF2’s role in cellular 
proliferation, they showed this was predominately due to the upregulation of G6PD 
and TKT, which when attenuated, significantly reduced tumour growth in murine 
models. Furthermore, they identified PI3K/ATK dysregulation as being responsible 
for causing nuclear activation in several cancer types and thus altering the metabolic 
pathways of these cancers to increase proliferation (possibly thorough the 
regulation of the KEAP1 inhibitor GSK-3). However experiments carried out in 
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non-cancerous KEAP1 KD mice only showed alterations in the metabolic profiles 
cells located in certain regions (such as in the Forestomach Epithelium), suggesting 
that proliferative signalling in conjunction with constitutive activation of NRF2 is 
required to see the discussed metabolic reprogramming (Mitsuishi et al., 2012b).  
 
Another group suggested that the PPP pathway is critical for NRF2s cytoprotective 
role (in particular NQO1 which uses NAPDH as a cofactor), and when the PPP 
pathway was inhibited (through altering glucose availability by serum starvation or 
by chemically disrupting G6PD) an inhibition in cytoprotective genes was seen 
(Heiss et al., 2013). This is at odds with the above Mitsuishi study which showed 
whilst serum starving KEAP1 KD MEFS reduced the expression of the 
cytoprotective gene NQO1, the cells still showed increased resistance to 1-chloro-
2,4,dinitrobenzene (CDNB) in comparison to the wild type. This inconsistency 
could be down to both studies measuring different cytoprotective genes (one 
measuring HO-1 and glutathione reductase (GR) with the other using NQO1 as a 
cytoprotective marker). While both studies used serum starvation to attenuate PPP 
genes to basal conditions, the Heiss study additionally chemically disrupted G6PD. 
However, this study only measured cytoprotective gene expression, whilst the 
Mitsuishi additionally treated the serum starved cells with CDNB and looked at cell 
viability. This raises the possibility that NRF2 could still produce a cytoprotective 
response, despite low levels of PPP activity, however it may use cytoprotective 
genes that are independent of the PPP pathway (Heiss et al., 2013, Mitsuishi et al., 
2012b). 
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As we have noted, NRF2 activity can be protective in some disorders and 
pathogenic in others, at times this “duality” can be seen in the same disorder. It has 
therefore been speculated that in a non-cancerous/early malignant cell, NRF2 
predominately plays a protective role preventing further DNA damage through its 
anti-oxidative and anti-inflammatory mechanism thereby acting as a tumour 
suppressor. However as the cell becomes more malignant this mechanism is 
hijacked by the cancer cells to aid survival and growth, i.e. increase tumour 
proliferation (through mechanisms such as metabolomic reprogramming) and 
reduce sensitivity to chemotherapy agents (Sporn and Liby, 2012). This is 
supported by a study which investigated the role of NRF2 in inducing lung cancer. 
Lung cancer was induced in wild type or NRF2 KD mice using urethane (which 
also causes nuclear NRF2 accumulation). The NRF2-deficient mice developed 
more tumours in the early stages of urethane treatment in comparison to wild-type 
mice treated with urethane to induce NRF2. However, as treatment continued the 
urethane treated wild type mice grew larger tumours, which were generally more 
invasive and had a worse gene expression profile in comparison to the NRF2 KD 
mice. Of particular interest, the urethane induced wild-type mice were more likely 
to have constitutive activation of the oncogene KRAS (Satoh et al., 2013). Overall 
this study provides an interesting bridge between NRF2 role as a chemo-
preventative and NRF2 as an oncogene.  
 
1.3.4 Oncogenic activation of NRF2 
As discussed previously, constitutive activation or overexpression of NRF2 can 
result in oncogenesis. There are three main mechanisms by which NRF2 can 
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become dysregulated in cancer, (i) mutations in either NRF2 or KEAP1, (ii) 
methylation of KEAP1, or (iii) activation of oncogenic signalling pathways 
(Taguchi and Yamamoto, 2017). 
 
KEAP1 insertion, missense, or deletion mutations have been identified in lung 
carcinoma and these occurs throughout KEAP1 and not just within the NRF2 
binding regions. In some circumstances this results in the loss of heterozygosity, 
causing impairment and/or loss of KEAP1 expression (Singh et al., 2006). This 
prevents KEAP1-NRF2 binding impeding NRF2 degradation (Taguchi and 
Yamamoto, 2017). These mutations have been found in several cancers including 
lung, breast, endometrial and hepatocellular carcinoma  (Singh et al., 2006, Nioi 
and Nguyen, 2007, Wong et al., 2011, Schulze et al., 2015). 
 
Mutations such as this are more common in KEAP1 than NRF2. NRF2 mutations 
are predominantly “gain-of-function” in nature and result in its constitutive 
activation. They often occur in the DLG and ETGE regions and therefore disrupting 
the binding between NRF2 and KEAP1. Mutations in the ETGE region prevent 
NRF2 ubiquitination (and therefore degradation) allowing it to accumulate in the 
cell. Similarly, mutations in DLG result in the stabilisation of NRF2 (Mitsuishi et 
al., 2012a). Again, these mutations have been identified in several cancers including 
head and neck, oesophageal and lung cancer (Shibata et al., 2008, Kim et al., 2010). 
Mutations have also been found in Cul3 in papillary renal cell carcinoma (Ooi et 
al., 2013).  
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Another way by which NRF2 may become constitutively expressed is through the 
methylation of CpG sites on the KEAP1 promoter, resulting in the repression of 
KEAP1 gene expression. This epigenetic regulatory mechanism is often seen in 
several cancer types including prostate and colorectal cancer (Jaramillo and Zhang, 
2013, Zhang et al., 2010, Hanada et al., 2012). 
 
Finally, NRF2 can be constitutively activated by oncogenic signalling. K-Ras, B-
Raf and Myc oncogenes have all shown to increase transcriptional levels of NRF2 
(DeNicola et al., 2011). Furthermore, as discussed in the next section, our lab have 
previously uncovered that the dysregulated NF-κB often found in cancer cells, 
results in constitutive activation of NRF2, a mechanism that was seen in AML 
cancer too (Rushworth et al., 2012). 
   
1.4 NRF2 regulation by NF-κB in AML 
In AML, the transcription factor nuclear factor-κB (NF-κB) was shown to be 
constitutively-activated by a number of signalling factors including the cytokine 
TNFα (Rushworth et al., 2010). The NF-κB family consists of p50 (NF-κB1), p52 
(NF-κB2), p65 (RelA), RelB and c-Rel transcriptionally-active proteins.  Their 
levels and functions are controlled by inhibitors such as IκBα, IκB, IκBε and BCL3 
(Oeckinghaus and Ghosh, 2009). NF-κB can become activated through two 
pathways classical and non-canonical. In the classical (or canonical) pathway NF-
κB is located in the cytoplasm. Here IκBα is phosphorylated at two sites- Ser32 and 
36, resulting in its ubiquitination and proteasomal degradation. This results in the 
release of NF-κB subunits (such as a typical p50-p65 complex), allowing it to 
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undergo nuclear translocation before binding and regulating its target region in the 
DNA (Ghosh and Karin, 2002, Demchenko et al., 2010). NF-κB is constitutively 
activated in haematological malignancies (such as AML), resulting in an increase 
in proliferation and an reduction in responsiveness to apoptotic stimuli (Rushworth 
et al., 2010). Previous work in the MacEwan lab identified NF-κB repression did 
not result in TNFα-mediated apoptosis, this being due in part to the subsequent 
upregulation of HO-1, which plays a key protective role (Rushworth and MacEwan, 
2008). HO-1 is regulated by NRF2, which was also found to be constitutively 
activated in AML, where it was identified that NF-κB positively regulated NRF2 
through binding to two NF-κB sites on the NRF2 gene’s promoter (Rushworth et 
al., 2012). The positive regulation between NF-κB and NRF2 may be cell type 
specific, as an inhibitory relationship is seen in other cell types (Wardyn et al., 
2015). Furthermore, constitutive activation of NRF2 in AML was found to be the 
result of aberrant signalling, as opposed to any mutation in the NRF2/KEAP1 
binding regions, that could account for dysregulation, as outlined above (Rushworth 
et al., 2012). This constitutive activation of NRF2 resulted in resistance to front-
line chemotherapy agents in AML, most notably cytarabine and daunorubicin 
(Rushworth et al., 2011a, Rushworth et al., 2012).  
 
1.5 micro RNAs (miRNAs) 
1.5.1 miRNA biosynthesis and physiological role 
miRNAs are small non-coding single-stranded RNA molecules that play a crucial 
role in epigenetic regulation by targeting and inactivating their corresponding 
mRNA sequences. The process of miRNA biogenesis begins with the transcription 
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of the primary miRNA transcript (pre-miRNA), this process occurs in the nucleus 
and is predominately carried out by RNA polymerase II but can also occur through 
RNA polymerase III (Lee et al., 2004, Borchert et al., 2006). The pre-miRNA 
generally contains the typical double stranded 33bp hairpin stem with a terminal 
loop, it is also flanked by a single stranded region both to the 5’ and 3’ of the stem 
(Winter et al., 2009). The pre-miRNA is cleaved by the Drosha/DGCR8 complex 
which leaves the precursor miRNA, this is a stem loop structure with a size of 
approximately 85 nucleotides (Han et al., 2006, Peng and Croce, 2016). 
Cytoplasmic translocation of the pre-miRNA is mediated by Ran/GTP and Exportin 
5 (Yi et al., 2003) and once cytoplasmic the pre-miRNA are again processed by the 
RNAase III enzyme Dicer (in conjunction with the RNA binding protein TRBP) 
leaving 20-22 nucleotide mature miRNA and passenger strand in a duplex (Peng 
and Croce, 2016). After being unwound, the mature miRNA is loaded with 
Argonaute proteins and becomes incorporated into the RNA induced silencing 
complex (RISC). The RISC is guided to the complementary mRNA sequences (to 
that of the miRNA), where it binds and silences expression.  The binding between 
the miRNA and mRNA is based on the 6-8 nucleotide “seed region” which binds 
to its complementary mRNA through Watson-Crick base pairing. This 
predominately results in a repression of protein translation and/or mRNA 
degradation (Peng and Croce, 2016, Winter et al., 2009). 
 
miRNAs play a crucial role in modulating post-transcriptional expression from the 
earliest stages of development. Pluripotent embryonic stem (ES) cells have the 
ability to differentiate into any cells in the human body and are characterised by 
Chapter 1: Introduction 
32 
 
high expression of transcription factors such as Nanog, Oct4, c-Myc and KLF4. 
Repression of these transcription factors results in differentiation of ES cells. ES 
cells have their own miRNA expression profiles and as these cells differentiate the 
mRNA profile changes (Houbaviy et al., 2003, Ivey et al., 2008). When Dicer 
(crucial for cleaving the pre-miRNA) was knocked-down in mice ES cells, they  do 
not form teratomas with all three germ layers present (the “gold standard” 
requirement for determining pluripotency) and lacked several key differentiation 
markers (Kanellopoulou et al., 2005). Furthermore, the knockout was 
embryonically lethal (Bernstein et al., 2003).  
 
1.5.2 miRNA in haematopoiesis 
Dicer knockout in HSCs results in apoptotic cell death and this can be rescued by 
the ectopic overexpression of miR-125a (through targeting BAK), which returns 
the long term HSC population demonstrating  its crucial role in haematopoiesis 
(Guo et al., 2010). 
  
HSCs also have a unique miRNA profile, and several miRNA are upregulated in 
the long term HSC population (miR-125a, miR-125b, miR-129, miR-155, miR-130 
and miR-181c). Ectopic overexpression of different miRNA skews differentiation 
towards certain haemopoietic lineages. miR-29a for example is upregulated in the 
long-term HSC population, and its expression decreases as the HSC cell becomes 
more committed (O'Connell et al., 2010). Ectopic expression results in a 
differentiation bias towards a myeloid lineage and miR-29a is upregulated in many 
patients with AML (Han et al., 2010). Similarly, when miR-125b is ectopically 
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expressed a myeloproliferative disorder is observed which can lead to AML 
(Bousquet et al., 2008a). 
 
The miRNA expression profile differs between the myeloid and lymphoid 
progenitor stem cell. One study identified miR-130a, miR-31 and miR-203 as being 
upregulated in myeloid progenitors, while miR-126 and miR-23a are increased in 
the lymphoid progenitor (Petriv et al., 2010). Expression of miR-223 is low in HSCs 
but increases in expression during granulocytic differentiation and when its 
expression was repressed in murine models the granulocytes produced were 
defective (i.e. more sensitive to stimuli as well as terminal maturation) (Johnnidis 
et al., 2008). 
 
In monocytes several miRNAs have been implicated in regulating differentiation 
into macrophages including miR-106a, miR-17 and miR-20a, which work through 
targeting M-CFR. These miRNAs also seem to be regulated by AML1 (which is 
upregulated during monocyte differentiation), as AML1 levels increase, these 
miRNAs decrease in expression (Fontana et al., 2007). 
 
Once differentiated, macrophages can be classified into M1- or M2-type 
macrophages depending on several factors including their mechanism of activation, 
cytokine production and general function. miR-155 was shown to play a crucial role 
in regulating the two by targeting IL-13Rα1 (IL-13 being a key M2 cytokine) and 
inhibiting STAT6 phosphorylation (Martinez-Nunez et al., 2011). miR-155 is also 
important in dendritic cells as its deletion inhibits them from stimulating T-cells. 
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(Dunand-Sauthier et al., 2011). Dicer knockouts in B or T precursor cells results 
again in defects in cellular processes, leading to an inhibition in the precursor B cell 
differentiation and in T cells inhibits CD4 and CD8 T lymphocyte levels. In the 
case of CD4+ cells this results in increased apoptosis (Koralov et al., 2008, Muljo 
et al., 2005). Overall miRNAs play a crucial role, transcriptionally regulating in 
both haematopoietic development and function. When dysregulated, these miRNAs 
can lead to a number of diseases and disorders including cancer. 
 
1.5.3 miRNA dysregulation in cancer 
miRNA expression profiling can be used to differentiate cancer types and can even 
be used to determine specific subtypes of cancers as well as their prognosis (Lu et 
al., 2005, Namkung et al., 2016). In pancreatic cancer, the expression of 19 miRNAs 
was sufficient to distinguish between high and mid/low risk prognosis (Namkung 
et al., 2016). In cancer, miRNAs can become dysregulated, acting either in an 
oncogenic manner (dubbed an OncomiR) or acting in a tumour-suppressor manner 
(dubbed a Tumour-Suppressor miR) (Fig 1.4). 
 
 




Figure 1.4: Dysregulation of cancer cells by miRNAs 
miRNAs can act as tumour suppressors or an oncomiR. A tumour suppressor 
miRNA represses target oncogene expression decreasing tumorigenesis. An 
oncomiR represses target tumour suppressor genes, increasing tumorigenesis 
 
miRNAs become dysregulated through three main mechanisms; amplification, 
deletion and through transcriptional regulation (Peng and Croce, 2016). The miR-
143/145 cluster located on 5q33 can be deleted in lung cancer resulting in a decrease 
in miRNA expression (Peng and Croce, 2016). This miRNA cluster is also reduced 
in both breast and colon cancer (Calin and Croce, 2006). In CLL, the 13q deletion 
is responsible for approximately 55% of genomic aberrations and within this region 
lies the miR-15a/16-1miRNA cluster. The cluster acts as a tumour suppressor miR 
by targeting BCL2 and MCL1  (Döhner et al., 2000, Pekarsky and Croce, 2015). 
 
miRNA expression can also be reduced through epigenetic modification. The 
tumour suppressor miR-127 is downregulated in breast cancer, primary prostate and 
bladder cancer and plays a key role by targeting BCL-6 (Chen et al., 2013, Saito et 
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al., 2006).  miR-127 is located in the vicinity of several CpG islands and is 
epigenetically repressed in many cancer cells (Saito et al., 2006). 
 
Amplification of miRNA can occur particularly through chromosomal 
translocations. 40% of Clear Cell Carcinoma (a subtype of Epithelial Ovarian 
Cancer) is characterised with an amplification of the 17q 23-25 region. miR-21 is 
located in an intron in the vicinity (17q23.2) and is upregulated in a range of cancers 
where it acts as an oncomiR by targeting PTEN expression. It is however unclear 
whether the amplification of the region is responsible for aberrant miR-21 
expression as one study finding no correlation between the amplification and high 
miR-21 levels (Hirata et al., 2014). 
 
miRNAs can also be regulated by transcription factors. For example, miR-34a is a 
tumour suppressor miR associated with apoptosis and directly regulated by p53 
(which binds to the miR-34a promoter increasing its expression) (Raver-Shapira et 
al., 2007). miR-34a targets SIRT1 (which plays a key role in de-acetylating p53, 
thereby preventing p53 transcription), this results in an increase of acetylated p53 
and thus an upregulation in the expression of p53 targets, including miR-34a 
creating a positive feedback loop (Luo et al., 2000, Yamakuchi and Lowenstein, 
2009). Conversely, c-Myc represses the tumour suppressor miR-122 in 
hepatocellular carcinoma through binding to a non-canonical c-Myc site in the miR-
122 promoter. miR-122 forms a negative feedback loop with c-Myc by targeting 
TFDP2 and E2F1 (E2F1 is a c-Myc activator with TFDP2 acting as a co-activator) 
(Wang et al., 2014a). 
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1.5.4 Oncogenic role of miRNA 
When dysregulated in cancer miRNAs can affect a variety of processes including 
cell death, cell proliferation, angiogenesis, and metastasis (Peng and Croce, 2016). 
p53 is a key pro-apoptotic protein and, as previously discussed, can both regulate 
and be regulated by miR-34a (Yamakuchi and Lowenstein, 2009). p53 has also 
shown to positively regulate miR-192, miR-194 and miR-215 in multiple myeloma 
where they act as tumour suppressor miRs by negatively regulating Mdm2 
expression (Pichiorri et al., 2010). Similarly, the tumour suppressor miR-122 
represses expression of cyclin G1 (upregulated in hepatocellular carcinoma) which 
also plays a key role by repressing MDM2 resulting in increased sensitivity to 
doxorubicin (Fornari et al., 2009). 
 
miR-221 and miR-222 have been characterised as both oncomiRs and tumour 
suppressors depending on the cancer type. In pancreatic cancer these miRNAs have 
been associated with an oncogenic role. Here one of their targets is the cyclin 
dependant kinase inhibitor (p27/Kip1), as well as capsase-10. Downregulation of 
p27/Kip1 is a known marker for an unfavourable prognosis. The upregulation of 
miR-221/222 was shown to increase proliferation in prostate cancer cells and 
repress sensitivity to TNFα (Galardi et al., 2007, Wang et al., 2015b). Conversely 
a study in lung cancer cells found another miRNA family (let-7) was downregulated 
compared to healthy patient samples. They also showed let-7 represses cell 
proliferation in both lung and liver cancer cell lines through the targeting of cell 
cycle targets including CDK6, cyclin D, Ras and CDC25a (thus inhibiting G1 to S- 
phase transition) (Johnson et al., 2007). 




Another key characteristic of cancers is metastasis, this predominantly involves an 
epithelial-mesenchymal transition (EMT). miR-21 for example has shown to act as 
an oncomiR in several cancers including breast, colon and prostate cancer. In breast 
cancer high levels of miR-21 have been associated with poor prognosis and lymph 
node metastasis (Yan et al., 2008). Similarly it is associated with metastasis in colon 
cancer (Roldo et al., 2006). This may be because it targets tropomysin 1 (TPM1) 
and programmed cell death 4 (PDCD4) (Zhu et al., 2008).  miR-155 has shown to 
act as an oncomiR in cancers such as hepatocellular carcinoma by promoting EMT. 
This is due to it targeting p85α (which represses the PI3K/AKT pathway)resulting 
in induction of SGK3 (Kong et al., 2016). SGK3 aids the phosphorylation of 
GSk3β, preventing it from degrading β-catenin. The stabilisation of β catenin is a 
key process in the Wnt pathway (whose activation is associated with EMT) (Kong 
et al., 2016). 
 
Angiogenesis refers to the creation and development of new blood vessels from pre-
existing vascular architecture, which supports the increasing growth of a tumour 
(Caporali and Emanueli, 2011). miRNAs can play a crucial role regulating this 
process, for example one study looked for miRNA that target VEGF. VEGF is a 
crucial factor in inducing both angiogenesis and vasculorigenesis. The study found 
several miRNA, including miR-16, miR-15b, miR-20a and b targeted and repressed 
VEGF levels (Hua et al., 2006). Furthermore these miRNA were repressed during 
hypoxic conditions (Hua et al., 2006). A subsequent study showed miR-20b also 
represses HIFα, thus creating a loop where miR-20b represses VEGFα and HIFα 
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expression, while HIFα represses miR-20b, this could possibly allow the tumours 
to adapt to different levels of oxygen (Lei et al., 2009). In breast cancer, miR-148a 
was shown to be downregulated, and when ectopically overexpressed can repress 
angiogenesis by targeting ERBB3 (a member of the EGFR family), VEGFα and 
HIF-1 (Yu et al., 2011, Mu et al., 2017). 
 
1.5.5 NRF2 and miRNAs 
Previous studies have shown NRF2 can be regulated and in turn regulate miRNA 
expression. For example, in Oestradiol induced breast cancer, miR-93 expression 
is increased and in turn targets NRF2. This results in a repression in apoptosis and 
an increase in oxidative stress mediated DNA damage (Singh et al., 2013b). In 
sickle cell anaemia, miR-144 was shown to target and reduce levels of NRF2, this 
results in a reduction of glutathione expression. The repression in glutathione levels 
can contribute to haemolysis (a crucial characteristic of sickle cell anaemia) 
(Sangokoya et al., 2010). 
 
NRF2 can also regulate miRNAs, either through binding to the promoter of a 
miRNA or indirectly through the regulation of its target genes, this in part was 
shown by a ChIP-Seq experiment which identified NRF2 binding sites in the 
promoter of several miRNA in lymphoid cells (Chorley et al., 2012). A detailed 
review on these NRF2 regulated miRNA can be found here (Shah et al., 2013). 
NRF2 can indirectly regulate miR-1 and miR-206 through modulating HDAC4 
(which translocates to the nucleus when reduced, this occurs with high levels of 
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NRF2 activation), resulting in increased expression of PPP genes (Singh et al., 
2013a). 
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1.6 Gene Editing 
1.6.1 Overview 
Gene editing refers to the ability to make specific alterations of a targeted region of 
DNA. Prior to the era of targeted nucleases, several other methods were used for 
genetic manipulation. One such method is the Cre-Lox recombinase. The 38 kDa 
protein Causes (Cre) recombinase (derived from the P1 bacteriophage) plays a 
critical role in the recognition of LoxP sites, thereby mediating both inter/intra 
molecular recombination (Hamilton and Abremski, 1984). LoxP sites consist of two 
inverted 13 bp regions flanking an 8pb non-palandromic spacer region. Essentially, 
if both LoxP sites are orientated in the same direction, the flanked DNA will be 
excised. However, if the LoxP sites are in an opposing orientation (i.e. facing each 
other), the flanked DNA will be reversed (due to recombination). When the LoxP 
sites are on different chromosomes recombination is promoted between both sites 
(Medberry et al., 1995, Nagy, 2000). 
 
Double-Strand Breaks can occur due to cellular processes (i.e. ROS as a by- product 
of metabolism) or through external sources (such as ionising radiation). During 
meiosis, double-strand breaks (DSB) occur to promote recombination by the 
enzyme Spo1 (Keeney et al., 1997). Two commonly used mechanisms to repair 
double-strand breaks are Non-Homologous End Joining (NHEJ) and Homologous 
Recombination (HR). During NHEJ, Ku70/80 responds to DSB by acting as a 
scaffold for other factors (Mari et al., 2006). This in turn activates DNA PKcs and 
Artemis, these two form a complex together. The PKcs/Artemis complex contains 
endonuclease activity allowing the removal of DNA overhangs (Lieber, 2010).  
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DNA polymerase µ and λ are recruited to fill in the overhang using dNTPs and 
rNTPs to polymerise the template (Davis and Chen, 2013, Nick McElhinny et al., 
2005). λ has the ability to remove damaged DNA bases (Ramadan et al., 2004). The 
DNA ends are ligated together using DNA ligase IV (Davis and Chen, 2013). This 
process is error-prone and can lead to insertion or deletion mutations (INDELs) 
(Rodgers and McVey, 2016). 
 
Homologous recombination is an accurate repair process as it uses the sister 
chromatid as a repair template (Rodgers and McVey, 2016).  After a double strand 
break occurs, it is recognised by the MRN complex (Mre11 RAD50, and Nbs1) 
which contains exonuclease activity, thereby allowing the 5’ end to be “nibbled”- 
back (leaving 3’ overhangs). The exposed 3’ strand then invades the 
complementary sister chromatid (which is used as a repair template), this process 
is mediated by RAD51, thereby creating a region of heteroduplex DNA (DNA 
containing both invading strand and the sister chromatid). The displaced and 
invading strand forms a displacement loop (D Loop). The invading strand is 
extended and can be resolved by two mechanisms, double strand break repair 
(DSBR), which can result in a crossover, or synthesis dependent strand annealing 
(SDSA). In gene-editing the process of homologous recombination can use a donor 
DNA template, (with homology to target sequence) to create a custom modification 
in the genome (Ran et al., 2013b).  
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1.6.2 Zinc Finger Nucleases 
One of the first targeted nucleases were Zinc Finger-fused nucleases. Zinc Finger 
proteins (Cys2His2) are based on the IIIA transcription factor found in Xenopus. 
Zinc fingers are between 28-30 amino acids in a Beta-Beta-Sheet-Alpha Helix 
(BBA) configuration. 
The alpha helix contains amino acids in contact with base pairs (typically three) in  
the major grooves of the DNA (Gaj et al., 2013). This ability allows Zinc Fingers 
to bind to most triplet bases in the genome. Zinc Finger proteins are fused with the 
FOK1 nuclease, thereby combining the DNA binding ability of the Zinc Finger with 
the nuclease activity of FOK1. Each Zinc Finger module will bind to a triplet code 
of DNA. Two Zinc Finger proteins (made up of approximately 3-6 modules) are 
designed to target opposite strands of DNA region of interest, binding in a “tail to 
tail” orientation with a 5-7 bp spacer region, which is used by FOK1 to dimerise 
(hence why the binding of both zinc finger proteins is necessary) and cleave, 
thereby creating a double strand break (Gaj et al., 2013). 
 
1.6.3 TALENs 
Transcription activator-like effector nuclease (TALENS) are an alternative 
nuclease used in gene editing. Derived from the proteobacteria Xanthomonas 
TALEs (transcription activator-like effectors). Similar to Zinc Fingers, TALEs are 
fused to FOK1. The TALEs are comprised of repeat arrays of 33-35 amino acids 
allowing specific base targeting. Binding is determined by the hypervariable region 
(amino acids 12 and 13) known as the repeat variable di residue (RVD). Amino acid 
13 is crucial in recognising the base to bind to, while 12 is important in stabilising 
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the interaction (Deng et al., 2012).  There are four commonly found hypervariable 
regions NN (guanine), NI (adenine), HD (cytosine), and NG (thymine) (Joung and 
Sander, 2013, Miller et al., 2011).  Similar to the Zinc- Finger nucleases, TALEN 
arrays bind to opposing DNA strands (separated by a short spacer region generally 
between 12-21 bp). With the spacer region binding to adjacent DNA strands, FOK1 
dimerises causing a DS break. 
 
While both ZFN and TALENS are challenging to design and construct, TALEN 
synthesis is streamlined using “Golden Gate Cloning”. This uses Type-IIS 
restriction enzymes, and plasmids that are configured to have non-compatible initial  
overhangs, but allow the next complementary construct to ligate . Each RVD is 
modularised allowing the TALEN constructs to be custom designed for the area of 
choice (Cermak et al., 2011). 
 
The effectiveness of TALENs is also dependent on the location of the targeted 
genomic location. A major setback to TALEN use is their inability to bind to 
methylated genomic regions (in particular 5‘methylated cytosine). One study using 
TALE to target Oct-4 showed a significant decrease in transcription activation post-
methylation. Treatment with a DNA methyltransferase can successfully reverse this 
inactivation suggesting chemical treatment may be a viable solution (Bultmann et 
al., 2012). However treatment with methyltransferases can cause a myriad of 
secondary effects such as genomic instability and cytotoxicity (Palii et al., 2008), 
Valton et al instead show using the RVD N*, instead of the HD hypervariable 
region (the * referring to a missing residue at that location.) (Valton et al., 2012) 
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Due to the missing glycine, the TALE is able to bind to the methyl group in the 
5mC, and therefore editing can reliably occur in cytosine methylated regions 
(Valton et al., 2012). 
 
1.6.4 CRISPR-Cas9 
Clustered Regulatory Interspaced Short Palindromic Repeats or CRISPR-Cas9 
system has recently been identified as an alternative to ZFN or TALENS. 
 
The CRISPR locus was originally identified in E.coli, where they play a crucial role 
as a reprogrammable adaptive immune response to protect these bacteria cells from 
viruses (Rath et al., 2015). Viral DNA is exposed to the Cas complex, where it is 
cleaved by Cas proteins and incorporated into as a sequence in a CRISPR array. 
These are transcribed and the pre-cRNA is processed into shorter, separate crRNA, 
complementary sequences on the invading viruses are recognised and targeted by 
Cas proteins (Rath et al., 2015, Koonin and Wolf, 2015). 
 
There are two main classes of CRISPR-associated (Cas) proteins, Class 1 (which 
encompasses approximately 90% of Cas loci) and Class 2 (Makarova et al., 2015). 
Class 1 (encompassing type I, III and IV) Cas systems requires several Cas proteins 
to form an effector complex that can target either DNA or RNA (Makarova et al., 
2015). In contrast Class 2 (encompassing type II, V and VI) only requires one Cas 
protein, thereby making them useful for gene editing. The most commonly used 
example of a Type-2 CRISPR system is Cas9, specifically that found in 
Streptococcus pyogenes (spCas9). Unlike the Class 1 systems, Cas9 alone can 
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process and cleave the DNA causing a double strand-break. Here the CRISPR-RNA 
(crRNA) hybridises with the trans-activating cDNA (which binds to the 
palindromic repeat on the crRNA), this in turn is processed by RNase III, allowing 
it to bind to Cas9. The Cas9-tracRNA (trans-activating crRNAs) complex will be 
directed to the region of DNA complementary to the corresponding crRNA 
sequence. Cas9 requires a consensus Protospacer Adjacent Motif (PAM) site 3’ 
downstream of the crRNA sequence (in the case of spCas9 5’-NGG-3’) in order to 
dock and bind that region of DNA. Assuming the crRNA sequence is 
complementary to the DNA sequence preceding the PAM site, Cas9 will cleave the 
DNA resulting in a double-strand break, which will be repaired by either NHEJ or 
HDR (Tsai and Joung, 2016). The recognition of the gRNA with its complementary 
DNA counterpart, along with the presence of a PAM motif, results in the unwinding 
of DNA strands, and forms an R-loop, thereby allowing the DNA strands to be 
exposed to cleavage by Cas9 (Jiang et al., 2016). The ability for Cas9 to cleave 
double-stranded DNA is due to the HNH (complementary) and RuvC (non-
complimentary) nuclease domains. Cas9 undergoes a conformational change upon 
binding of the guide RNA to genomic DNA, resulting in both the HNH and RuvC 
domains cutting their respective DNA strand (Sternberg et al., 2015).  
 
The realisation that the tracr- and CRISPR-RNA can be fused to create a single 
guide RNA (sgRNA) has meant that CRISPR-Cas9 has become the preferred tool 
for genome editing as it its easily “re-taskable”. The sgRNA is the synthetic fusion 
of the tracrRNA and crRNA and acts to target Cas9 to precise genomic locations 
(as discussed below). 




The sgRNA retains the ability to bind to Cas9 and cause a conformational change, 
as well as direct it to regions of DNA complementary to that of the gRNA (Cong et 
al., 2013, Jinek et al., 2012). A schematic of Cas9 binding to double stranded DNA, 
in the presence of an sgRNA guide and PAM site can be seen in Fig 1.5A, 
Interestingly, in mammalian cells RNAse III (required for the processing of the 
tracrRNA and maturation of the crRNA in the prokaryotic systems) is not required 
for successful editing. This suggests the RNAse/s present in mammalian cells are 
sufficient for processing and successful CRISPR editing (Cong et al., 2013). As 
discussed above a double strand break will be repaired by either NHEJ or HDR (Fig 
1.5B). NHEJ generally results in an INDEL mutation in the vicinity of the double 
strand-break, and is a useful mechanism for creating “knock -out” cells. Unlike 
NHEJ, HDR (in conjunction with a DNA repair template) can be used to accurately 
edit the targeted locus allowing for specific targeted changes to be made to the 
genome (Ran et al., 2013b). 
 
spCas9 is the most commonly used Cas9, with its NGG PAM site occurring 
approximately once every 8 bp (Graham and Root, 2015). While this is sufficient 
for experimental CRISPR knockout/knock-ins, it does pose a problem for those 
wishing to generate cells with a specific targeted mutation. The size of the Cas9 
protein also makes it difficult to introduce into cells or incorporate into viral vectors, 
which is required for editing in hard to transfect cells (such as most AML cell lines). 
Recently there has been a push to identify additional Cas9 variants or orthologues. 
One example of this is SaCas9 (derived from Staphylococcus aureus) which is a 
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smaller variant the regular Cas9 being 3.2 kb in size and recognises a PAM site 
consisting of NGRRT or NGRRN. An initial in vivo study packaged SaCas9 into 
an AAV vector with guides targeting PCSK9, they showed 35-45% INDEL, and no 
detectable off-target effects. They also found SaCas9 requires a slightly larger guide 




Figure 1.5: Overview of Gene editing with CRISPR-Cas9 A) Cas9 binds to DNA 
complementary of the sgRNA (in blue), upstream of the NGG PAM site. Triangles 
indicate location of double strand break. B) The double strand break can be resolved 
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by either NHEJ or HDR. NHEJ results in insertion or deletion mutations. HDR 
requires the presence of a repair template and results in precise editing based on the 
template sequence. Adapted with permission from Springer Nature: Nature 
Protocols (Ran et al., 2013b). 
 
1.6.5 Other nucleases (i.e. CPF1) C2C2 FnCas9 Cas13 (RNA) 
The class II type V Cas9 variant, Cpf1, was first derived from Francisela novicida, 
and is made up of nine spacer regions, separated by 36 nucleotide repeats (Schunder 
et al., 2013). Subsequently several additional CPF1 orthologs have been identified 
including AsCpf1 (from Acidaminococcus sp. BV3L6) and LbCpf1 (from 
Lachnospiraceae bacterium). Similar to Cas9, Cpf1 contains a RuvC nuclease 
domain, however it lacks the HnH domain. Instead RuvC is sufficient to cleave both 
DNA strands, as shown in mutations to the RuvC domain in fnCPF1, which ablate 
DNA cleavage. Contrasting mutations in Cas9 turn it into a “nickase”, which is only 
able to cleave one strand of DNA. (Zetsche et al., 2015a). Cpf1 has shown to have 
similar editing efficiency to Cas9, and has a TTTN PAM site (Zetsche et al., 2015a). 
This T-rich PAM site allows the targeting of AT rich regions, which may lack the 
Cas9 NGG PAM site. 
 
There are several advantages to CPF1 over Cas9, for example CPF1 does not 
require a tracerRNA sequence to aid crRNA processing, thereby reducing the size 
of the guide RNAs (to approximately 42 nucleotides) which provides an advantage 
when using viral vectors. CPF1 also cuts 18-23 nucleotides downstream of the PAM 
site, and leaves a staggered overhang (Zetsche et al., 2015a). This provides two 
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advantages, first since Cas9 cuts approximately 3 nucleotides 5’ to the PAM site, 
NHEJ often results in the destruction of the PAM site, preventing further editing at 
this locus. This problem is not seen with Cpf1 due to it cutting away from the PAM 
site, meaning further editing could occur, this may be particularly useful when 
generating “knock-in” mutations. Secondly, the staggered ends themselves are 
thought to improve editing in quiescent cells  (Zetsche et al., 2015a).  The Cpf1 
guides can also be multiplexed and expressed from a single CRISPR array. While 
multiple Cas9 guides can be expressed, additional regulatory sequences are required 
(for example separate promoters per guide), thus increasing the size of the construct. 
Cpf1 on the other hand, can express multiple guides from a single U6 Polymerase 
III promoter (Zetsche et al., 2017). 
 
Cas13a (formally named C2C2), was initially identified as a Class 2-type VI Cas 
variant which targets single-stranded RNA (ssRNA). Cas13a contains a double 
Higher Eukaryotes and Prokaryotes Nucleotide binding (HEPN) site, which allows 
it to act as a ribonuclease (i.e. binds and cleaves RNA molecules) (Abudayyeh et 
al., 2016). Despite studies in bacteria, which show off-target cleavage by Cas13a 
due to its remaining activity post binding, studies in mammalian cells have shown 
no evidence for off target cleavage of RNA (Abudayyeh et al., 2017).  Cas13a has 
shown to have similar targeting efficiency with significantly lower off-target effects 
in comparison to shRNA (Abudayyeh et al., 2017). Furthermore, similar to Cpf1, 
Cas13a orthologs (such as LwaCas13a) have also been shown to be able to be easily 
multiplexed (Abudayyeh et al., 2017). 
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1.6.6 Research and Therapeutic Potentials 
Gene editing is revolutionising research and shows promise therapeutically. 
Mutations in CCR5, a crucial receptor for HIV entry, have shown to increase 
viability of CD4 T cells, and thus resistance to HIV. One study designed two Zinc 
finger arms to target CCR5 in CD4 T cells in vitro. The cells were expanded and a 
sample of patients suffering from HIV infections were treated with the modified 
CD4+ T cells. The treatment succeeded in increasing resistance to the HIV virus 
(Tebas et al., 2014). Another study used Zinc finger proteins to accurately correct 
a mutation on IL2RG in HSCs. This mutation is responsible for X-linked severe 
combined immunodeficiency (SCID-XI), and the HSCs were derived from a patient 
suffering from the disease.  The corrected HSCs were expanded allowing the 
potential for them to be re-transplanted into a patient (Genovese et al., 2014). 
 
Mutations in cystic fibrosis transmembrane regulator (CTFR) inhibits the function 
of chloride transporters, thereby causing cystic fibrosis. One study wished to use 
CRISPR to target and repair the ΔF508 mutation. Skin cells were derived from a 
patient carrying this mutation and iPSC cells were derived. The ΔF508 mutation 
was targeted by CRISPR in iPSC cells using a donor vector containing a GFP-Puro-
TK cassette flanked by piggyBac (a transposon) sites and the corrected CTFR 
sequence. The cassette was integrated into the iPSC cells, and positive clones were 
selected for by puromycin selection. The cassette was then excised using the 
piggyBac transposase, leaving behind the corrected ΔF508 mutations without any 
residual DNA. Cells without the donor cassette removed are selected against 
through ganciclovir treatment (which targets TK). The corrected iPSCs were then 
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differentiated into lung epithelial cells and normal function was shown. This study 
provides a viable methodology to treat patients suffering from cystic fibrosis by 
genetically editing the ΔF508 from their derived cells (Firth et al., 2015). 
Despite the relative ease of designing and using CRISPR constructs, there still 
remains several issues which prevent it from being used in the clinic. Off- target 
effects remain the primary issue and this is less of a concern with TALENS and 
ZFN due to them acting as monomers (i.e. both arms are required for successful 
editing) (Nemudryi et al., 2014). Hence despite being less versatile, TALEN and 
Zinc Fingers are still predominately used in a therapeutic setting.  
 
 Improvements have been made to the CRISPR Cas9 system to address this problem 
including the use of a Cas9 nickase (nCas9). These Cas9 variants are designed with 
a mutation at either D10A in RuvC domain or H840A in HnH domain, thereby only 
having one active nuclease domain (Cong et al., 2013). The Cas9n are used in 
conjunction with sgRNA. Nickases like TALENS and Zinc-finger nucleases act as 
monomers and both must be introduced to get a DSB. On their own an individual 
nickases will cause a single-strand break, which is repaired by using base excision 
repair. The use of nCas9 results in a 50-1000 fold reduction in off-target effects 
(Ran et al., 2013a). Other methods include shortening the region of the sgRNA 
complementary to the target, the synthesis of catalytically inactive Cas9 (dCas9) 
(these can be fused to Fok1 to improve specificity) and the generation of high 
fidelity variants of Cas9  (Fu et al., 2014, Guilinger et al., 2014, Kleinstiver et al., 
2016).  
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Recent work in ALL has shown the potential for TALEN gene-editing to be used 
to modify the patient’s own cells. Such an approach has been seen to be effective 
in the treatment of chemotherapy-resistant B-ALL children, in at least two cases 
(11 and 18 month old children) where CAR-T cells with TALEN-modified target 
TCRαβ, were used as this novel treatment option (Qasim et al., 2017). 
The success of the TALEN-based editing ‘living drug’ breakthrough has led those 
research teams to look towards CRISPR- or other targeted nuclease-based 
technologies to improve genetic modification of donor cells for common use in 
cancer patients worldwide. 
dCas9 has no endonuclease activity, preventing editing from occurring, however it 
still retains its ability to bind to DNA which means it can be used to target specific 
DNA sequences. Studies have combined the dCas9 or Cas9 nickases with a cytidine 
deaminase resulting in “base-editors” which allow the conversion of cytosine to 
thymine without the need for a DSB (Komor et al., 2016). The first generation of 
base editing used the cytosine deaminase rAPOBEC1 and this was sufficient to 
convert C-T within 5 nucleotides of the targeted sequence (Komor et al., 2016). The 
third generation (BE3) used the “nickase” ability of Cas9 to create a single strand 
break on the non- targeted strand, the rationale being the previously edited strand 
will act as a template, therefore copying the mutation on the targeted strand (i.e. C-
G will become T-A). While this increased efficiency, it also increased the number 
of off-target effects (Komor et al., 2016). Since then improvements have been made 
to increase both efficiency and specificity of the base editing enzymes. These 
improvements include the use of other deaminases (such as AID), allowing for a 
higher level of customisation (Nishida et al., 2016). One study mutated the cytidine 
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deaminase allowing for C-T targeting within 2bp (Kim et al., 2017). Recently, 
studies have created a DNA adenosine deaminase through directed evolution from 
a transfer RNA adenosine deaminase (as none existing naturally). Four adenine 
base editors (ABEs) were developed, allowing an A to G alteration to occur with 
the targeting to be between 4-9 nucleotides (Gaudelli et al., 2017). Both the Cas9-
fused cytidine and adenosine deaminase provide a potential mechanism to correct 
specific targeted mutations in the genome with little off target effects. 
 
In addition to its potential therapeutic use, CRISPR has tremendous potential in 
research and diagnostics. For example, the CRISPR system can be used to identify 
the role of genes or signalling pathways in a disease of interest. Combining large 
CRISPR libraries with Lentiviral delivery has revolutionised forward genetic 
screening. 
 
One study used a CRISPR library with an enriched pool of 73,151 sgRNA 
(targeting 7114 genes) and a lentiviral vector for delivery. Cells were transduced 
with the library, before being treated with the selection control drug 6-thioguianine 
(6-TG). The treated cells were compared to those not exposed to 6-TG by high 
throughput sequencing. Here the sgRNA act as a barcode allowing identification 
(Wang et al., 2014b). This is an example of a negative screen. Alternatively, post 
treatment, the surviving cells can be analysed by sequencing, with those that have 
survived contain mutations that provide a survival advantage. This is known as a 
positive screen method. Overall these CRISPR libraries provide an invaluable tool 
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to better understand the role of different genes in diseases and thus find novel 
prognostic targets. 
 




Our lab has previously shown the presence of constitutively-activated NRF2 in 
AML, with its activation being linked to chemotherapy-resistance. In this study we 
wished to fully elucidate the effect of NRF2 signalling in Acute Myeloid 
Leukaemia. Despite a fair understanding of its role in chemo-resistance, its impact 
in promoting oncogenesis is still to be determined. Recently, miRNAs have been 
shown to play a key role in regulating a myriad of cellular mechanisms, and of 
particular relevance in cancer. They can function in both an oncogenic and tumour 
suppressor capacity.  
 
In this study, we will investigate: 
a) The capacity of the transcription factor NRF2 to regulate miRNAs in AML, 
b) Characterise the NRF2-regulated miRNAs and explain their function in 
AML. 
c) The potential for gene-editing technology to further understand NRF2 
signalling networks in AML. 
  






Chapter 2  
 
Materials and Methods 
  





All reagents and consumables were purchased from either the Sigma Aldrich 
Chemical Company (Poole, Dorset) or as otherwise stated. Biological samples and 
cells are described below, where appropriate. 
 
2.2 Cell Biology Protocols 
2.2.1 Cell Culture 
All cell lines were obtained from either ATCC (Virginia, USA), ECACC 
(Salisbury, UK) or DSMZ (Braunschweig, Germany). AML cell lines (THP-1, HL-
60, U937, OCI-AML3 and MV4-11) and the CML cell line K652s were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 containing 1% GlutaMax, 10% heat-
inactivated Foetal Bovine Serum (FBS) and 10 U/ml Penicillin and Streptomycin. 
HEK-293 and HCT-116 were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) containing high glucose (5000 mg/ml), L-glutamine, and HEPES. As 
before the media is supplemented with 10% FBS and 10 U/ml Penicillin and 
Streptomycin. Cell were grown at 37°C in a humidified atmosphere containing 5% 
CO2 and were maintained by routine passage every 2-3 days. 
 
2.2.2 Freezing cells 
Cells were grown to confluency, before being centrifuged at 500 x g for 5 minutes. 
Cell pellets were resuspended in freezing media (FBS containing 10% DMSO) at a 
concentration of around 5 x 106 cells/ml. Cells were then frozen in 1.8 ml 
CryoTubes (Nunc) and placed into a ‘Mr Frosty’ Freezing Container 
(ThermoFisher Scientific, Loughborough UK) containing isopropanol. Storage of 




this container at -80°C allows samples to freeze slowly (at 1°C per minute). 
Following overnight storage cells were transferred to liquid nitrogen for long-term 
storage. To resurrect cells, Cryotubes were placed in a 37°C water bath, once 
defrosted the cells were washed in medium (to remove residual DMSO), 
centrifuged then resuspended in either fresh RPMI or DMEM media before being 
placed into a T25 flask (Nunc, ThermoFisher Scientific). 
 
2.2.3 Assessment of cell viability using Cell Titer GloTM 
The Cell-Titer Glo Luminescent Cell Viability Assay (Promega) determines cell 
viability through determination of cellular ATP content. The assay was carried out 
according to the Manufacturer’s instruction. Briefly, cells were transferred to an 
opaque 96 well plate and the Cell-Titer-Glo reagent added to 5 x 105 cells at a 1:1 
ratio. Cells were incubated for 5 minutes on an orbital shaker after-which the plate 
was read on a plate reader with luminescence detection capabilities, FLUOstar 
Omega Microplate Reader (BMG Labtech, Germany). Luminometric results were 
normalised and expressed as a percentage compared to the control samples. 
 
2.2.4 Annexin-V and Propidium Iodide staining 
Apoptosis was assessed using Annexin-V/Propidium Iodide (AV/PI) staining. 1 x 
106 cells were pelleted, washed in PBS and resuspended in Annexin buffer (10 mM 
HEPES, pH 7.5, 137 mM NaCl and 2.5 mM CaCl2). Cells were then stained with 
an Annexin-V-FITC conjugate for 10 minutes in the dark. Propidium Iodide (0.1 
mg/ml in PBS) was then added and cells stained for a further 5 minutes on ice before 
analysis by flow cytometry BD Acuri C6, or the Attune Acoustic Focusing 




Cytometer (Applied Biosystems). Annexin-V detects apoptotic cells by binding to 
phosphatidylserine on the outer leaflet of the plasma membrane. PI detects late 
apoptosis with staining indicating both the plasma and nuclear membranes have 
both ruptured.  
 
2.3 Primary cell culture 
2.3.1 AML patient samples 
Primary AML patient samples were collected from the Norfolk and Norwich 
University Hospital (NNUH) under ethical approval (LRECref07/HO310/146). 
Peripheral blood was carefully layered on HistopaqueTM (Sigma) before spinning 
at 400 x g for 20 minutes (with both accelerator and break turned off). The “buffy-
coast” layer containing AML blasts were extracted and washed in Hank’s Balanced 
Salt Solution, before being frozen down or cultured in RPMI 1460 (with GlutaMax, 
supplemented with 10% FBS). Before use, the AML blast percentage was 
calculated using a flow cytometer measuring CD34+ cell surface marker. If the 
population contained less than 80% AML blasts, the sample was further purified 
with using the Miltenyi MACs system and CD34 Microbead selection kit (Miltenyi 
Biotec, Surrey UK).  
 
2.4 Biochemical Techniques 
2.4.1 Preparation of lysates for SDS-PAGE 
Cell lysates were prepared either in SDS sample buffer (50 mM Tris/HCl pH 7.5, 
4% SDS containing 0.01% Bromophenol Blue) or Triton lysis buffer (50 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 10% Glycerol, 1% Triton X-100 (v/v) 




supplemented with protease inhibitors aprotinin, pepstatin A, E64 and leupeptin (all 
at 1 µg/ml)). When using the SDS sample buffer, the cell pellet was mixed with the 
buffer prior to sonication (to aid cell lysis). When using the Triton lysis buffer cells 
were lysed on ice for 30 minutes following which lysates were cleared by 
centrifugation at 12,000 RPM for 20 minutes. Supernatant was collected and protein 
concentration was determined using the DC Protein Assay (BioRad).  
 
2.4.2 SDS-PAGE 
Protein lysates were reduced using β-mercaptoethanol, boiled (>95ºC), before being 
separated on a Tris-Glycine PAGE gel. The percentage of acrylamide in the gel 
used is based on the molecular weight of the protein being examined. The gel was 
electrophoresed at 100 V until the samples had passed the stacking gel following 
which the voltage was increased to 135 V. 
 7% 10% 15% stacking 
ddH2O 12.5 ml 10.1 ml 6 ml 12 ml 
Acrylamide (30%) 6 ml 8.4 ml 12.5 ml 3 ml 
5 x gel buffer 6.5 ml 6.5 ml 6.5 ml 5 ml 
10% APS 150 µl 150 µl 150 µl 150 µl 
TEMED 30 µl 30 µl 30 µl 30 µl 
  
Table 2.1: SDS-PAGE gel recipes: Ammonium Persulphate (APS) and 
Tetramethylethylenediamine (TEMED) were added last to facilitate 
polymerisation. Resolving Gel Buffer: 1.5 M Tris/HCl (pH 8.8) containing 0.4% 
SDS. Stacking Buffer: 0.5M Tris/HCl (pH 6.8) containing 0.4% SDS. 
 




2.4.3 Western Blotting 
Following electrophoresis, proteins were transferred to Nitrocellulose at 100V for 
60 minutes. Membranes were then washed in TBST (Tris-buffered Saline 
containing 0.1% Tween-20) and blocked with TBSMT (TBST containing 5% (w/v) 
MarvelTM) for 30 minutes. After a brief wash with TBST membranes were 
incubated in primary antibody overnight at 4ºC (Table 4.2). The next day 
membranes were washed twice for 10 minutes then incubated with the appropriate 
HRP-conjugated secondary antibody (NEB, Nottingham UK for 1 h. The 
membrane was again washed twice in TBSMT followed by two further washes in 
TBST before being developed with enhanced chemiluminescence (ECL). 
Membranes were visualised either by X-ray film or by using the ChemiDoc 
Imaging System (BioRad).   
Antibody Source Species Dilution 
NRF2 (c-20) Santa Cruz Rabbit  1:200 
NRF2 (16396-1-AP) Proteintech Rabbit 1:1,000 
NRF2 (ab62352) Abcam Rabbit (mAb) 1:2,000 
NRF2  (D1Z9C) CST Rabbit (mAb) 1:100 (ChIP) 
KEAP1 (10503-2 AP) Proteintech Rabbit 1:1,000 
HO-1 (ab13248) Abcam Mouse (mAb) 1:1,000 
NQO1 (ab80588) Abcam Rabbit 1:10,000 
Cas9 CST Mouse (mAb) 1:5,000 
B-actin (A53-16) Sigma Mouse (mAb) 1:5,000 
Anti-mouse HRP CST Horse 1:2,000 
Anti-rabbit HRP  CST Goat 1:2,000 
Anti-goat HRP conjugate Santa Cruz Donkey 1:2,000 
 
Table 2.2: Antibody sources and dilutions used for Western blotting or CHiP 
CST- Cell Signaling Technology 
 




2.4.4 Chromatin immunoprecipitation assay (CHiP) 
CHiP was performed using the Simple CHiP Enzymatic Chromatin 
Immunoprecipitation (IP) kit according to the manufacturer’s protocol (Cell 
Signaling Technology (CST)). Briefly, 4 x 106 cells were plated in 15 cm dishes 
and grown till ~90% confluent. Following treatments, cells were first fixed with 
Formaldehyde and then lysed using micrococcal nuclease. Chromatin was then 
sheered by probe sonication and the cross-linked DNA immunoprecipitated with an 
NRF2 antibody (CST). Positive (Histone H3) and negative (control IgG) were 
included as control IPs. IPs were performed overnight at 4°C using magnetic 
Protein-G Sepharose beads (CST). The next day following a washing step, the 
cross-linking was reversed and bound DNA purified. qPCR was then carried out to 
quantify the “input DNA” and results were presented relative to the control. The 
primers used for qPCR are shown in the table below (Table 2.3). 
 
 5'-3'  oligos for ChIP analysis 
miRNA Forward Primer Reverse Primer 
miR-125B1 
ARE1 ATGTTTCCAAACCAGGCTGA CTAACACTGCAGGCTCACCA 
miR-125B1 
ARE2 CAGAGCCAGCTGTCAATGAA CCAGAATGGGAGAAATGGAG 
miR-125B1 
ARE3 GTTGAGGCCTCTCCAGTGTC GCCACCAAAAATGAAAGGAA 
miR-29B1 
ARE4 TCAAGGTGCAGGATCTTTCC GTCTACCTTGGATGGCCTCA 
miR-29B1 
ARE5 CACATCTGGGCAACATCATC CTCCAAGGGGGTGTCCTTAT 
 
Table 2.3: qPCR primers used for ChIP analysis on the ARE sites 
 




2.4.5 Luciferase Reporter Assay 
A 2.6 kb fragment of the miR-125B1 promoter (which included the ARE3 site) was 
cloned into the pGL4.11 promoter/reporter plasmid. Briefly, we designed primers 
(Forward: 5′ AGAAAGGCCACCAAGATTCAC 3′ and Reverse:                                                 
5′ TGAGAGGAGCGCAACAATG 3′) and cloned a 2.6 kb fragment to create 
ppGL4.11 p125b.  Both pGL4.11 (Empty vector) and the p125b were transfected 
into THP-1 cells using Diethylaminoethyl (DEAE) dextran. Cells were incubated 
for 48 hours then washed in PBS and lysed with passive lysis buffer (Promega). 
Lysates were treated with LARII and “Stop and Glo” reagent, before luminescence 
measurements for FireFly and Renilla were taken using the plate reader, FLUOstar 
Omega Microplate Reader (BMG Labtech, Germany). 
   
2.4.6 Site Directed Mutagenesis 
The ARE site in the miR-125b1 promoter was mutated using the QuikChangeXL 
kit (Agilent) according to the manufacturer’s instructions. Briefly, a primer 
containing the required point mutations was designed, 5′-
GCTGTGGCTGtTTTGTtATTCTCTTTGACTAG-3′, and used to mutate the wild-
type pGL4.11 125b plasmid. The non-mutated plasmid was digested with Dpn1 
before the mutated nicked plasmid was transformed into E.coli XL10 Gold cells 
and plated onto agar plates containing ampicillin (100 µg/ml). The following day 
colonies were picked and DNA was extracted using the miniprep protocol (see 
Section 2.5.5). The mutated plasmid was sequenced prior to transfection into THP-
1 cells. 
 




2.5 Molecular Biology Techniques 
2.5.1 Plasmids 
All plasmids were from AddGene (Boston, USA) or constructed and a kind gift 
from Dr Nicholas Harper (University of Liverpool, UK), unless otherwise 
indicated. 
 
2.5.2 Bacterial strains and Culture conditions 
NEB “Stable” E.coli (New England Biolabs) were used for all manipulation as its 
RecA-  phenotype making it particularly suitable for cloning repeated sequences 
(such as the 3’ and 5’ Lentiviral repeats). 
 
2.5.3 Preparation of Competent Cells 
Competent cells were generated using the Mix and go E.coli transformation kit 
(Zymo Research, Cambridge Bioscience).  A 5 ml culture of SOB medium (10% 
Tryptone, 5% Yeast Extract, 1 mM MgCl2, 1 mM MgSO4 and 0.5 mM KCl) was 
inoculated and grown overnight without antibiotics. The following day 500 µl of 
this culture was used to inoculate a 50 ml culture of SOB in a 500 ml Erlenmeyer 
Flask. Bacteria were grown at 26°C with shaking until the Optical Density (OD) 
600 nm was between 0.4 and 0.6. The cells were rapidly chilled on ice and 
processed according to the Manufacturer’s instructions. Competent E.coli were 
aliquoted and stored at-80°C until required. 
 




2.5.4 Transformation of E.coli 
Plasmid DNA was added to an aliquot of competent E.coli and incubated on ice for 
20 minutes. Bacteria were then subjected to heat-shock (42°C, 1 minute) and 
allowed to recover on ice for 5 minutes. 350 µl of SOC medium (SOB including 
1% glucose) was then added and the cells grown at 37°C with shaking for 1 hour. 
The transformation was then plated onto a Luria Broth (LB)-Agar plate containing 
the required antibiotic for colony selection. Plates were then incubated overnight at 
37°C. 
 
2.5.5 Isolation of Plasmid DNA 
DNA Mini-prep was carried out using the Qia-Quick Mini-Prep kit (Qiagen) 
according to the manufacturer’s instructions. Briefly, 4 ml of an overnight bacterial 
culture was pelleted and re-suspended in Buffer P1. Cells were then lysed in Buffer 
P2, and proteins and genomic DNA precipitated with Buffer N3. Precipitated was 
removed by centrifugation and the supernatants added to the provided spin 
columns. Columns were washed sequentially with Buffers PB and PE and finally 
plasmid DNA eluted with DNase/RNase-free water. 
 
MAXI-Preps were performed using the PureLink HiPure Plasmid Filter Maxiprep 
Kit (Invitrogen, ThermoFisher Scientific) were used when larger amounts of 
plasmids were required. 1 ml of bacteria from a 5 ml starter culture was used to 
inoculate a 200 ml LB culture (containing the relevant antibiotic) and shaken 
overnight at 37°C. The culture was pelleted then resuspended in Buffer R3 
(containing RNaseA), lysed with L7, and protein/genomic DNA precipitated with 




Buffer N3. The precipitate was removed by filtration and supernatant applied to the 
provided maxiprep columns (which has been pre-equilibrated). The columns were 
washed in buffer W8, before DNA eluted using Buffer E4. DNA was precipitated 
using Isopropanol and at this stage was stored at -20ºC overnight (to aid 
precipitation). DNA was pelleted by centrifuging out the isopropanol solvent at 




2.5.6 DNA Electrophoresis - Agarose and PAGE 
Agarose (Invitrogen, ThermoFisher Scientific) powder was weighed out and mixed 
with 1 x TAE buffer (40 mM TRIS, 20 mM acetic acid and 1 mM EDTA), the exact 
percentage of agarose used is dependent on the PCR product size tested. Ethidium 
bromide (EtBr) was added to the molten gel before pouring into the gel tank, EtBr 
is a DNA intercalator which fluoresces when exposed to UV light. The DNA was 
run at 135 V until sufficient separation of was seen. Separation was initially judged 
by the running of the loading dye, then visualised through exposure to UV light. 
 
Polyacrylamide gel electrophoresis (PAGE) was carried out to determine the size 
of an DNA product with higher resolution than agarose gels. The PAGE gels were 
set up (10 ml 30% acrylamide, 12.5 ml 2 x TAE, 2.5 ml H20, 150 µl APS, and 30 
µl TEMED) and 1.5 mm 10-well combs were used. DNA samples were separated 
on the gel for 90 minutes at 135 V. After running, the gels were post-stained with 
EtBr and visualised through exposure to UV light.  




2.5.7 Cloning of DNA 
The DNA sequence for the region of interest was identified from the NCBI database 
(https://www.ncbi.nlm.nih.gov/nucleotide/) and flanking primers designed 
(Integrated DNA Technologies, Leuven Belgium). Primers were made up to the 
working concentration of 10 µM. The region of DNA was amplified by polymerase 
chain reaction technique. 
 
2.5.8 Polymerase chain reaction (PCR) 
PCR conditions varied depending on the experiment, with conditions such as 
annealing temperature changing based on predicted product size and/or the G:C 
ratio of the fragment being cloned. The two polymerases most commonly used in 
this thesis are OneTaq and Phusion High Fidelity Polymerase (NEB). Below (Table 
2.4) is a typical PCR reaction with OneTaq and Phusion. 
 
Polymerase One Taq Phusion 
Buffer 5 µl (2x) 10 µl (5x) 
H2O 2 µl 31 µl 
dNTPs (10 µM) N/A 1 µl 
Forward and Reverse primer mix (10 µM) 0.5 µl 5 µl 
DNA (250 ng) 2 µl 2 µl 
Polymerase n/a 1 µl 
 
Table 2.4: Example of typical PCR reaction with One Taq or Phusion 
 
2.5.9 Restriction Digestion of Plasmid DNA 
Restriction enzymes were used to digest either the Plasmid DNA or the amplified 
DNA fragment (dubbed the “insert”). Plasmid maps were used to determine 
restriction enzyme sites. 5 µg of plasmid was digested with the appropriate enzyme. 




See Table 2.5 below for a typical digest. Control samples were also made up 
omitting the restriction enzyme (thus no DNA cleavage). Samples were incubated 
for four hours at 37°C, before being either gel extracted or PCR purified using the 
Wizard SV Gel and PCR Clean-up system (Promega).  
 
Component  
Plasmid 5 µg 
CutSmart (10 x) 8 µl 
Restriction Enzyme 2 µl (per enzyme) 
H2O up to 80 µl 
 
Table 2.5: Example of a typical Restriction Digest 
 
2.5.10 Ligation of digested DNA fragments 
Ligation reactions were set up as detailed in the table below in 0.5ml 
microcentrifuge tubes as (Table 2.6). Reactions were incubated at 4°C overnight, 
before being used for transformation (see Section 2.5.4) 
 
Component Vector + Ligase V:I (1:2) V:I (1:4) 
Vector 25 ng 25 ng 25 ng 
Insert n/a 100 ng 200 ng 
T4 DNA ligase 0.5 µl 0.5 µl 0.5 µl 
10x ligase buffer 1 µl 1 µl 1 µl 
H2O to 10µl to 10 µl to 10 µl 
 
Table 2.6: Example of a typical ligation reaction 
Vector and Insert was incubated at a ratio of 1:2 and 1:4 
 




2.5.11 Colony PCR 
Colony PCR was used to check correct insertion of ligated DNA fragments. 
Bacterial colonies were picked and a PCR screen was carried out (following the 
OneTaq polymerase protocol and using a vector and insert-specific primer pair). 
Positive clones were marked and used to inoculate overnight cultures. 
 
2.5.12 Transfection of DNA into Mammalian Cells 
With adherent cells, DNA was transfected into cells using JetPei (Polyplus 
Transfection). Essentially 3.5 × 105 HEK-293 or 5 x 105 HCT-116 cells were seeded 
into a six-well plate. The following day following the manufacturer protocol, 100 
µl of 150 mM NaCl was mixed with 4 µl of JetPei. Separately 100 µl of NaCl was 
mixed with between 1-2 µg of plasmid DNA. The NaCl/JetPei mix was then added 
to the NaCl/DNA, vortexed and incubated at room temperature for 20 minutes. 
DNA/JetPEI complexes were then added to the cells dropwise and cells incubated 
at 37°C for 72 hours. An eGFP control plasmid was included to ensure the 
transfection has been performed correctly. 
 
2.5.13 Transfection of siRNA 
Suspension cells were centrifuged, washed in serum-free RPMI media and 
resuspended at a density of 1 × 106 cells/ml. 100 µl of cells were then aliquoted into 
1.5 ml microcentrifuge cells and siRNA was added (the concentration of siRNA 
was varied depending on the experiment). The cell/siRNA mix was transferred to 
an electroporation cuvette (Lonza) and electroporated (Program T-001) in an 
Amaxa Nucleofector II (Lonza, Cambridge U.K). Following electroporation, the 




cells were mixed with complete RPMI media, seeded into a six-well plate and 
incubated for 72 hours before analysis. 
 
2.5.14 Isolation of Genomic DNA 
Cells were either scraped (adherent) or thoroughly mixed (suspension) and 
transferred to a 1.5 ml microcentrifuge tube. Cells were then pelleted and washed 
in PBS. Cells were then resuspended in 300 µl of “tail” lysis buffer (50 mM 
Tris/HCL (pH 7.5), 150 mM NaCl, 1 mM EDTA and 0.2% SDS) containing 20 
mg/ml proteinase-K and 50 mg/ml RNaseA. 
Cells were then left to digest overnight at 55°C. The following day the proteinase-
K was inactivated at 95°C for 10 minutes then left on ice to cool for 5 minutes. 
DNA was precipitated by the addition of 400 µl of isopropanol and glycogen (1 µl 
of a 100 mg/ml stock). Tubes were incubated on ice for up to 30 minutes before the 
DNA pelleted by centrifugation at 20,000 x g for 1 h. The pellet was then washed 
in 70% ethanol before being resuspended in DNase/RNase-free water. Samples 
were then incubated at 55°C to allow for resuspension of DNA and quantified by 
nanodrop. 
 
2.6 Real-time PCR 
2.6.1 RNA extraction 
RNA extraction was carried out using the RNeasy Mini Kit (Qiagen). We followed 
the manufacturer protocol but essentially cells were pelleted in 1.5 ml 
microcentrifuge tubes and washed in PBS. Cells were lysed in RLT buffer using 
the included QiaShredder columns. 70% ethanol was added to the lysate which was 




then applied to an RNeasy Spin Column. The column was washed with the buffers 
RW1 and RPE. After which the empty spin column was centrifuged to remove any 
traces of ethanol before being eluted using 50 µl DNase/RNase-free water. The 
concentration of the extracted RNA was determined by nanodrop. 
 
2.6.2 Reverse Transcription 
RNA was converted to cDNA using the iSCRIPT Select cDNA Synthesis Kit 
(BioRad). The amount of RNA used in the reverse transcription (RT) was 
dependent on the individual experiment, but generally 100-200ng of DNA was 
added to each RT reaction. A typical RT reaction can be seen below (Table 2.7). 
 
Component   
RNA (100-200 ng) (100-200 ng) 
5 x iScript select reaction mix 4 µl 
Oligo dT 1 µl 
Random Hexamers 1 µl 
iSCRIPT Reverse Transcriptase 1 µl 
DNase/RNase-free water to 20 µl 
 
Table 2.7: Example of a typical Reverse Transcription reaction using iSCRIPT 
 
Once the above reaction was set up, the samples were incubated for 5 minutes at 
25°C (required for Random Hexamer cDNA synthesis), 90 minutes at 42°C 
(required for Oligo-dT cDNA synthesis), and finally 5 minutes at 85°C (to 
inactivate the reverse transcriptase). 
  




2.6.3 Quantitative real time-PCR (qPCR) 
qPCR was used to quantify gene expression in cells. cDNA was diluted 1:10 to 
make up the working solution for qPCR. A typical qPCR reaction is shown below 
(Table 2.8). 
Component  Amount 
2 x SYBR Green Mix (Roche) 10 µl 
Forward and Reverse primers (10 µM) 1 µl 
DNase/RNase-free water to 20 µl 
cDNA 5 µl 
 
Table 2.8: Example of a typical 20µl qPCR reaction using SYBR Green 
 
Short Spanning Forward and Reverse primers were designed to flank the genomic 
regions of interest (see table 2.8). Reactions were set up as in the table above and 
plated into white-walled 96-well plates (Roche). Plates were then sealed with PCR 
sealing foil (Roche) and briefly spun. qPCR was performed using the LightCycler 
480 (Roche) and used the SYBR Green qPCR protocol. SYBR Green binds to 
double stranded DNA and emits fluorescence at 520 nm. Therefore, as PCR cycles 
increase so does the fluorescence (known as acquisition). 
 
The qPCR protocol was carried out as follows, initial denaturation (95°C, 2 
minutes), then followed 45 amplification cycles of 95°C (denaturing), 60°C 
(annealing) and 72°C (extension) for 10 seconds each stage. Acquisition was taken 
at each cycle end. Once the PCR was complete, the samples were heated to 97°C, 
with the acquisition every 0.5°C, the aim here was to observe the temperature that 
the PCR products denature (known as the melt curve analysis). The presence of a 
single peak on the melt curve indicates a single PCR product has been amplified. 




GAPDH was used as an internal control/housekeeping gene for mRNA and SnU6B 
as an internal control for miRNA. To generate the threshold cycle (CT) value, a 
threshold is set at the point where the PCR products have reached amplification. 
The cycle number where the individual PCR products have reached this threshold 
is noted as the CT value. The qPCR results are analysed using the change in CT 
(∆CT) method. Essentially the CT values of the samples were subtracted from the 
CT values of GAPDH (∆CT). ∆CT values were then subtracted from the 
experimental control and the fold change was calculated.       
  
2.7 Lentivirus 
2.7.1 Lentiviral vectors 
A 3rd generation lentivirus system was used composing of pCMV-VSVG, pMDLG 
and pRSV-Rev as packaging plasmids. Gene of interest (GOI) plasmids included a 
modified LentiCRISPR plasmid containing an SFFV promoter, pLJM1 and 
pLeGO. All plasmids were obtained from AddGene, Boston USA.  
 
2.7.2 Production of lentivirus 
4 x 107 HEK-293T cells were plated into 10 cm3 dishes and allowed to adhere 
overnight. Lentiviral plasmids were then transfected into the cells using JetPei. 
Essentially 200 µl of 50 mM NaCl and 20 µl of JetPei (1 mg/ml) were mixed. 
Separately 2 µg of each packaging vector (pRev, pMDLG, and pVSVG) and 4 µg 
of a GOI plasmid was diluted in another 200 µl of NaCl. The NaCl/JetPei mix was 
added to the NaCl/DNA followed by vigorous vortex mixing. Following incubation 
for 20 minutes at room temperature the DNA/PEI complex was added to the cells. 




24 hours after transfection, the media was changed and 72 hours post-transfection, 
the media (containing the viral particles) was removed, cleared using a 0.45 µm 
filter and concentrated in an SW40Ti rotor at 110,000 x g for 2 hours. The 
supernatant was then removed and the pellet air dried then resuspended in 200 µl 
OptiMEM (ThermoFisher Scientific) 
 
2.7.3 Transduction with Lentivirus  
Six-well plates were set up with either adherent or suspension cells. Polybrene (4 
µg/ml) and 20 µl of concentrated virus was added to each well and the cells were 
spinoculated for one hour at 400 x g, then incubated. 24 h after the transduction, 
medium was replaced and cells incubated for a further 48 h after which they were 
either genotyped or passaged on for selection. 
 
2.8 miRNA techniques 
2.8.1 miRNA extraction 
miRNAs were extracted and purified using the miRvana miRNA isolation kit 
(miRvana, ThermoFisher Scientific). The kit uses a mixture of both solid phase and 
organic extraction. Briefly, the cells are lysed and RNA is purified using an acidic 
phenol/chloroform solution. Total RNA is precipitated using ethanol (1.25 × 
volumes) and purified on the supplied spin-columns. To extract enriched small 
RNA (siRNA or miRNA) ethanol was added (1/3rd volume) and spun through a 
second column. After-which the column is washed again with ethanol (2/3rds 
volume), and washed several times using a wash buffer. Finally, small RNA are 




eluted. Quantification of both total and small RNA was carried out using the 
nanodrop.  
2.8.2 miRNA Reverse Transcription and real time PCR (miRNA) 
Reverse transcription was carried out using the miScript kit (Qiagen). The 
proprietary 5× HighFlex buffer was used along with the extracted RNA and a 
reverse transcriptase. miRNA were first polyadenylated (using polyA polymerase) 
before being converted to cDNA using an oligo dT primer. RNA was incubated for 
60 minutes at 37°C, before being heated up to 90°C for 5 minutes (to inactivate the 
reverse transcriptase). The RNA was diluted for use in qPCR. 
 
2.8.3 miR-mimics and antagomir 
miRNA levels were manipulated using miRNA mimics and antagomirs. In 
haematopoetic cells (such as THP-1s), the same protocol was followed as siRNA 
transfection as described in Section 2.5.13. The miRNA mimic/antagomir was 
transfected using the Amaxa nucleofector and cells incubated for 48-72 h before 
harvesting. 
2.8.4 Designing miRNA primers 
Real-time PCR primers for mature miRNA were designed using the mature 
sequence of miRNA with a universal reverse primer. The immature miRNA primers 
were designed using the DNA sequence for the miRNA being tested and sequences 
flanking the miRNA, these primer sequences were subjected to BLAST (NCBI) 
analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure specificity. 
 




2.9 qPCR primers 
Gene Forward Primer Reverse Primer 
GAPDH GAPDH was purchased from Qiagen 
NRF2 TGATTCTGACTCCGGCATTT GCCAAGTAGTGTGTCTCCATAG 
HO-1 TCTTGGCTGGCTTCCTTAC CATAGGCTCCTTCCTCCTTTC 
NQO1 GGGATGAGACACCACTGTATTT TCTCCTCATCCTGTACCTCTTT 
KEAP1 TGTCCTCAATCGTCTCCTTTATG CTCGTTCCTCTCTGGGTAGTA 
MYBL2 CACACTGCCCAAGTCTCTATC GAGCAAGCTGTTGTCTTCTTTG 
AKT2 AGTGGCTCATGCCTGTAATC GATGAAGGTCTCCCTATGATGC 
CXXC6 CCAGAGATTCCTGGTGCTATTC GGACAACACTCCCACTCATAC 
Dnmt1 CGGCCTCATCGAGAAGAATATC TGCCATTAACACCACCTTCA 
TGFβ CCTGCCTGTCTGCACTATTC TGCCCAAGGTGCTCAATAAA 
PIK3R1 GCTTTGCCGAGCCCTATAA ACATTGAGGGAGTCGTTGTG 
CDK4 ATGTGGAGTGTTGGCTGTATC CAGCCCAATCAGGTCAAAGA 
SP1 GATGTGTGGGCTTCTGAGTTTA ACTGGCTGATGCTCCTTATTG 
CBFB CACAGGAACCAATCTGTCTCTC CCTTGCCTGCTTCTCTTTCT 
KLF13 GTCTGGGAGAGAGAGTGGAATA TTTGGAACTGGGCATGAAGA 
ABTB1 ACAGTGACGTGGTCTTTGTAG ACACTCTTGCCCTTCCATTT 
MAPK14 GGCCAAGGTGTTTCCATTTC CCTTCCTTCTTGCTCCAGTT 
STAT3 GAGAAGGACATCAGCGGTAAG CAGTGGAGACACCAGGATATTG 
CDK6 CTAGCAACCATCCCTCCATTAC CTCAGAGCATTCTGAAGACAGTA 
BCL2 GGCCAGGGTCAGAGTTAAATAG GGAGGTTCTCAGATGTTCTTCTC 
MCL1 GTGAAGATGGTAGGGTGGAAAG TCGGCGGGTAATCAATTCTATG 
BAK1 AGGGCTTAGGACTTGGTTTG GGGATTCCTAGTGGTGTTGATAG 
 
Table 2.9 Primer sequences used for qPCR. All primers (except GAPDH) were 
designed and purchased from Integrated DNA Technologies (www.idtdna.com). 
 
2.9 Statistical analysis  
Statistical analysis was carried out using Microsoft Excel or GraphPad Prism 6. 
Densitometry was performed using Image J. Further details on the precise statistical 
tests used can be found in the results section for the individual experiments       








Chapter 3  
 
Regulation of miRNAs by NRF2 
  




3. 1 Introduction 
Acute Myeloid Leukaemia (AML) is underpinned by a myriad of genetic 
abnormalities found predominantly in myeloid progenitor cells. Despite the 
heterogeneous nature of this disorder, the existence of shared signalling 
abnormalities between subtypes is highly likely (Kvinlaug et al., 2011). 
 
Our lab has previously worked on the transcription factor NRF2, the master 
regulator of the antioxidant response mechanism which protects cells from reactive 
oxygen species through the regulation of cytoprotective genes such as HO-1, NQO1 
and GCLM (Alam et al., 1999, Venugopal and Jaiswal, 1996, Zipper and Mulcahy, 
2000). This mechanism can be hijacked in a range of malignancies (for example 
breast, lung and liver cancer), resulting in resistance to chemotherapy. (Solis et al., 
2010, Yoo et al., 2012, Nioi and Nguyen, 2007). Furthermore, recent studies have 
demonstrated that aberrant NRF2 signalling often results in malignant cells 
becoming more tumorigenic, displaying increased proliferation and resistance to 
apoptosis (Zhang et al., 2010).  This dysregulation in signalling predominately 
occurs due to somatic mutations in either NRF2 or its inhibitor KEAP1. These 
mutations usually prevent NRF2-KEAP1 binding allowing NRF2 to freely enter the 
nucleus and leads to cells having higher basal NRF2 activity (Sporn and Liby, 2012, 
Shah et al., 2013). 
 
We have previously shown the presence of elevated levels of NRF2 in AML, and 
this results in resistance to commonly used chemotherapy agents in both AML cell 
lines and primary patient samples (Rushworth et al., 2011b). Interestingly in AML, 




unlike solid tumours, we identified aberrant NRF2 signalling was not due to a 
mutations in NRF2 or KEAP1 but instead as a result of upstream signalling 
pathways, in particular NF-κB (Rushworth et al., 2012). 
 
miRNAs are short non- coding RNA molecules (approximately 20-30 bp) that bind 
and repress their target mRNA. Under normal conditions they play a crucial role in 
regulating various cellular processes, under pathological conditions, however, 
tumour cells can hijack their normal physiological roles leading to the terms 
OncomiR and Tumour Suppressor miR (Hwang and Mendell, 2006). OncomiRs are 
miRNAs traditionally elevated in cancer cells that target and repress tumour 
suppressor genes. Tumour suppressor miRs target oncogenes and are traditionally 
downregulated in cancer cells (Svoronos et al., 2016). Studies looking at global 
miRNA expression have not only shown changes between different cancers, but 
significant variation can be detected within subsets of the same malignancy (Lu et 
al., 2005, Marcucci et al., 2009). Theoretically these miRNAs can regulate a 
plethora of mRNA targets, however the exact mRNA target being regulated, and 
the cellular effect of miRNA expression, often varies between different tissues. 
 
3.1.1 Aims/Rational 
Our previous work has indicated that NRF2 potentially plays a greater role in AML 
than just the regulation of antioxidant genes. We therefore wished to investigate the 
ability of NRF2 to regulate miRNA and further explore the significance of these 
NRF2 regulated miRNA in primary AML samples. 
 




3.2 Results  
3.2.1 miRNA array methodology 
To establish whether NRF2 plays a role in modulating miRNA in AML we used 
miRNA expression profiling. A real-time PCR-based miRNA array consisting of 
primers to detect 93 miRNAs commonly dysregulated in cancer was designed (Fig 
3.1A). miRNA profiling was then performed by qPCR on RNA extracted from 
THP-1 and HL60 AML cell lines following treatment with the NRF2 activator 
sulforaphane. 
 
Figure 3.1: miRNA Screening Array Schematic A) Schematic of a miRNA array 
based on commercially available SA Bioscience array consisting of probes to detect 
93 miRNA commonly dysregulated in cancers. B) Criteria for determining miRNA 




regulation by NRF2. Change in CT values following NRF2 knockdown plotted 
against control cells miRNA showing either a 1.5-fold increase or 0.2-fold decrease 
were chosen 
 
The CT values were plotted, and a standard curve was generated, this was used as 
a threshold determining which miRNA are positively or negatively regulated by 
NRF2 is shown in Fig 3.1B. The ∆CT values were plotted onto a scatter graph (after 
being subtracted from the internal control RNU6B). A trendline was plotted and 
any miRNA above the line was determined to have increased expression in response 
to elevated NRF2, miRNA below the line represent decreased expression. We were 
interested in any miRNAs which showed either a 1.5-fold increase or 0.2-fold 
decrease in CT values in response to both sulforaphane and the NRF2 lentiviral KD. 
Whilst these were arbitrary cut-off values, steps were taken to reduce false positives 
and negatives. Sulforaphane treatment was repeated in two AML cell lines, and 
these results were combined with that of the NRF2 KD. Only miRNAs which were 
consistently altered in all three conditions would be taken forward. Potential targets 
will be further confirmed by additional qPCR experiments 
 
3.2.2 Effect of NRF2 activation on miRNA expression array 
The effect of sulforaphane (5 µM) on the 93 cancer-related miRNAs in the array 
are shown in Fig 3.2. miRNAs were standardised against the control RNU6B (U6) 
with Sn25 also present as an additional control. For the purposes of this study we 
were interested in both miRNA that were positively and negatively regulated by 
increased levels of NRF2 in two AML cell lines, THP-1 and HL-60. In THP-1 cells 




sulforaphane-induced miRNA included the let-7 family, miR-7, miR-92a, miR-103,  
miR-107, miR-125a/b, miR-15a, miR-21, miR-25, miR-132, miR-181d, miR-185, 
miR-191, miR-192, miR-196a, miR-197 and miR-200a. Those with decreasing 
expression included miR-29b, miR-140, miR-193b and miR-200c (Fig 3.2A). To 
demonstrate activation of NRF2 by sulforaphane in these cells we analysed the 
expression of two NRF2 targets, HO-1 and NQO1. As expected we saw over a 12-
fold increase in HO-1 and over a 3-fold increase in NQO1 expression by 
sulforaphane indicating activation of NRF2 targeted gene products (Fig 3.2C). The 
increased expression of HO-1, compared to NQO1 in response to sulforaphane is 
in line with previous studies in our lab (Rushworth et al., 2008). 
 




Figure 3.2: Effect of Sulforaphane on miRNA expression in AML cells Nrf2 
was induced using 5uM Sulforaphane in THP-1 and HL-60 cells and miRNA 
signature was detected using qPCR. Delta CT values were calculated by subtracting 
the CT values for RNU6B from the CT values post Sulforaphane treatment, these 
are shown in the graphs. A) qPCR array in THP-1 cells. B) qPCR array in HL-60 
cells. C) THP-1 cells treated with 5μM of Sulforaphane and mRNA levels of Nrf2 
targets HO-1 and NQO1 were measured by qPCR. GAPDH was used as an internal 
control. Statistical significance was determined by a student’s t-test (p=0.05). 
 
In HL-60s there were increases in the let-7 family, miR-103, miR-125a, miR-125b, 
miR-15a, miR-17, miR-17*, miR-191, miR-195, miR-196a, miR-197, miR-95, 
miR-200b, miR-210, miR-222, miR-223, miR-23a, miR-24, miR-28, and miR-301. 
We saw a decrease in miR-21, miR-26b, miR-26b, miR-377, and miR-29b (Fig 
3.2B). 
 
Taken together this data shows that the NRF2 activator sulforaphane can induce or 
decrease several miRNA and NRF2 target genes in AML cell lines.  
 
3.2.3 miRNA profile following NRF2 knockdown 
While sulforaphane is known as a potent activator of NRF2, it also activates ERK, 
AKT and other pathways that interact with the NRF2 signalling pathway, such as 
NFκB (Negi et al., 2011). To demonstrate the miRNA changes observed were a 
direct result of its effects on NRF2 and not on any of these other pathways, we used 
a lentiviral NRF2 miRNA knockdown construct to reduce NRF2 levels. To 




specifically increase NRF2 levels we used a viral construct that would knockdown 
the NRF2 inhibitor KEAP1. THP1 cells were transduced at 5 x 104 cells for 72 
hours after which knockdown was confirmed by Western blot (Fig 3.3A). Basal 
levels of NRF2 were low in these cells however we saw a decrease in protein levels 
following NRF2 miRNA Lentiviral transduction. We saw an increase in NRF2 
levels post transduction with an KEAP1 miRNA Lentivirus. As shown in Fig 3.3B, 
in response to the NRF2 KD, we identified 29 miRNA that showed greater than 
0.2-fold decrease in expression, including miR-125b, miR-200b, miR-221, mR-
15b, miR-30a, miR-200c, miR-18a, miR-27a/b, miR-195, miR-196, miR-141 and 
miR-34a.  We also identified several miRNAs which increased in expression (by at 
least 1.5-fold) as a result of the NRF2 KD, these included miR-29a/b, miR-93, miR-
132, miR-146a, miR-154, miR-181b, miR-200a, miR-202, and miR-372. 
 
Figure 3.3:  miRNA expression changes following NRF2 knockdown THP-1 
cells were transduced with a lentivirus to knockdown NRF2. and miRNA signature 
detected using qPCR. A) NRF2, KEAP1 and β-actin protein levels were detected 
by Western Blot post NRF2 or KEAP1 lentiviral knockdown. B) qPCR miRNA 




array carried out in THP-1 cells post NRF2 lentiviral knockdown. ∆CT values were 
plotted on a scatter graph and calculated by subtracting the control miRNA RNU6B 
from the CT value. 
 
Overall, this data provides a more specific assessment of the miRNAs modulated 
by NRF2 in the AML cell line THP-1. Taken together with the sulforaphane data, 
there does seem to be a change in the expression of a subset of miRNA in response 
to NRF2 modulation. 
3.2.4 Analysis of miRNA array data: identification of NRF2-regulated 
miRNAs  
To identify just the NRF2-regulated miRNAs, we combined the results of miRNA 
profiling obtained following sulforaphane treatment and NRF2 KD (Fig 3.3). We 
were particularly interested in miRNA which showed a 0.2-fold decrease or a 1.5-
fold increase in NRF2 expression. We also ensured the miRNAs chosen were 
responding to NRF2 modulation, ie higher expression with increased NRF2 and 
lower expression with the NRF2 KD or vice versa. We also took into consideration 
the individual CT values and melt curves from the qPCR. SYBR Green can only 
bind to double stranded DNA, thus its fluorescence increases through successive 
PCR cycles. As the amplicon is heated to 95°C, the DNA denatures (the exact 
temperature depending on the constituent nucleotides) creating a decrease in 
fluorescence. Generally, if a single PCR amplicon is present, then a single 
denaturing peak will be observed. We identified several miRNAs that met our 
criteria including miR-125a, miR-125b, miR-221, miR-222, miR-223, miR-29b, 




miR-154, miR-15a, miR-17, miR-191, miR-195, miR-196, miR-197, miR-200b, 
miR-210, let-7-a1, and miR-103. 
 
3.2.5 Identification of NRF2-regulated miRNA promoters using 
bioinformatics 
Having identified a correlation between NRF2 and specific miRNAs, we now 
wished to investigate whether NRF2 was directly regulating these miRNA through 
ARE elements within the miRNA promoter regions. We used public databases such 
as NCBI to identify nucleotide sequences 5000 bp upstream and downstream from 
the miRNA start sequence. While we were primarily interested in putative binding 
sites in the 5’ promoter regions near the miRNA start sequence, we were also aware 
that in certain circumstances transcription factors are known to regulate 
mRNA/miRNA at a large distance from the consensual promoter site (known as 
distal regulatory regulation) (Maston et al., 2006). A transcription factor binding 
programme-P-match (http://gene-regulation.com/cgi-  
bin/pub/programs/pmatch/bin/p-match.cgi), was used to identify consensual ARE 
motifs. P-match uses the Transfec database (in particular its weight matrix) as well 
as pattern recognition (Chekmenev et al., 2005). 
 
Consensus ARE sites were identified with a 95% match. These sites were also 
compared against the ENCODE database (https://genome.ucsc.edu/encode/) in 
particular, transcription factor binding “hotspots” were focused on, as well as 
typical Pol2 sites within the vicinity of these miRNAs. We were also interested in 




areas with high methylation. A schematic of the putative ARE binding sites is 
shown in Fig 3.4. 
 
Figure 3.4: Schematic of miRNA promoter regions with putative NRF2 ARE 
binding sites. Putative ARE sites were identified using the transcription factor 
binding program p-match. Binding sites identified 5000bp 5’ and 3’ to the miRNA 








3.2.6 Validation of putative NRF2-regulated miRNA 
We next wished to further validate several of the miRNAs identified using the array. 
As discussed above sulforaphane is not a specific NRF2 activator, therefore, in 
order to specifically implicate NRF2 in the regulation of these miRNAs we also 
created a lentiviral-mediated KD construct for the NRF2 inhibitor KEAP1. 
Reduction of KEAP-1 leads to the direct upregulation of NRF2 in cells (Zhang and 
Hannink, 2003).  
THP-1 cells transduced with the KEAP-1 KD showed significant increases in miR-
125b, miR-221, miR-222 and miR-223 levels and this was accompanied by a 
decrease in miR-29b expression. As before, reduction in NRF2 resulted in a 
significant decrease in miR-125b and an increase in miR-29b expression (Fig 3.5). 
Although there was a slight decrease in expression of other miRNAs, such as in 
miR-221 and miR-222, but this was not found to be statistically significant. 
 
mRNA expression for KEAP1, NRF2 and its target gene HO-1 were used as a 
negative and positive control respectively. As expected NRF2 KD in THP-1 cells 
resulted in a significant decrease in NRF2 and HO-1 expression but no change in 
KEAP-1 mRNA. Whereas the KEAP-1 KD resulted in a significant increase in HO-
1 expression (around 3-fold) and as expected a decrease in KEAP-1 expression. 
 
The KEAP1 KD showed a decrease in KEAP1 protein levels, and a slight increase 
(0.6 fold) of NRF2 levels.  This indicated that while a KEAP1 KD does not increase 
NRF2 on a mRNA level, it does seem to increase the amount of NRF2 protein 
possibly by preventing its Cul3 mediated ubiquitination and degradation and 




increasing the ability for NRF2 to translocate to the nucleus and regulate its target 
genes, as demonstrated by the strong increase in HO-1 at both the mRNA and 
protein levels. 
 
Figure 3.5: Confirmation of NRF2 dependent miRNA regulation miRNAs were 
measured by qPCR (miR-125b, miR-221, miR-222, miR-223, miR-29b, miR-154) 
along with HO-1, NRF2 and KEAP1. Student’s t-test carried out to determine 
statistical significance, * indicates P< 0.05 (n=3). 
 
3.2.7 Correlation between NRF2 and expression levels of miRs-125b and -29b 
in AML patient samples 
The qPCR data identified a correlation between NRF2 expression and levels of 
miR-125b and miR-29b (Fig 3.5). So far, all experiments were carried out in AML 
cell lines, while these provide a useful model to characterise the disease they have 
inherent limitations. For one, the cell lines are only representative of the specific 
AML subsets they represent. THP-1s for example are acute monocytic leukaemia 




(FAB M5), while HL-60 are acute promyelocytic leukaemia (FAB M2/3). AML is 
a heterogeneous disorder made up of a range of various cytogenetic abnormalities, 
each with different prognostic outlook and variable sensitivity to chemotherapy 
agents. 
 
We therefore wished to look at the regulation of these miRNAs in primary AML 
blasts extracted from the peripheral blood of AML patients. AML patient samples 
were characterised, by World Health Organisation (WHO) classification and 
cytogenetics (Table 3.1). The percentage of AML blasts present in each sample was 
also calculated. Samples used were from patients with a spectrum of cytogenetic 
and genetic disorders. CD34+ cells (n=8) were isolated from normal healthy 
volunteers to act as controls. 
 
Table 3.1: Characterisation of the 27 primary AML samples used in this study 
WHO and cytogenetics have been characterised, percentage of AML BLASTS were 
determined through Flow Cytometry. NRF2, miR-125b1 and miR-29b1 expression 
was determined by qPCR (relative to that in CD34+ cells). 




We first aimed to identify basal NRF2, miR-125b and miR-29b expression in AML 
blasts compared to the normal CD34+ cells. As previously shown in the AML cell 
lines, there is a significant increase in NRF2 mRNA and miR-125b expression, and 
a significant decrease in miR-29b in the AML blasts (Fig 3.6). We then compared 
the expression of total miR-125b or miR-29b levels with that of miR-125b1 or miR-
29b1 in primary AML Blasts. We found a similar expression in these miRNA 
paralogs in comparison to the total levels, perhaps indicating they are the subset 




Figure 3.6: Expression of miRNA in AML blasts compared to normal CD34+ 
cells RNA was extracted from AML patient blasts and CD34+ cells. Using qPCR 
NRF2 and total miR-125b/miR-125b1 and miR-29b/miR-29b1 levels were 
measured. 




Using Pearson correlation analysis, a significant positive correlation was seen 
between NRF2 mRNA and miR-125b expression and a negative correlation 
between NRF2 mRNA and mir-29b in the AML blasts (Fig 3.7A). Taken together 
these results confirm the results seen in the AML cell lines, suggesting that NRF2 
regulates miR-125b and miR-29b, possibly through binding to an ARE site in their 
respective promoter regions. 
 
To modulate NRF2 levels in the patient samples we transfected both a scrambled, 
and NRF2 targeting siRNA (Fig 3.7B). We found in general AML samples with a 
higher transfection efficiency (i.e. lower levels of NRF2), for example AML #25, 
also had lower levels of miR-125b1 and higher levels of miR-29b1. Likewise, AML 
samples with a lower transfection efficiency, such as AML #4 showed no change 
in miR-125b or 29b levels compared to cells treated with the control scrambled 
siRNA. 
 





Figure 3.7: miR-125b and miR-29b in primary AML NRF2 levels were 
measured by qPCR in primary AML blasts (n=18) and CD34+ cells (n=8) from 
healthy donors. A) Pearson’s correlation between NRF2 and miR-29b1/miR-125b1 












3.3 Conclusions and Discussion    
In this chapter, we aimed to show whether NRF2 could modulate miRNA 
expression in AML. We analysed 93 miRNA that had previously been associated 
with malignancies in AML cell lines and modulated NRF2 expression using the 
NRF2 activator sulforaphane or an NRF2 miRNA lentiviral knockdown in THP-1 
and HL60s. We identified several miRNAs (miR-125b, miR-29b, miR-221, miR-
222, miR-223 and miR-154) from the array that showed either a positive or negative 
correlation with NRF2 levels. Further, both lentiviral KEAP1 and NRF2 KD 
identified miR-125b and miR-29b as being positively and negatively regulated by 
NRF2. 
 
In primary AML cells, higher levels of NRF2 was identified in the AML blasts 
compared to the CD34+ cells. We also found a positive correlation between NRF2 
and miR-125b, and a negative correlation between NRF2 and miR-29b. To show 
NRF2 affects miR-29b and miR-125b levels, we modulated NRF2 levels in the 
AML blasts using either a control or NRF2 siRNA. Here we saw a trend between 
AML samples successfully transfected with NRF2 siRNA, and levels of miR-125b 
or miR-29b. Finally, we found the miRNA paralogs (miRNA sequence with the 
same core “seed” region but resides on another chromosome) miR-125b1 and miR-
29b1 showed similar expression to that of miR-125b or miR-29b suggesting they 
may be the subset dysregulated in AML. 
 
This study demonstrated that both AML cell lines and patient samples have high 
levels of NRF2 and miR-125b and low levels of miR-29b.  With regards to the high 




mRNA levels of NRF2 in the primary AML blasts (compared to the CD34+ cells), 
it must be remembered the patients these samples are derived from are likely 
undergoing chemotherapy treatment, which may explain the high NRF2 levels. 
However our lab has previously shown that NRF2 is constitutively active in a high 
proportion of AML samples than control CD34+ cells (Rushworth et al., 2012). 
 
Both miR-125b and miR-29b have been implicated in a range of cancers including 
AML. miR-125b is a known oncogene in glioblastoma, colorectal cancers, and non-
small cell lung cancer (Wu et al., 2013, Nishida et al., 2011, Yuxia et al., 2012).  In 
haematological malignancies, it is particular associated with the t(2;11)(p21;q23) 
translocation which can lead to between a 6–90 fold upregulation found in a subset 
of patients with MDS or AML (Bousquet et al., 2008b). miR-125b is also important 
in the AML subtype acute promyelocytic leukaemia (FAB M3) where its 
upregulation blocks differentiation and reduces its sensitivity to apoptotic signalling 
(Bousquet et al., 2012). 
The negatively regulated miR-29b is a known tumour suppressor in several cancers, 
including leukaemias. It was previously shown to be downregulated in several 
AML cell lines and patient samples and when expression was increased, the cells 
became more sensitive to apoptosis and AML mouse xenografts showed a reduction 
in their tumours (Garzon et al., 2009a). miR-29b can also regulate promoter 
methylation through the regulation of DNMTs. In AML for example miR-29b can 
regulate and repress DNMT1, DNMT3A and DNMT3B, resulting in the expression 
of several tumour suppressor genes (Garzon et al., 2009b). 
 




The role between NRF2 and miR-125b/ miR-29b in AML cells requires further 
investigation. So far, we have shown a correlation between NRF2 and both miRNA, 
however we have not demonstrated whether NRF2 directly regulated these miRNA 
by binding to an ARE site in their promoters, or if its indirect through NRF2 target 
genes. To do this we need to further characterise the ARE binding sites in the 
vicinity of both miRNA, and test the ability of NRF2 to bind to these sites using a 
chromatin immunoprecipitation assay (ChIP), DNA-binding assays or a promoter-
reporter assays. 
 
miRNA can exist as paralogs, i.e. multiple copies of the same miRNA in the 
genome. These paralogs contain the same functional seed region but exist in 
different genomic locations indicating that these paralogs can be individually 
regulated. Initial work in this study (Fig 3.7) has demonstrated total levels of miR-
125b and miR-29b is similar to that of the paralogs miR-125b1 and 29b1. Further 
studies need to be undertaken to understand whether NRF2 can modulate the 
expression of the paralogs miR-125b1 / miR-29b1, or if another paralog is 
responsible (i.e. miR-125b2 or miR-29b2). We also need to elucidate the function 
of miR-125b and miR-29b in AML and their downstream targets. 
As mentioned above miR-125b and miR-29b has previously been characterised as 
a oncomiR/ tumour suppressor miR respectively. We would therefore like to 
characterise the miRNA targets genes important in AML and elucidate if NRF2 can 
indirectly regulate these targets. 
  





Chapter 4  
 
Regulation of miR-125b and 
miR-29b by NRF2   




miR-125b is a member of the miR-125 miRNA family and has been associated with 
a wide range of pathologies (Sun et al., 2013). As with other miRNAs, when 
dysregulated miR-125b can act as an oncomiR or tumour suppressor miR by 
repressing the expression of tumour suppressor or oncogene mRNA targets 
respectively. For example, in hepatocellular carcinoma miR-125b is downregulated 
and when overexpressed decreases cell proliferation (Jia et al., 2012). Furthermore, 
miR-125b reduces metastasis in hepatocellular carcinoma through repression of 
LIN28B (Liang et al., 2010). miR-125b is also downregulated in breast cancer, 
ectopic upregulation of the miRNA inhibits proliferation and migration through the 
targeting of ERBB2, ERBB3, EST1, and MUC1 (Scott et al., 2007, Zhang et al., 
2011b, Rajabi et al., 2010). 
 
miR-125b plays a key role in regulating haematopoiesis, It is one of the most 
upregulated miRNA in long-term cultured haematopoietic stem cells (HSC) and its 
expression decreases as the HSC cells differentiate into a more mature lineage 
(O'Connell et al., 2010). Overexpression results in an increased myeloid and 
lymphoid population along with a marked decrement in differentiation (Bousquet 
et al., 2008b). One study using bone marrow-derived murine 32D cells identified 
miR-125b as being regulated by G-CSF and  ectopic expression resulted in the 
arrest of granulocytic differentiation (Surdziel et al., 2011). miR-125b has also 
shown to play a role in inflammation through targeting the TNF pathway through 
stabilisation of the NF-κB inhibitor NKIRAS2 (Murphy et al., 2010). There is 
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evidence that NF-κB can both increase and repress miR-125b expression, thereby 
creating a feedback loop (Tili et al., 2007). 
 
miR-125b has also been shown to play a key role in leukaemias. In AML (and 
MDS), miR-125b is upregulated in patients exhibiting the translocation 
t(2;11)(p21;q23) (Bousquet et al., 2008b). Its upregulation in AML leads to the 
arrest of differentiation and the promotion of proliferation. Ectopic overexpression 
of miR-125b in mouse bone marrow models results in leukaemia, with the exact 
subtype being dependent on the level of expression of miR-125b (Bousquet et al., 
2010). As shown in other cancers, increased miR-125b levels also inhibits 
differentiation and decreases its responsiveness to apoptotic signalling. According 
to one study miR-125b blocks apoptosis through the targeting of several proteins in 
the p53 pathway (such as BAK1) and differentiation through targeting CBFB, a key 
transcription factor involved in myeloid differentiation (Bousquet et al., 2012, 
Vargas Romero et al., 2015). 
 
Similar to miR-125b, miR-29b can act both as an oncomiR or tumour suppressor 
miR but in the case of AML, it has previously been characterised as a tumour 
suppressor miR. miR-29b is downregulated in AML Blasts, and when ectopically 
overexpressed in murine models results in increased apoptosis and a decrease in 
tumour size (Garzon et al., 2009a, Yan et al., 2015). The increase in apoptosis is 
partly down to the regulation of the anti-apoptotic genes MCL-1 and BCL-2  
(Garzon et al., 2009a, Xu et al., 2014). miR-29b also controls the expression of 
tumour suppressor genes through the targeting of DNA methylation. miR-29b was 
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shown to directly bind and target DNMT3A and DNMT3B and indirectly regulate 
DNMT1 through modulation of SP1 (resulting in demethylation of tumour 
suppressor genes such as ESR1 and CDKN2B (Garzon et al., 2009b). The AML 
subtype AML-ETO (characterised by chromosomal rearrangement affecting the 
transcription factor RUNX1) shows downregulation of miR-29b (due to direct 
repression of AML1-ETO). miR-29b, on the other hand, can also target and 
therefore repress AML1-ETO, thereby creating a feedback loop. One result of 
dysregulated AML1-ETO is an arrest in myeloid differentiation, which is partially 
prevented if miR-29b levels are ectopically over-expressed (Zaidi et al., 2017). 
 
4.1.1 Aims and Rationale 
In the previous chapter we identified two miRNAs, miR-125b and miR-29b, 
regulated by the transcription factor NRF2. We next wished to understand the 
regulatory relationship between NRF2 and both miR-125b and miR-29b, in 
particular, the capability of NRF2 to directly regulate both miRNAs. 
 
Both miRNA have previously been shown to play a significant role in various 
malignancies and we wished to characterise the role of both miRNA in AML cell 
lines and AML Blasts to elucidate the functional relationship between NRF2 and 
both miRNA expression in AML. 
 
Finally, if successful we aim to characterise the mRNA targets which these 
miRNAs bind to and repress with a particular emphasis on those important in AML. 
 




4.2.1 Genomic location of miRs-125b and miR-29b paralogs 
In the previous chapter we identified a correlation between NRF2 and levels of the 
miRNAs, miR-125b and miR-29b. As this regulation is most likely by NRF2 
binding to the promoter region of these miRNA, we looked at the genomic regions 
in the vicinity of these miRNA. miR-125 and miR-29 both exist in miRNA families 
which consist of several miRNA homologs; miR-125a, and miR-125b; miR-29a, 
miR-29b and miR-29c. These homologs share the same seed region, the region 
where miRNAs bind to repress their target mRNA, but differ in their end mature 
sequences. 
 
miRNAs also exist as paralogs, miR125b for example exists as two paralogs, miR-
125b1 and miR-125b2, both with the same core seed region, but residing in different 
genomic locations (miR-125b1 is located on chromosome 11, while miR-125b2 is 
located on chromosome 21). Similarly, miR-29b exists as two paralogs, miR-29b1 
(chromosome 7) and miR-29b2 (chromosome 1). A schematic of these miRNA is 
shown in Fig 4.1. The differing locations of these paralogs suggest they are likely 
to be independently regulated. 
 
 




Figure 4.1: Schematic of genomic location of miR-125b and miR-29b and 
paralogs. miRNA in the vicinity of miR-125b1, miR-125b2, miR-29b1 and miR-
29b2 can be seen in boxes.  Putative NRF2 “ARE” binding sites are indicated in 
circles. 
 
4.2.2 NRF2 regulation of miRs-125b and miR-29b homologs and paralogs 
We next wished to identify which miR-125 and miR-29 family members were being 
regulated by NRF2. Since these miRNAs have the same seed region and similar 
mature sequences it is likely that they have similar functions and may tend to 
synergise with each other. As before we used specific primers to the miRNA-
specific mature sequences following NRF2 knockdown. 
 
We found significant modulation (Fig 4.2) in expression in miR-125b 
(downregulation), miR-29a and miR-29b (upregulation). miR-125b1 showed a 40% 
downregulation in expression, while miR-29b expression increased by two-fold. 
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miR-29a increased to a lesser extent by 1.8-fold., while no significant changes were 
seen in miR-29c levels. 
 
We next wished to identify which miRNA paralogs are (i.e. miR125b1/2 and miR-
29b1/2) regulated by NRF2. As these miRNA paralogs have the same seed region 
and mature sequence (despite residing in separate genomic location) they both, 
should in theory, have the same function. However, due to differences in their 
genomic location, they may be independently regulated differently (i.e. by different 
transcription factors), thereby changing their exact physiological role despite 
coding for the same mature sequence/targeting the same mRNAs. To identify which 
paralog NRF2 was regulating, qPCR was once again used to following NRF2 
lentiviral knockdown. In the previous miRNA qPCR amplification, we used the 
mature sequence as the forward primer and a universal primer as the reverse. This 
was not possible when measuring miRNA paralogs as they contain the same mature 
sequence. We therefore designed primers for the flanking regions (i.e. the immature 
miRNA sequences) around the different paralogs (which would differ to one 
another due to locational differences). Several primers were designed and tested on 
an agarose gel post-PCR endpoint (data not shown), the best primers were utilized 
in qPCR (using the normal mRNA PCR method). 
 
Knock-down of NRF2 resulted in a significant decrease in miR-125b1 expression 
(approximately 40%) and upregulation of miR-29b1 (around 2-fold). No significant 
change was seen in miR-125b2 and miR-29b2 expression (Fig 4.2). This indicates 
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while NRF2 regulates miR-125b1 and miR-29b1, it likely does not regulate miR-
125b2/29b2 expression. 
 
Of interest, the total levels of miR-125b and miR-29b, following NRF2 knockdown, 
(Fig 3.5) are comparable with levels of miR-125b1 and miR-29b1 under the same 
conditions. This further suggests the dysregulation of miR-125b/29b by NRF2 is 
down to 125b1/29b1 rather than its paralogs.  
 
Figure 4.2 Real time PCR detection of miRNA cluster members in THP-1 cells 
following NRF2 lentiviral knockdown A) miR-125b1 (miR-125b1, miR-100, and 
let-7-a2) miR-125b2 (miR-125b2, miR-99a and let-7c) and HO-1 B) miR-29b1 
(miR-29b1 and miR-29ba)  and miR-29b2 (miR-29b2 and miR-29 c) Student’s t-
test carried out to determine statistical significance, * indicates P< 0.05. 
 
4.2.3 NRF2 regulates miRs-125b and -29b through their individual promoters 
We next wished to understand the mechanism by which NRF2 regulates miR-125b 
and miR-29b. miRNAs can be regulated through their own individual promoter or 
co-regulated alongside other miRNAs in “miRNA clusters”. miR-125b1 lies 
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downstream (approx. 47 kb) from miR-100 and let-7-a2. miR-125b2 similarly lies 
downstream (50 kb) of miR-99a and let 7-c. The miR-29b paralogs lie closer to 
their respective clusters with miR-29b1 located approximately 700 bp away from 
miR-29a, while miR-29b2 is approximately 600 bp from miR-29c (Fig 4.3). 
Admittedly 50 kb is a large distance for miRNA co-regulation however reports have 
suggested these miRNA do associate with one another to create a physiological 
effect (Wang et al., 2011). These miRNA cluster regions also exhibit a high 
genomic conservation suggesting they can be of regulatory importance. 
 
 
Figure 4.3: Schematic of the miR-125b-1 and miR-29b-1 promoter regions 
Putative “ARE” binding sites in the vicinity of the miRNA paralogs miR-125b1 
and miR-29b1. 
 
The first question we wished to answer was whether miR-125b or miR-29b were 
being regulated through their own independent promoters, or alongside other 
miRNA clusters. Again, we used qPCR (on THP-1 cells treated with the lentiviral 
NRF2 KD) to amplify the mature miRNA in the cluster (i.e. miR-100, let 7-a2, 
miR-99, let7c, miR-29a, miR-29c) and the immature miRNA sequences for those 
with the same seed region (i.e. miR-125b1, miR-125b2, miR29b1 and miR-29b2). 
mRNA for the NRF2 HO-1 was used as a positive control. As shown in Fig 4.2 
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there was no change in miR-100, let-7-a2, miR-99, let7. As discussed above only a 
slight increase in miR-29a expression was observed following NRF2 knockdown. 
 
As no significant change in expression was seen in the miR-125b1 or miR-125b2 
cluster this suggested that NRF2 may regulate miR-125b1 and miR-29b1 
independently of the other miRNA in its cluster. This also suggests that the ARE 
binding site responsible for miR-125b1/29b1 is likely to be in the vicinity of these 
miRNA (as opposed to around the other miRNA cluster members). 
 
4.2.4 Identification of potential ARE sites in the miRs-125b and -29b 
promoters 
We have identified miR-125b1 and miR-29b1 as the miRNAs targeted by NRF2. 
As described previously, we used the transcription factor binding program, Pmatch, 
to identify novel NRF2 (ARE) binding sites close to miR-125b1 and miR-29b1 start 
sites. We identified three putative ARE sites in the vicinity of miR-125b1, one 
located at -41 kb, another at -4.3 kb and the third one at 900 bp from the miRNA 
start site. We also identified two sites near miR-29b1 located approximately 17 kb 
and 8 kb from the miRNA start site. While these putative AREs are located a fair 
distance away from miR-29b1 start site there are reports indicating SMAD3 binding 
sites exist 22 kb away from the miR-29b paralog miR-29b2. This suggests it is 
possible for a transcription factor to bind and regulate miR-29b1 from such a 
distance (Kriegel et al., 2012). Another study used RACE to amplify the genomic 
5’ ends of miR-29b1 and identified a primary miRNA start site and promoter region 
approximately 36 kb upstream of the mature miRNA start site (Eyholzer et al., 
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2010, Chang et al., 2008), again indicating the possibility of NRF2 regulating miR-
29b1 from quite a distance away from its mature sequence. A diagram of the miR-
125b1 and 29b1 schematic can be seen in Fig 4.3 along with a visual schematic 
detailing the ARE sites 1-5. The exact genomic locations seen in Table 4.1. 
 
miRNA Sites position ARE sequence 
miR-125B1 ARE1 40923-40933 ATGACTCAGTG 
miR-125B1 ARE2 4537-4548 TGATCTCAGCA 
miR-125B1 ARE3 1357-1368 GCTTTGTCATT 
miR-29B1 ARE4 16788-16799 AGCTGAGTCAC 
miR-29B1 ARE5 7647-7658 TGCTGAGTCAT 
 
Table 4.1: Location and sequences of putative ARE sites in the miR-125b1 or 
miR-29b1 promoters 
 
4.2.5 Identification of ARE binding sites using CHiP  
As discussed above three ARE sites were identified on miR-125b1 and two on 
miR29b1. To determine which, if any, of these sites NRF2 binds to, we used a 
Chromatin Immunoprecipitation Assay (CHiP). 
 
CHiP was performed on THP-1 cells using an antibody to immunoprecipitate NRF2 
and any bound DNA, following cross-linking with formaldehyde. Specific PCR 
primers were designed to flank the regions of each putative ARE site for qPCR 
analysis (Fig 4.4). From the five ARE sites identified we saw the biggest enrichment 
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in NRF2 at ARE3 (-1 kb from miR-125b1) and ARE5 (-8 kb from miR-29b1).  The 
enrichment on ARE5 seems to be larger than that of the other ARE sites tested. To 
further confirm site activity in vivo, we upregulated NRF2 expression by targeting 
KEAP1 suppression with siRNA. In agreement with our previous results we saw a 
significant enrichment in AREs 3 and 5 in comparison to cells treated with a 
scrambled siRNA control suggesting increased NRF2 is binding to these areas of 
DNA upon up-regulation. We did see small, but not statistically significant, 
enrichment in ARE2 and ARE4 when compared with the control IgG 
immunoprecipitation. When KEAP1 was downregulated, no significant change was 
seen in ARE2, but a small enrichment was seen at ARE4, raising the possibility this 
site may not be completely transcriptionally inactive, however for the purposes of 
our study only AREs 3 and 5 were used. 
 
Figure 4.4: Chromatin Immunoprecipitation assay (ChIP) was used to 
determine Transcription factor (TF) binding NRF2 antibody was used with 
rabbit IgG as the control. A) qPCR was carried out on both immunoprecipitated and 
input DNA. B) qPCR was carried out on both immunoprecipitated NRF2 DNA 
from THP-1 cells post negative or KEAP1 siRNA transfections for 24 hours. A 
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two-way Anova was carried out prior to the post-hoc Bonferroni correction, and 
used to determine statistical significance within each ARE site, * indicates P< 0.05 
 
Overall, the CHiP assay indicates that NRF2 can bind in vivo to ARE3 on miR-
125b1 and ARE5 on miR-29b1. Furthermore, when NRF2 levels are raised, 
increased NRF2 recruitment is seen at these sites, thereby attesting to NRF2’s 
ability to bind to both ARE sites. 
 
4.2.6 Development of Luciferase p125b and p125bAREmut constructs  
The previous data has demonstrated that NRF2 can bind to ARE3 (on miR-125b1) 
and ARE5 (on miR-29b1) in AML cells (Fig 4.3 and 4.4). To test whether these 
sites were transcriptionally active, we used a luciferase-based promoter/reporter 
assay. We cloned each of the ARE sites into the pGL4.11 luciferase vector (Fig 
4.5A) upstream of the FireFly luciferase reporter. To clone the promoter for miR-
125b1 we designed primers- Forward 5′-AGAAAGGCCACCAAGATTCAC-3′ 
and Reverse 5′-TGAGAGGAGCGCAACAATG-3′) to clone the 2.6 kb fragment 
(which included the ARE3 site). Site-directed mutagenesis was carried out on the 
p125b sequence using the primer 5′-
GCTGTGGCTGtTTTGTtATTCTCTTTGACTAG-3′ to introduce a single point 
mutation to generate the p125b NRF2 MUT. A schematic of the site directed 
mutagenesis can be seen in Fig 4.5B. The pGL4 (empty vector) p125b and p125b 
NRF2 MUT were all transfected into THP-1 cells using the transfection reagent 
diethylaminoethyl (DEAE) dextran for 48 hours, after which, a luciferase assay was 
conducted. 





Figure 4.5: miRNA promoter/reporter assay A) Map of pGL4.11 Luciferase 
reporter construct B) A cartoon of w/t and mut ARE 3 (miR-125b1) 
promoter/reporter inserts 
 
4.2.7 Validation of the miR-125b ARE site  
As discussed above, we designed the dual luciferase pGL4 miR-125b constructs to 
test the transcriptional activity of ARE3. ARE5 is ~8 kb away from the miR-29b1 
start site and we were unable to clone a fragment of that size into the pGL4.11 
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plasmid. We first transfected both the pGL4 and p125b (0.5 µg) into THP-1 cells 
without a NRF2 modulator, as previous work in our lab had demonstrated AML 
cells are characterised with high basal expression levels of NRF2. As shown in Fig 
4.6A, when the p125b plasmid was transfected alone into THP-1 cells, we found an 
eight-fold upregulation in reporter activity in comparison to the empty vector  pGL4 
control. When we treated THP-1 cells with pGL4/ p125b alongside siRNA to 
KEAP1, the p125b reporter showed significant increased reporter activity, no such 
change was seen in the pGL4 control vector. 
 
We performed site directed mutagenesis on site ARE3 (as discussed in the previous 
section): the construct was designated p125b NRF2 MUT. Admittedly, when 
transfected into THP-1 cells, we saw a four-fold increase in reporter activity 
(compared to the vector control), however this is still significantly lower (four-fold) 
then the results seen with the p125b plasmid. Furthermore, in cells treated with 
KEAP1 siRNA, we found no change in reporter activity with p125b NRF2 MUT, 
but significant increase activity in p125b. When treated with NRF2 siRNA no 
change in reporter activity was seen in either p125b or p125b NRF2 MUT. The 
results (shown in Fig 4.6B) seen were in line with what was expected, increasing 
levels of NRF2 correlated with increased levels of p125b activity, plus decreased 
NRF2 levels resulted in p125b activity to decrease to that of p125b NRF2 MUT. 
This shows that NRF2 can transcriptionally control the ARE3 site on miR-125b1. 
 





Figure 4.6 Transcriptional activity of the putative NRF2 binding sites on the 
miR-125b1 promoter. A) Luciferase reporter expression in THP-1 cells 
transfected with p125b NRF2 w/t and mut. B) Reporter expression of p125b wt/ 
p125b NRF2 mut in THP-1 cells following NRF2 or KEAP1 knockdown. Student’s 
t-test carried out to determine statistical significance, * indicates P< 0.05. 
 
4.2.8 Manipulation of miR-125b and miR-29b using antagomiRs and miR 
mimics 
We have shown NRF2 can transcriptionally regulate miR-125b1 (through ARE3) 
and can bind to the miR-29b1 promoter (through ARE5). We next wished to 
identify the functional role of both miR-125b1 and miR-29b1 towards NRF2 
signalling. To do this we manipulated expression of these miRNAs using an 
miRNA mimic (miR-29b) or an antagomiRs (miR-125b). Mimics are small 
molecules made to mimic the function of a particular miRNA i.e. bind and repress 
their target mRNA. AntagomiRs are complementary to the miRNA of interest and 
therefore duplex to and block the miRNA function. 
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We first had to validate that the mimic and the antagomir blocked their respective 
miRNA function and so both were transfected into THP-1 cells and levels of each 
miRNA analysed using qPCR. When transfected the miR-29b mimic resulted in a 
3.5-fold increase in total miR-29b expression and conversely, the miR-125b 
antagomiR resulted in a significant decrease in total miR-125b levels (Fig 4.7). No 
changes were observed with the scrambled miRNA control. As an additional 
control, we measured miRNA levels following NRF2 or KEAP1 knockdown. In the 
NRF2 knockdown cells, we found decreased levels of miR-125b to the same level 
as the cells treated with the miR-125b antagomiR. The miR-29b levels increased 
(by just under two-fold), however, not to the same extent as when cells were treated 
with the miR-29b mimic, although this was to be expected as the mimic artificially 
increases specific miRNA expression. Furthermore, in the KEAP1 knockdown cells 
we saw increased levels of miR-125b, and lower levels of miR-29b. This data shows 
that both the mimic and antagomir are capable of modulating expression of their 
respective miRNAs in the THP-1 cells. 
 




Figure 4.7: Effect of a miR125b anatagomiR and a 29b mimic on miR125b and 
29b expression in THP-1 cells A miR-125b antagomir and a mIR-29b mimic were 
transfected into THP-1 cells for 48h following which miR-125b and miR-29b levels 
were detected by qPCR. NRF2 and KEAP1 Lentiviral knockdown were used as 
positive/negative controls respectively. 
 
4.2.9 Modulation of miR-125b and miR-29b using antagomiRs and miRNA 
mimics induces apoptosis in AML cell lines 
Previous studies have shown both miR-125b and miR-29b play a role in regulating 
apoptosis. miR-125b is a well-known oncogenic miRNA in haematological 
malignancies, and miR-29b is a known tumour suppressor miR (Bousquet et al., 
2012, Garzon et al., 2009a). 
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In order to assess their role in apoptosis in AML, THP-1 cells were transfected with 
an miR-125b antagomiR or an miR-29b mimic for 48 hours, after which apoptosis 
was measured using Annexin V and Propidium Iodide (PI) staining. As shown in 
Fig 4.8A we saw a minor increase in cell death when miR-125b levels were 
decreased (approximately 8%) or miR-29b levels were increased (approximately 
10%). We did not see any significant change in Annexin V/ PI levels when miR-
125b levels were increased or miR-29b was decreased, this could possibly be due 
to their aberrant expression in AML (data not shown). As discussed previously 
miR-125b levels are increased in AML blasts compared to CD34+ cells and miR-
29b shows the opposite trend. We speculated as levels of miR-125b are already 
raised in AML, its target mRNAs are already being repressed and therefore 
artificially increasing levels of miR-125b have no apparent functional effect. We 
further speculate miR-29b shows the opposite trend. While both the mimic and 
antagomir had only minor effects on cell death when transfected individually, more 
surprisingly, when the two miR regulators were co-transfected there was a 
singularly more impressive 43% increase in the amount of cell death observed. 
 
Similar to the AV/PI results, Fig 4.8B shows a decrease in miR-125b (or increase 
in miR-29b) resulting in a minor decrease in cell viability (around 12–15%), 
however when cells were transfected with both the miR-125b antagomir / miR-29b 
mimic, the cell viability fell by 63%. To show this synergistic effect was not specific 
to THP-1, the Cell-Titer Glo was repeated in Kasumi-1 cells (an AML cell line 
characterised by the translocation t(8;21)). The same trend was seen, however the 
Kasumi-1 cells seemed less sensitive to alteration by individual miR-125b 
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antagomiR (3% reduction in cell viability) or miR-29b mimic (8% reduction in cell 
viability). Synergistic expression of both the miR-125b antagomiR and miR-29b 
mimic resulted in a 43% reduction in cell viability. 
 
Figure 4.8: Modulation of miR-125b/29b induces cell death in AML A) 
Annexin V/PI staining on THP-1 cells post modulation of miR-125b and/or miR-
29b. B) Cell viability assays on THP-1 and Kasumi cells post modulation of miR-
125b and/or miR-29b. 
 
We have shown NRF2 can increase levels of miR-125b1 and repress miR-29b1 
through binding to an ARE sites on their promoter. Whist only a modest response 
was seen when miR-125b levels were decreased or miR-29b levels were increase, 
we were surprised to see a large increase in apoptosis when the miR-125b 
antagomiR and the miR-29b mimic were co-transfected together. Overall this 
suggests NRF2 can synergistically regulate miR-125b1 and miR-29b1. Levels in 
AML cells  
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4.2.10 Cell death induction by antagomiRs and miRNA seen in primary AML 
blasts 
We have successfully shown manipulating levels of both miR125b and miR-29b in 
AML cell lines can modulate cell death. As previously discussed, AML is a 
heterogeneous disorder made up of a vast number of cytogenic and genetic 
abnormalities. While AML cell lines provide useful models they represent a limited 
repertoire of the complexities clinically seen in primary AML. We therefore wished 
to look at the effect of the miRNA mimics and antagomiRs in primary AML blasts 
derived from patients. AML blasts were extracted from the peripheral blood of 
AML patients samples and CD34+ cells from the peripheral blood of healthy 
volunteers. Both CD34+ cells and AML blasts were transfected with mimic and 
antagomiR for 24 hours after which cell death was measured using an ATP-
utilisation assay (Cell-Titer Glo) (Fig 4.9A and B).  
 
 
Figure 4.9 miR-125b/29b modulation induces cell death in primary AML cells 
Cell viability assay was carried out on A) CD34+ and B) AML blasts following 
transfection with miRNA mimics and/or antagomIRs. Student’s t-test carried out to 
determine statistical significance. 
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A decrease in viability was seen when AML blasts were treated with a miR-125b 
antagomiR, while a lesser decrease was seen in blasts treated with the miR-29b 
mimic. As previously shown in the AML cell lines, when the AML blasts were 
transfected with both the miR-125b antagomiR and the miR-29b mimic, a 
significant decrease (around 40%) in cell viability was seen. The CD34+ cells 
showed no difference in cell viability post transfection with the miR-125b 
antagomiR. Meanwhile a slight (but not significant) decrease was seen upon 
transfection with the miR-29b mimic alone or when co-transfected with both the 
miR-125b antagomiR and miR-29b mimic. 
 
In agreement with the AML cell lines, the primary AML blasts showed significant 
(but limited response) to single mimic or antagomiR, but a much larger decrease in 
cell viability when both the miR-125b antagomiR and miR-29b mimic were 
combined. The large sensitivity towards the miR-125b antagomiR / miR-29b mimic 
in primary samples is further evidence that NRF2 synergistically regulates both 
miR-125b1 and miR-29b1 to increase cell survival and proliferation. Some 
variation was seen within the AML blasts (and the CD34+ cells), particularly when 
co-transfected with the miRNA mimic and antagomiR, which is to be expected due 
to the rather heterogeneous nature of these samples. 
 
4.2.11 AntagomiRs and miRNA mimics sensitise AML cells to 
chemotherapeutic agents 
Chemotherapy-resistance is a major problem in AML. While remission rates are 
approximately 75-85%, the five-year survival rate is only around 30–40%. Survival 
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rates are particularly low in patients over the age of 65 and this can be further 
complicated by resistance occurring to currently available chemotherapy (De 
Kouchkovsky and Abdul-Hay, 2016, Almeida and Ramos, 2016). Previous work in 
our lab has identified NRF2 as a key regulator of chemotherapy-resistance in AML. 
We therefore wished to investigate whether the dysregulation of miRNA by NRF2 
plays a role in this resistance.  
THP-1 and Kasumi-1 cells were transfected with miRNA mimic and antagomiR, 
24 hours later increasing concentrations of daunorubicin were added. Viability was 
measured and IC50 measurements were carried out (Table 4.2),  
As expected, we found a slight increase in daunorubicin sensitivity following 
transfection with the miR-125b antagomiR or the miR-29b mimic. The highest 
levels of sensitivity were seen when cells were co-transfected with both the miR-
125b antagomir and the miR-29b mimic. THP-1 cells seemed to show a greater 
response to miRNA manipulation then Kasumi-1s, with a 20% decrease in IC50 post 
miR-125b downregulation, a 45% decrease post miR-29b mimic, and a 65% 
decrease consequently when transfected with both miRNA simultaneously. The 
Kasumi-1 cells showed a 17% decrease post transfection with a miR-125b 
antagomiR, an 8% decrease post miR-29b mimic and a 30% decrease when 
presented with both miRNAs. 




Table 4.2: Modulation of miR125b and miR-29b increases daunorubicin 
sensitivity in AML cell lines Cell viability was calculated on THP-1 IC50 was 
measured on THP-1 and Kasumi cells treated with increasing concentrations of 
daunorubicin for 48 hours post miRNA mimic or antagomir transfection 
 
4.2.12 Increased sensitivity to chemotherapeutic agents in primary AML 
samples following treatment with antagomiRs and miRNA mimics 
We next wished to confirm drug-sensitivity in primary AML blasts. In the previous 
section we confirmed the trend that AML blasts were susceptible to manipulation 
of miR-125b and miR-29b levels. Next, we compared a CD34+ cell alongside 
primary AML BLAST with both high (sample AML#25) and normal levels of 
NRF2 (sample AML#27). As shown in both Table 4.3 and Fig 4.10A, AML#27 
from the outset were more sensitive to daunorubicin treatment than AML #25. 
Primary samples were transfected with either the miRNA mimic or antagomiR 
before treatment with daunorubicin. AML # 25 when transfected with the miR-125b 
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antagomiR showed a decrease in IC50 by 26%, while the miR-29b mimic had a 49% 
decrease in its IC50. When co-transfected with both the miR-125b antagomiR and 
miR-29b mimic, there was a 64% decrease in the IC50. AML#27 showed no 
sensitivity towards either the miRNA mimic or antagomiR individually or in 
conjunction with one another following daunorubicin treatment. Likewise, normal 
CD34+ cells, which contain lower levels of NRF2 than that of most AML cases, 
showed limited sensitivity towards daunorubicin. 
 
We decided to closely compare the two AML samples, AML #25 and #27 which 
are characterised by different underlying disorders, AML#25 has the WHO 
classification of “AML without maturation” with complex cytogenetics (Table 3.1). 
In the previous chapter qPCR was carried out comparing levels of NRF2, miR-
125b1 and miR-29b1 in all primary AML blasts used, relative to that of the CD34+ 
cells (Table 3.1). In AML #25, we identified a 3.2-fold upregulation in NRF2 
mRNA, 6.5-fold upregulation in miR-125b1 and a 0.4-fold downregulation in miR-
29b1 levels. 
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Table 4.3: Daunorubicin sensitivity of AML blasts following miRNA 
manipulation Daunorubicin sensitivity was measured in AML BLASTS 
characterised with high (AML-25)/normal (AML-27) NRF2 levels and normal 
CD34+ cells. 
 
AML #27 is characterised as a core binding factor (CBF) AML which contains a 
t(8;21) (q22;q22) translocation between the RUNX1 and RUNX1T1. In table 3.1, 
we saw a 1.2-fold increase in NRF2 mRNA, a 1.4-fold increase in miR-125b1 and 
a 0.5-fold decrease in miR-29b1 levels. As expected AML #27 showed NRF2 levels 
closely resembling that of CD34+ cells (and therefore only a minor increase in miR-
125b1 levels). Despite the normal basal levels of NRF2, we did see a significant 
decrease seen in miR-29b1 levels, however this may be more attributable to the 
underlying cytogenetics of this sample. The t(8;21) translocation is strongly 
associated with a gain of KIT function. KIT has been reported to indirectly represses 
miR-29b through aberrant Myc signalling. Myc alongside SP1 (also an miR-29b 
target) represses levels of miR-29b (Liu et al., 2010a). 
 
NRF2 levels were next increased in AML #27 by transduction with an KEAP1 KD 
(Fig 4.10B), these cells were then treated with daunorubicin. The KEAP1 KD AML 
#27 showed a higher resistance to daunorubicin then those with the control 
treatment, further illustrating the importance of NRF2 levels in mediating drug-
resistance in AML (Fig 4.10C). KEAP1 KD AML #27 was transfected with the 
miR-125b antagomiR and a miR-29b mimic, after which cells were treated with 
daunorubicin (Fig 4.10D). We saw little change in daunorubicin-resistance post-
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treatment with the antagomiR and mimic, however when both the miR-125b 
antagomiR and miR-29b mimic was co-transfected together, we did observe a 
significant decrease in daunorubicin-resistance, which once again suggests aberrant 
NRF2 activity is partially responsible for the oncogenic role of miR-125b and miR-
29b in AML. 
 
Figure 4.10 Modulation of miR-125b and miR-29b increases daunorubicin 
sensitivity in AML blasts A) AML BLASTs #25 and #27 were transfected with 
miRNA control, miR-125b antagomir, 29b mimic and combined miR-125b 
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antagomir and miR-29b mimic for 24 hours. After which cells are treated with 
increasing doses of daunorubicin for 48 hours. Cell viability is calculated by Cell-
Titer Glo. 
B) AML BLAST #27 was transduced with a KEAP1 KD lentivirus, after-which 
treated with increasing doses of daunorubicin and KEAP1 protein was detected by 
Western Blot.  C) Cell viability was detected in AML BLAST #27 after 
transduction with an KEAP1 KD lentivirus. Cells were then treated with 
increasing doses of daunorubicin for 48 hours, after which a Cell-Titer Glo assay 
was performed. D) The transduced AML #27 was transfected with miRNA 
mimics and antagomir. Cells were then treated with increasing doses of 
daunorubicin for 48 hours, after which a Cell-Titer Glo assay was performed.  
 
 
4.2.13 Identification of miRNA targets through manipulation of miR-125b / 
miR-29b 
We have identified NRF2 can synergistically regulate miR-125b and miR-29b, and 
NRF2 dependent dysregulation of these miRNA lead to a decrease in apoptosis and 
a resistance to frontline chemotherapy agents such as daunorubicin. miRNAs can 
traditionally target a range of mRNAs, many of which are disease-dependent. We 
therefore wished to elucidate which mRNAs (and resulting proteins) were being 
affected by both miRNAs (miR-125b1 / miR-29b1) in AML. Using both a literature 
search and public miRNA target databases (such as miRdb) we identified seventeen 
experimentally validated targets for either miR-125b and miR-29b, the majority of 
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which had previously been validated as targets in haematological malignancies (see 
Table 4.4). 
Gene name Function/disease Reference 
miR-29B targets   
MYBL2 AML (Garzon et al., 2009a) 
AKT2 EOC (Teng et al., 2015) 
Cxxc6 AML (Garzon et al., 2009a) 
DNMT1 AML (Garzon et al., 2009b) 
TGFB1 Trabecular meshwork (Chou et al., 2013) 
PIK3R1 Liver (Wang et al., 2015a) 
CDK4 Osteosarcoma (Zhu et al., 2016) 
SP1 AML (Liu et al., 2010b) 
miR-125B 
targets   
CBFβ AML subtype-APL (Bousquet et al., 2012) 
KLF13 Haematopoietic stem cells (Ooi et al., 2010) 
ABTB1 AML subtype-APL (Bousquet et al., 2012) 
MAPK14 Head and neck squamous cell carcinoma (Zhang et al., 2014) 
STAT3 Myelopoiesis (Surdziel et al., 2011) 
miR-125B/mIR-
29B targets   
CDK6 Mantle cell lymphoma (Iqbal et al., 2012) 
BCL2 Hepatocellular carcinoma (Zhao et al., 2012) 
MCL1 Hepatocellular carcinoma (Jia et al., 2012) 
BAK1 AML/Breast Cancer (Zhou et al., 2010) 
 
Table 4.4: List of putative miR-125b and miR-29b mRNA targets and their 
associated disorders. 
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THP-1 cells were transfected with miR mimic and antagomiR both singularly and 
in combination with one another. mRNA of miR-125b and miR-29b targets were 
measured by qPCR (Fig 4.11A). Treatment with the miR-125b antagomiR resulted 
in a significant increase in the miR-125b targets MAPK14, STAT3, and BAK1. We 
also saw no change in CBFB. Treatment with the miR-29b mimic resulted in a 
significant decrease in the miR-29b targets MYBL2, AKT2, CDK4, SP1 and BCL2. 
When both the miR-125b antagomiR and miR-29b mimic were co-transfected 
together, we saw a significant decrease in CDK4, and AKT2. A significant up-
regulation of MAPK14 and BAK1 was also identified. We next measured the 
whole-cell protein expression of three of the miRNA targets: AKT2, STAT3, and 
BAK1 (Fig 4.11B). After transfection with the miR-125b antagomiR, we saw no 
increase in AKT2 protein levels, but an increase in STAT2 and BAK1. 
 





Figure 4.11: Detection of miR-125b and miR-29b targets THP-1 cells were 
transfected with miR-125b antagomir and miR-29b mimic A) mRNA levels of 
miRNA targets were detected by qPCR. Student’s t-test was carried out to 
determine statistical significance, * indicates p< 0.05. B) Western blot was used to 
measure protein levels of AKT2, STAT3, and BAK1. Levels of AKT2, STAT3 and 
BAK1 were normalised against β-actin by densitometry. 
 
4.2.14 Confirmation of targets miRNA targets through NRF2 inhibition and 
KEAP1 knockdown 
We have identified potential targets for miR-125b and miR-29b in AML. We next 
wished to test the regulation of these mRNA targets by NRF2 and KEAP1. Fig 
4.12A indicates that when NRF2 was knocked down in AML, we saw a significant 
decrease in mRNA levels of AKT2, while a significant increase was seen in STAT3 
and BAK1. When cells were transfected with a KEAP1 KD, we saw an increase in 
AKT2 levels, but no significant change in STAT3 or BAK1. No change was seen 
either in MCL1 levels post NRF2 or KEAP1 KD. When protein expression was 
measured (Fig 4.12B), we saw a slight decrease in AKT2, an increase in BAK1, 
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and no change in STAT3 (post NRF2 KD). Post KEAP1 KD, we saw a slightly 
larger increase in AKT2 (0.7-fold) and a slight decrease in STAT3 and BAK1 
protein levels. It should be noted that while the change in protein levels is not large, 




Figure 4.12: miRNA targets confirmed through NRF2 modulation THP-1 cells 
were transduced with an NRF2 or KEAP KD lentivirus. a) qPCR was used to 
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measure AKT2, STAT3, BAK1, and MCL1 mRNA levels in transduced cells. 
Student’s t-test carried out to determine statistical significance, * indicates p< 0.05. 
b) AKT2, BAK1 and STAT3 protein levels were measured by Western blot. 
 
4.3 Conclusions and Discussion 
We have identified NRF2 can manipulate miRNA expression, including positively 
regulating miR-125b1 and negatively regulating miR-29b1 through binding to their 
promoter regions at -1 kb (miR-125b1) and -8 kb (miR-29b1). A CHiP assay was 
used to show the potential of NRF2 to binds to the ARE site on the miR-125b1 and 
miR-29b1 promoter. The functional regulation of the miR-125b1 ARE site by 
NRF2 was shown by a luciferase assay. We next showed we could successfully 
manipulate NRF2, miR-125b and miR-29b in our AML cell lines and AML blasts. 
Manipulating the dysregulated miRNA levels indicated they play a crucial role in 
protecting the AML cells from apoptosis. Furthermore, dysregulation of both 
miRNA are in part responsible for resistance to front line chemotherapy agents in 
AML. We took an AML blast sample (AML#27) which was underlined by low 
levels of NRF2 and found to be more sensitive to daunorubicin treatment than other 
AML Blasts characterised by high NRF2 levels. When NRF2 was ectopically 
overexpressed in AML#27 using a lentiviral mediated KEAP1 KD, we found a 
significant increase in resistance to daunorubicin. The KEAP1 KD AML#27 was 
then transfected with both an miR-125b antagomir and a miR-29b mimic. The 
synergistic reduction in miR-125b and increase in miR-29b attenuated its resistance 
to daunorubicin. We finally looked at the mRNA levels of several miR-125b and 
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miR-29b targets, identifying STAT3, AKT2, and BAK1.  Of these targets we 
confirmed at a protein level STAT3 and BAK1 are indirectly regulated by NRF2. 
 
The oncogenic role of NRF2 has been alluded to in other studies, from chemo-
resistance to metabolic reprogramming (Rushworth et al., 2012, Mitsuishi et al., 
2012b). This study demonstrates an interesting mechanism by which NRF2 can 
post-transcriptionally regulate a range of anti-apoptotic and pro-proliferative targets 
through the regulation of miR-125b1 and miR-29b1. Due to the scope of this study 
we only analysed a limited number of well characterised miR-125b and/or miR-29b 
target genes. While this did provide a useful insight into the role of these miRNAs 
in AML, a more thorough global profiling of the target mRNAs, would be required 
to fully establish their role in AML and in particular the effect of NRF2 on miR-
125b1 and miR-29b1. Of interest are the DNA methylation genes DMNT1, 3A and 
B. DNA hypermethylation remains an issue in AML, in particular with those 
suffering from myelodysplastic syndrome or relapsed patients (Ley et al., 2010, 
Kroeger et al., 2008). Whilst we did not see any changes in the indirect miR-29b 
target DMNT1, DNMT3A or B were not analysed in this study. It would therefore 
be of great interest to see if NRF2 regulation of miR125b/29b results in the 
methylation of tumour suppressor genes. It should also be noted this study only 
used one AML cell line THP-1 (FAB M5) to determine miR-125b/29b target genes. 
While we did see an increase in cell death in a range of AML Blasts upon treatment 
with an miR-125b antagomiR and miR-29b mimic, indicating a shared or similar 
mechanism of action, a further study needs to be done to establish if the same or 
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different mRNA targets are responsible for the miRNA effects in different AML 
subtypes. 
 
Both miR-125b and miR-29b have both been previously characterised as key 
oncomiR and tumour suppressor miR respectively in AML (Bousquet et al., 2010, 
Garzon et al., 2009a). It would be interesting to determine whether the cumulative 
effect of NRF2 on miR-125b1/ miR-29b1 expression is significant in other 
malignancies. 
 
In this study we provide a rationale behind the plausibility of targeting either NRF2 
or miR-125b1/29b1 as a future therapeutic target in AML, both to increase 
apoptosis among the leukaemic blasts and to improve sensitivity towards 
chemotherapy agents used in the clinic. 
  





Chapter 5  
 
Modulating the NRF2 Pathway 








NRF2 plays a dual role in a myriad of oncogenic malignancies, in that it protects 
healthy cells from DNA damage caused by ROS, however it can also protect 
malignant cells from chemotherapy-induced damage. 
 
Recent evidence suggests high NRF2 levels (for example in lung, and breast 
cancers) can aid various oncogenic processes such as cell proliferation, 
metabolomic and oncogenic reprogramming (Jaramillo and Zhang, 2013). Despite 
this, more needs to be done to elucidate the mechanisms by which NRF2 acts, in 
particularly in haematological malignancies, where this pathway is not well 
characterised. 
 
Manipulation of genes in haematological cells is particularly challenging. Previous 
attempts to manipulate NRF2 (i.e. through siRNA and Lentiviral mediated miRNA 
knock-down) while effective were transient and relatively inefficient. 
 
Lately there has been increasing interest in gene-editing technologies such as 
TALENS and CRISPR-Cas9. Gene editing allows alterations to be made to a 
specific area of DNA, in recent times using targeted nucleases guided by user-
defined sequences to bind and cleave DNA. This results in a double-strand break 
which can be repaired by the cell using one of two mechanisms; Non-Homologous 
End Joining (NHEJ) or Homologous Recombination (Zaboikin et al., 2017). 
 
NHEJ is an “error-prone” mechanism which results in an insertion or deletion 
(INDEL) mutation leading to the disruption of a gene (Rodgers and McVey, 2016).  
Homologous Recombination is a more specific process, which can accurately repair 
DNA when presented with a DNA template homologous to the “break”, this is 
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generally the opposing DNA strand (Rodgers and McVey, 2016). If, an additional 
“repair” template is available (i.e. through co-transfection with the nuclease) this 
process can be leveraged to introduce custom modifications into the genome. These 
two mechanisms make site-directed nucleases invaluable tools in genomic research. 
 
The Type 2 CRISPR system nuclease, Cas9, was initially identified as a member of 
the bacterial adaptive immune response (Rath et al., 2015). Cas9 derived from 
Streptococcus pyogenes (spCas9) is the most common type used in gene editing 
(Gasiunas et al., 2012). The CRISPR-Cas9 system is made up of the nuclease Cas9 
(containing both HNH and RuvC nuclease domains) and a crRNA fused to a tracer 
RNA known as the single-guide RNA (sgRNA) (Cong et al., 2013, Jinek et al., 
2012). 
 
The sgRNA is responsible for directing Cas9 to the region of DNA complementary 
of itself. In the presence of an Protospacer Adjacent Motif (PAM), NGG in the case 
of spCas9, Cas9 will bind DNA and create a double strand break 3-5bp upstream 
(5’) to the PAM site (Tsai and Joung, 2016). This process can be used to create an 
INDEL (through NHEJ) or, in the presence of a repair template, insert a custom 
DNA sequence (through HDR). Despite suffering from increased off-target effects 
compared with previous iterations of targeted nucleases (such as TALENs), 
CRISPR has become the preferred method of gene editing. This is in part due to its 
ease of use, requiring the design of a sgRNA guide to target a specified region of 
DNA (Cong et al., 2013). 
 
To date, there are several issues with SpCas9, including limited targeting to 
sequences near an NGG PAM site, off-target cleavage, and targeting efficiency (a 
problem in “hard to transfect” cells). To account for these limitations, several 
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modifications have been made to the CRISPR system including the modification of 
sgRNA (increasing targeting efficiency), discovery of other Cas9 variants 
(containing different PAM sequences) and other class II CRISPR variants (Ding et 
al., 2016).  
 
Aims and rationale 
To date we have used a miRNA-based system to manipulate levels of NRF2 and 
KEAP-1. While this system significantly reduces the mRNA levels, the knockdown 
is not complete and residual mRNA levels are still present. The knockdown is 
transient, and over a period of time the cells regain levels of NRF2.  
We would like to explore the use of a number of gene-editing techniques to see 
whether we can effectively and efficiently use a site directed nuclease to create cells 
with disrupted NRF2.  
 
 




5.2.1 Cloning guides into LentiCRISPR 
LentiCRISPR-V2 was a gift from Feng Zhang (as described in (Sanjana et al., 
2014)). The plasmid contains an ampicillin resistance and puromycin selection 
markers and the original EFS-NS promoter was replaced with an SFFV promoter 
as this has previously been shown to work well in haematopoietic cells lines  (Baum 
et al., 1997). 
 
To determine the guide RNA (gRNA) sequences we obtained the DNA sequence 
of NRF2 using the NCBI database (https://www.ncbi.nlm.nih.gov/). To design the 
guide sequences, we used the CRISPR design tool at the Broad Institute 
https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). As with 
all PCR primers, the gRNA sequence was synthesised and ordered from IDT. The 
oligos were phosphorylated with T4 Polynucleotide Kinase and annealed. Before 
the guides were ligated into the plasmid, the plasmid was digested with BsmB1 to 
remove the stuffer leaving 3’ and 5’ overhangs. Guide oligos were also designed 
with overhangs already available when annealed. 
 
Following transformation and plasmid extraction (as described in Materials and 
Methods) the plasmids were sequenced to ensure correct guide incorporation. The 
plasmid map and cloning strategy for LentiCRISPR is shown in Fig 5.1.  





Figure 5.1: Overview of CRISPR guide cloning LentiCRISPR-SFFV plasmid is 
digested with BsmB1 to remove the stuffer region. This generates overhangs for 
insertion of a guide oligo with compatible sequences (in red). Annealed oligos are 
ligated into digested plasmid. 
 
5.2.2 Genotyping Primers  
Before testing the guide plasmids, we designed and optimised primers to detect the 
genomic regions being targeting (Exons 1, 2 and 4 in NRF2 and Exon 1 in KEAP1). 
Primer design spanned each Exon ensuring the guide sequences and PAM sites 
were within the amplified region. A schematic of the primers and their location 
with-respect-to the guide sequences is shown for NRF2 Exon 1 (Fig 5.2A) NRF2 
Exon 2 (Fig 5.3A) and NRF2 Exon 4 (Fig 5.4A). All primers sets were checked 
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using the NCBI BLAST algorithm (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to 
ensure specificity. 
 
Multiple primer sets were tested on genomic DNA extracted from HEK-293 cells. 
 
Exon 1: multiple PCR products were detected in the genotyping PCR for NRF2 
Exon 1, and some primer sets (such as NRF2 Exon1 1F/2R) resulted in products 
that differed from the predicted sizes (Fig 5.2B and C). These regions appeared GC 
rich and we therefore repeated the Exon 1 genotyping PCR using a “Hot-Start” 




Figure 5.2:  NRF2 Exon 1 A) Exon 1 location of genomic primers and guide 
sequences B) simulated agarose gel showing predicted product size using Exon 1 
genotyping primers. C) agarose gel showing actual product size using Exon 1 
genotyping primers. 
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Exon 2: a genotyping PCR was carried out for NRF2 Exon 2 using a combination 
of two forward and two reverse primers. No difference was observed between the 
predicted product size and that found when carrying out the PCR, indicating all 




Figure 5.3: NRF2 Exon 2 A) Exon 2 location of genomic primers and guide 
sequences. B) simulated agarose gel showing predicted product size using Exon 2 
genotyping primers. C) agarose gel showing product size of PCR using Exon 2 
genotyping primers. 
Exon 4: two forward and reverse primer combinations were tested for NRF2 Exon 
4, and all primer pairs amplified products matching the predicted size (Figs 5.4 B 
and C) again indicating all pairs work successfully. 





Figure 5.4: NRF2 Exon 4 A) Exon 4 location of genomic primers and guide 
sequences. B) Simulated agarose gel showing predicted product size using Exon 4 
genotyping primers. C) agarose gel showing product size of PCR using Exon 4 
genotyping primers. 
5.2.3 Determining CRISPR editing by T7 endonuclease assay 
CRISPR-Cas9 disrupts gene function by creating a double-stranded break at a 
specific locus which, due to the inefficiency of the NHEJ pathway, results in small 
indels being introduced into the genomic DNA. These indels are too small to resolve 
from a non-modified genomic locus and therefore we use a DNA-mismatch assay 
to assess editing efficiency (Fig 5.5).  
 




Figure 5.5: DNA mismatch assay using a T7 Endonuclease genotyping on edited 
cells will result in homoduplexes of both w/t and mutated products. Denaturing and 
Re-annealing will result in the formation of some heteroduplex DNA (w/t bound to 
mutated). These mis-matched duplexes can be cleaved by a T7 Endonuclease and 
the resulting cleaved products are detected using DNA-PAGE. 
 
This assay relies on the fact that a DNA endonuclease can digest mismatched or 
cruciform DNA structures. Following genotyping at a given modified locus, the 
PCR products will consist of homoduplexes of wild-type and modified sequences. 
By denaturing and re-annealing the PCR products heteroduplexes of wild-type and 
modified DNA will then be present (as well as the wild-type and modified 
homoduplexes). The endonuclease is then able to cleave the mismatched 
heteroduplexes fragments which are then resolved using DNA-PAGE (see 
Materials and Methods). 
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5.2.4 Guide efficiency in HEKs 
A schematic of the guide sequences and adjacent PAM sites can be seen for NRF2 
Exon 1 (Fig 5.6A), Exon 2 (Fig 5.7A) and Exon 4 (Fig 5.8A). All Exons apart from 
Exon 1 (due to its size) were targeted with at least 2 guide sequences. LentiCRISPR 
plasmids containing the various guide sequences were then transfected into 
HEK293T cells for 72 h before genomic DNA was extracted and analysed. 
HEK293T cells were used for guide validation as they are easy to transfect with 
high efficiency. Genotyping PCRs were performed for all targeted Exons and a 
small amount of the PCR reaction was separated on a 1.5% agarose gel to check for 
amplification. 
 
The remainder of the PCR reaction was denatured and slowly re-annealed to allow 
formation of heteroduplex DNA. The re-annealed product was either left untreated 
(uncut) or digested with a T7 Endonuclease (cut) prior to separation on a DNA 
PAGE gel. 
 
Exon 1: The PCR product for NRF2 Exon 1 showed successful amplification 
showing a product running at the same size as the untransfected, control genomic 
DNA (Fig 5.6B). Unexpectedly, when the PCR products were denatured and 
annealed two additional bands were seen in the control genomic DNA sample and 
these were processed with the T7 endonuclease. It is unclear what these bands 
represent but as they were not apparent on the Agarose gel and are not smears they 
likely represent specific mutations introduced by the Taq polymerase. When 
genomic DNA was analysed from 2 repeats of a guide#1 transfection these bands 
were absent and only 2 cleavage products were observed with a combined size of 
the intact PCR product (Fig 5.6C). These fragments are thus a consequence of 
guide#1 cleaving the genomic DNA and suggests INDEL mutations have occurred.  
 




Figure 5.6: T7 endonuclease assay on Exon 1 guides A) Sequence of guide and 
corresponding PAM site (red). B) Amplified Exon 1 DNA run on an agarose gel. 
DNA was extracted from control (u/t) or HEK-293 cells transfected with guide #1. 
Transfection was repeated twice (#1A and #1B). C) Amplified DNA was denatured 
and re-annealed. Re-annealed DNA was separated on a DNA PAGE gel without 
(uncut) or following incubation with the T7 Endonuclease (cut). 
 
Exon 2: Four guides were tested targeting Exon 2 (#3, #9, #11, and #14). Successful 
amplification from transfected cells was seen on an agarose gel (Fig 5.7B). No 
cleavage fragments were on the uncut gel however smearing was apparent above 
guides #9, #11 and #14. Mobility of heteroduplex DNA on DNA PAGE gels is 
retarded compared to homoduplexes and the smearing is a good early indicator that 
editing has occurred. Following incubation with the endonuclease a number of 
cleavage products were observed with guides #9, #11 and #14 (Fig 5.7C). The 
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“smearing” in these lanes was also reduced. This indicates these guides were cutting 
efficiently. No cleavage fragments or smearing was observed with guide #3, 
indicating no editing has occurred. 
 
 
Figure 5.7: T7 endonuclease assay on Exon 2 guides A) Sequence of guide #3, 
9, 11 and 14 and corresponding PAM site (in red). B) Amplified Exon 2 DNA 
separated on an agarose gel. DNA was extracted from control (u/t) or HEK-293 
cells transfected with guide #3, 9, 11 or 14. C) Amplified DNA was denatured and 
re-annealed. Re-annealed DNA was separated on a DNA PAGE gel without (uncut) 
or following incubation with the T7 Endonuclease (cut). 
 
Exon 4: Two guides (#4 and #5) were tested targeting NRF2 exon 4. Both guides 
were transfected individually or co-transfected (4+5). Exon 4 was PCR amplified 
and subjected to a T7 assay. No band-shift was seen in the uncut gel, however post 
Chapter 5: Modulating the NRF2 Pathway Through Gene Editing 
146 
 
incubation with T7-endonuclease, a successful band-shift is seen in #4, #5 and #4+5 
(Fig 5.8C). This again confirms the ability of the CRISPR/guide construct to target 
exon 4 of NRF2. 
 
Figure 5.8: T7 endonuclease assay on Exon 4 guides A) Sequence of guide #4 
and 5, along with the corresponding PAM site (in red). B) Amplified Exon 4 PCR 
was denatured and re-annealed. Re-annealed DNA was separated on a DNA PAGE 
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5.2.5 Editing NRF2 Exon 4 with TALENs 
One alternative to using CRISPR is Transcription Activator-Like Effector 
Nucleases or TALENS. Unlike CRISPR-Cas9 or CRISPR-Cpf1 which both use an 
RNA component to target DNA with TALENS the DNA recognition domain is a 
protein component fused to the Fok1 nuclease.  
 
CRISPR is popular as it is easily “re-taskable”, and multiple guide constructs can 
be made and validated within a short time period. TALEN construction is somewhat 
challenging, and the entire array must be re-made to “re-task”.  TALENS are also 
much more sensitive to base changes (such as SNPs) or DNA methylation (Valton 
et al., 2012). However, because of this and the bipartite structure of the Fok1 
nuclease their “off-target” effects are considerably lower than with CRISPR. The 
only reported gene-editing on primary cells that have been “returned” to patients 
has been using TALENs (Qasim et al., 2017). 
 
We designed a TALEN pair targeting Exon 4 of NRF2 using ChopChop 
(http://chopchop.cbu.uib.no/) (Montague et al., 2014). Each TALEN targets 
opposing strands of DNA and when both bind within ~20bp of each other, then the 
Fok1 nuclease is able to dimerise and create a double-strand DNA break. The 
sequence of the chosen TALEN pair is shown in Fig 5.9A. 
 
The TALE modules are identical apart from two central amino acid residues the 
RVDs which confer the DNA binding ability of the TALEN. NN binds Guanine, 
NI -Adenine; HD – Cytosine and NG – Thymidine. When arrayed within each 
plasmid and fused to the Fok1 nuclease they collectively make up the DNA binding 
domain. The two TALENs containing the arrayed repeats are shown in Fig 5.9B.  
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TALENs are constructed using “golden-gate” cloning. This relies on Type II 
restriction enzymes (e.g. Bsa1, Bbs1 or BsmB1) which unlike other restriction 
enzymes cleave adjacent to their binding site. The orientation of the binding site 
determines whether the cleavage is 5’ or 3’ to binding, importantly this also means 
that the exposed DNA ends can be incompatible. 
 
The set of plasmids used here were from the Voytas lab (Cermak et al., 2011). Each 
RVD module is contained within one plasmid flanked by Bbs1 restriction sites. 
Each RVD is contained within 1 of 10 plasmids and each plasmid must be used 
sequentially. For example, if HD NI NG is required plasmids pHD1, pNI2 and 
pNG3 are used for assembly. The plasmids are arranged within one 
digestion/ligation reaction and cycled (37°C and 16°C) for digestion and ligation. 
 
The arrays are made in 2 parts. Part 1 assembles the first 8 RVDs, part 2 RVDs 9-
18 with the final RVD added when the two parts are assembled. Construction of the 
Left-Hand TALEN is shown in Fig 5.10. DNA from clones were mini-prepped and 
PCR screened. The repetitive nature of the TALEN repeats means that positive 
clones do not give a single band (corresponding to however many TALE repeats 
are in the assembly) but instead show a smearing or ladder-like effect due to 
polymerase slippage (Hommelsheim et al., 2014). We obtained several clones 
(marked in green) which exhibited this smearing, and these were used for the final 
assembly. The finished TALEN constructs were sequenced before use and a linear 









Figure 5.9: Construction of TALEN pair targeting NRF2 Exon 4 A) map of 
Nrf2 Exon 4 with Left- and Right-Hand TALEN target sites on opposing DNA 
Chapter 5: Modulating the NRF2 Pathway Through Gene Editing 
150 
 
strands B) maps of Left- and Right-Hand TALEN pair, the RVD repeats on both 
pairs are shown 
 
Figure 5.10: Construction of Left-Hand TALEN construct linear map of Left-
Hand TALEN.  Map and PCR screen of part#1 (modules #1-8) and part#2 (modules 
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#9-18). Due to nature of the repeated sequences smears and laddered bands indicate 
successful assembly - positive lanes marked in green 
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Figure 5.11: Validation of TALEN pairs on NRF2 Exon 4 A) linear map of 
final Left and Right Hand TALENs B) Exon 4 PCR following transfection of 
HEKs with single and TALEN pairs. C) Amplified DNA (from TALEN -
transfected HEKs) was denatured and re-annealed. Re-annealed DNA was 
separated on a DNA PAGE gel without (uncut) or following incubation with the 
T7 Endonuclease (cut). 
The TALENS were validated in HEK293T cells and transfected both as single 
plasmids and as pairs. As with CRISPR the cells were left for 72h before cells were 
harvested for genotyping and T7 assay. A single band was seen on an Agarose gel 
following genotyping of this region (Fig 5.11B) although TALENs act in pairs they 
create only one double-strand break unlike when using CRISPR pairs. When a T7 
Endonuclease assay was performed no cleavage was observed in untransfected, or 
when the TALENs were transfected alone Fig 5.11C. However, when they were 
transfected as a pair extensive heteroduplex formation was seen on the uncut PAGE 
gel and these products were heavily processed following incubation with the 
Endonuclease. 
This data shows that the constructed TALEN pair is capable of efficiently editing 
Exon 4 in NRF2.  
 
5.2.6 Cpf1 guides targeting NRF2 Exon 4 
Cpf1 is a Class II Type-V variant of Cas9 which contains the RuvC but not the HnH 
domain with the RuvC being able to cleave both DNA strands. There are several 
advantages of using Cpf1 compared with Cas9 these include; shorter guide 
sequences, a different PAM site and a cleavage site distal to the PAM leaving a 
staggered end. Perhaps most importantly, unlike Cas9, Cpf1 guides can be easily 
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multiplexed without the need for additional/individual promoters or splicing 
elements (Zetsche et al., 2015a).  
To assess whether Cpf1 would be able to edit NRF2 we designed guides to Exon 4 
using the design tool at Benchling (https://benchling.com/). Cpf1 has an unusual 
requirement as its tracer RNA is located 5’ to the guide sequence (unlike that with 
Cas9) and it favours a 5’ XTTT 3’ PAM site. Guides were cloned into pY108, a 
lentiviral plasmid which expresses AsCpf1 and the tracer RNA under the control of 
















Figure 5.12: Cloning Cpf-1 guides A) map of pY108 plasmid, expressing both the 
Cpf1 nuclease and tracer RNA B) overhangs following BsmB1 digestion with an 
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example annealed guide oligonucleotides C) guide ligation into the pY108 plasmid 
under a U6 promoter. 
As before, the plasmid was cut with BsmB1, and the stuffer excised. Five guides 
were designed, targeting Exon 4 of NRF2. Oligos were annealed and 
phosphorylated, before being ligated into BsmB1-digested pY108 and sequenced 
(5.12B and C). A linear map of NRF2 Exon 4 detailing the Cpf1 guide sequences 
is shown in Fig 5.13A. 
 
 
Figure 5.13: Validation of Cpf1 guides on NRF2 Exon 4 A) The location and 
sequences of Cpf1 guides and the corresponding XTTT PAM sites (in red) B) Cpf1 
guides were transfected into HEK-293 cells as single or paired plasmids for 72h. 
Genotyping of Exon 4 following guide transfection paired guides will remove a 
region of genomic DNA resulting in a smaller PCR product. 
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Plasmids were transfected into the HEK-293 cells individually or as pairs. As with 
the Cas9 constructs, cells were incubated for 72 hours then genomic DNA was 
extracted and Exon 4 amplified. A single product was seen in all single guide 
samples and no other bands were present (Fig 5.13B). However, when transfected 
as pairs an additional band was seen below the band seen in the untransfected cells. 
Guide pairs #1/5, #2/4, #2/5, #3/4 and #3/5 all produced a double band indicating 
these guide combinations are successfully excising part of Exon 4. 
This data shows that Cpf1 guides are able to edit NRF2 Exon 4 especially when 
paired with other guides. The guides pairs were transfected as separate plasmids but 
the fact that Cpf1 guides can easily be multiplexed under the same U6 promoter 
within the same plasmid means several of those identified here could be assembled 
without significantly affecting plasmid size.  
Some of the single guides are likely to successfully edit cells, a T7 endonuclease 
assay is required to confirm this. Clearly though the use of multiple guides 
facilitates genotyping of edited cells as it negates the requirement for the 
Endonuclease assay. 
 
5.2.7 Cloning KEAP1 guides and editing KEAP1 in HEK-293 cells 
Similar to NRF2, guides were designed to target Exon 1 of KEAP1 using the online 
tool at the Broad website. Unlike NRF2, the guides were spaced apart from each 
other the rationale being if successful cleavage occurs by two guides simultaneously 
excision of a fragment from Exon 1 would occur. This could potentially allow us to 
genotype cells without the use of a T7 endonuclease assay. Genotyping primers 
were also designed to flank the guide sequences Fig 5.14A. The sequence of the 
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two CRISPR guides targeting KEAP1 (#1 and #3) can be seen in Fig 5.14B along 
with the PAM sites (in red). 
Guides were cloned into the LentiCRISPR-SFFV gRNA vector using the same 
method as previously described for NRF2. Guides were sequenced and before 
transfection into HEK-293T cells. Cells were incubated for 72 hours before DNA 
was extracted, and KEAP1 Exon 1 was amplified. The amplified DNA was 
denatured and slowly reannealed before being separated by DNA-PAGE.  
 
The uncut gel showed a single band in the u/t, guide #1 and guide#2. Multiple 
products were seen when both guide #1 and 2 were transfected together (Fig 5.14C). 
There appeared to be very little of the intact Exon 1 PCR product remaining 
suggesting a fragment of Exon 1 has been excised. When these products were 
digested with the T7 endonuclease cleavage products were observed with the two 
single guides, but the digestion was even more extensive when both guides were 
used together. This again indicates successful genome editing has occurred. 
 
The use of the two guides together appears to have two consequences a) it makes 
genotyping easier as only an agarose gel is required to see whether both guides have 
cut and b) the efficiency of the guides together appeared to be much greater than 












Figure 5.14: Keap1 guides A) Keap-1 Exon 1 schematic showing position of 
genotyping primers and guides B) sequence of two Exon 1 guides (#1 and #3) C) 
DNA was extracted and amplified post transfection with Keap1 Exon 1 guides. 
Amplified DNA was denatured and re-annealed. Re-annealed DNA was separated 
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5.2.8 Generation of NRF2 and KEAP1 deficient HCT-116 
Now we have shown the LentiCRISPR constructs can successfully show genome 
editing, we wished to create an NRF2 edited cell line. Whilst we still aim to make 
NRF2 deficient leukaemia cells, AML cells are torturously difficult to transfect and 
a viral vector will likely be necessary. We picked an easier to transfect cell line and 
thus decided to modify both NRF2 and KEAP1 in the colorectal cancer cell line 
HCT-116. 4x105 cells HCT-116 cells were transfected with LentiCRISPRv2 
targeting exon 4 of NRF2 (using the guides NRF2 #4, #5 and #4+#5). Exon 1 of 
KEAP1 was also targeted (KEAP1 #1, #2 and #1+#2). Genomic DNA was 
extracted after 72 hours, however limited evidence of editing was seen (data not 
shown).  
The LentiCRISPRv2 plasmid contains a puromycin selection marker, thus allowing 
us to positively select those successfully transfected with the plasmid. Two 
concentrations of puromycin was used (2.5 and 5 µg/ml), and the cells were 
incubated for 72 hours. after-which genomic DNA was extracted from these cells. 
NRF2 exon 4 and KEAP1 exon 1 was amplified. The DNA was denatured and re-
annealed before being run on a PAGE gel with/ without T7 endonuclease 
incubation. 
The NRF2 Exon 4 (Fig 5.15A) uncut gel showed a single PCR product in all 
samples. Smears were seen above all NRF2 samples transfected with a guide and 
with both concentrations of puromycin, suggesting the presence of heteroduplex 
DNA. This was confirmed by the cut gel, showing a band shift in all transfected 
samples compared to the u/t. The lack of the upper band in samples treated with 
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5ug/ml puromycin suggests a high proportion of the selected population has 
undergone editing.  
Similarly KEAP1 exon 1 (Fig 5.15B) uncut gel showed a single PCR product for 
the individual guides (#1 and #2) in both concentrations of puromycin. The double 
guide (#1+#2) showed multiple bands in both puromycin concentrations, indicating 
successful editing has occurred. The cut gel confirmed these results, with a band 
shift detected in all transfected sample.    




Figure 5.15: Generation of NRF2- and KEAP1-deficient HCT116 cells A) 
NRF2 Exon 4 guides #4, #5 and #4+5. b) KEAP1 guides #1. #2 and #1+2.  Cells 
were transfected with NRF2 and KEAP1 guides for 72 hours before the addition of 
puromycin (2.5 or 5µg/ml). DNA was amplified and denatured/ re-annealed. T7 
endonuclease assay was performed on un-transfected and puromycin-selected cells 
as indicated 
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The CRISPR-Cas9 system does not create a defined mutation instead most 
commonly creates an INDEL 3-5bp upstream of the PAM. The puromycin-selected 
cells will therefore contain a population with varied mutations both heterozygous 
and homozygous.  
In order to create populations of HCT-116 cells deficient in NRF2 we would need 
to clonally isolate the cells. To achieve this, we performed serial dilutions of the 
selected cells and plated them at approximately 0.5 cells/well into 96-well plates.  
We identified individual clones visually using standard light microscopy. Wells 
with colonies originating from a single source were identified as single clones. 
Those with cells growing from multiple sources (or containing no clones) were also 
marked. Once the clones had reached confluency, they were split into 2x further 96-
well plates.  
At this stage we needed to identify which clones were expressing NRF2 and so one 
the “daughter” plates was treated with the proteasome inhibitor MG-132 (to 
stabilise NRF2) for 2h. Protein was extracted (using SDS sample buffer), and 
lysates Western blotted for NRF2 or β-actin. 48 clones were tested per guide (144 
in total). The lack of an NRF2 band in a lane with a β-actin band would correspond 
to a deficient clone. 
As shown in Fig 5.16, NRF2 expression was detected in a number of clones (i.e. 
Guide #4 clone 3+4), however we were unable to detect NRF2 in several clones 
(for example Guide #4 clone 2 and 5). In addition, we also detected clones 
expression NRF2 but running at a lower molecular weight than expected (for 
example Guide #2 clone 43). This could indicate a truncation has occurred. We 
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picked 34 clones that were negative for NRF2 and expanded them for further 
analysis 
Once confluent, we tested three clones per guide to confirm the absence of NRF2. 
Clones were again treated with MG-132 but as there were more cells available 
lysates were prepared and protein assays performed to normalise protein loading. 
Lysates were then Western blotted for NRF2 and β-actin with untransfected HCT-
116 cells used as a positive control.  
MG-132 was able to induce NRF2 expression in the wild-type HCT-116 cells, but 
not in any of the nine clones chosen. The β-actin band present in all the clonal 
samples re-confirms these clones were deficient in NRF2 (Fig 5.17).  
 
 








Figure 5.17: Confirmation of NRF2-deficient HCT-116 clones 3 clones per 
guide were treated without/ with 10µM MG-132 for two hours to stabilise NRF2. 
Protein expression was detected by Western blot using NRF2 and β-actin 
antibodies. 
 
5.2.9 Generation of NRF2-deficient K562 cells  
We next wished to see whether we could use some of the NRF2 targeting plasmids 
we have characterised earlier to knock-out NRF2 in haematopoietic cells lines. 
These lines are notoriously hard to transfect, compared to HEK293T or HCT-116 
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cells, and therefore we used the Exon 4 LentiCRISPR plasmids to make Lentivirus 
to transduce the cells. We initially started out in the Chronic Myeloid Leukaemia 
cell line, K562 as they have been shown to be more transducible with Lentivirus 
than AML lines (such as THP-1s). To create viral particles HEK-293T were 
transfected with the viral packaging vectors pRSV-REV, pMDLG-RRE and 
pCMV-VSVG and either LentiCRISPR containing NRF2 guide #4 or #5. The 
lentiviral particles were harvested in the supernatant and concentrated by 
ultracentrifugation before use. To test the editing ability of the viral particles, we 
first transduced HEK-293T cells. DNA was extracted from the virally transduced 
cells, after 72 h and Exon 4 amplified and a T7 endonuclease assay was carried out. 
A cleavage fragment was observed with guide #5 but not #4 (data not shown).  
K562 cells were then transduced with two concentrations of concentrated guide #5-
expressing virus for 72 hours before the transduced cells were selected with 
puromycin for 7 days. Genomic DNA was extracted from cells both before and after 
puromycin selection. Again, NRF2 Exon 4 was amplified before being incubated 
with T7 endonuclease. 
 
As shown in Fig 5.18, the uncut gel showed a single specific PCR product in all 
samples. A smear is seen above post puromycin selection indicating the presence 
of heteroduplex DNA. These results are confirmed upon incubation with T7 
endonuclease where a cleavage fragment is present in these samples, but not in the 
wild type or non-puromycin selected samples. 
 





Figure 5.18: Generation of NRF2-deficient K562 cells K562 cells were 
transduced with two concentrations Lentiviral particles expressing NRF2 guide #5 
for 72 hours. Cells were selected with 6µg/ml puromycin as indicated. A T7 assay 
was performed on selected cells to assess editing efficiency. 
 
The puromycin selection creates a heterogeneous population of cells. Some will 
have mutations in both Exon 4 alleles some in just one, while others may not be 
modified at all. As with the HCT-116 cells we needed to obtain clonal lines from 
this population. Since K562 is a suspension cell line, we could not use limiting-
dilution as we have previously been unable to generate clonal haematopoietic cell 
lines using this method. 
 
To this end we used a “semi-solid” media based on resuspending the cells in 2.5% 
Methycellulose dissolved in RPMI. 700 cells/ml were mixed with the 
Methylcellulose/RPMI solution using a syringe with a blunt ended needle before 
being plated 1ml/well into 12 well plates. The plates were incubated without 
disturbance for 7-10 days when discreet clumps of cells became apparent. 
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Colonies were picked into 96-well plates using a light microscope which had been 
placed in a hood, an inbuilt screen allowed for accurate colony identification and 
picking. Clones were then grown to confluency and expanded. 
 
As with the HCT-116 cells, the 96-well plate was split and one “daughter” plate 
treated with MG-132 for two hours. Cells were lysed, and lysates analysed for 
NRF2 by Western blot. By this large-scale screening we identified several clones 
deficient in NRF2 expression and several clones were chosen and expanded further 
(data not shown). To confirm the results from the 96 well plate, 12x clones were 
grown to confluency before being treated with MG-132 (10µM) for two hours. 
Protein lysates were subsequently extracted and NRF2 detected by Western blot. 
 
MG-132 increased NRF2 expression in un-transfected K562 cells. Of the 12x 
clones picked 9 failed to show NRF2 induction following MG132 treatment 
suggesting the editing had been successful in these lines (Fig 5.19). NRF2 induction 
was seen in clones #2, 7 and 11 indicating the CRISPR editing was not successful 
or complete, or the population was mixed. A slight induction is also seen in clone 
5. Clones #4, #5, and #6 were passaged onwards.  
 





Figure 5.19: Deriving NRF2-edited clones from puromycin-selected K562 cells 
Puromycin-selected K562 cells were single-cell cloned by culturing in semi-solid 
medium before expansion. Isolated clones were treated with MG-132 (10 µM) for 
two hours to stabilise NRF2. Protein expression was detected by Western Blot using 
NRF2 and β-actin antibodies 
 
MG-132 is a proteasome inhibitor and therefore acts by preventing NRF2 
degradation allowing the protein to stabilise, however it remains unclear if it is able 
to transcriptionally activate NRF2 expression. Thus, to confirm these clones were 
indeed NRF2 deficient, we treated them with the NRF2 inducers CDDO and 
Sulforaphane. Protein was extracted, normalised through protein determination 
assays and western blots were performed (Fig 5.20).  
 





Figure 5.20: NRF2 inducers CDDO and Sulforaphane in NRF2-deficient K562 
cells K562 clones (#4, #5 and #6) were treated with 10uM MG-132 (MG) or the 
NRF2-inducers (100mM) CDDO-Me (C) and (5 µM) Sulforaphane (S). Protein 
expression was detected by Western Blot using NRF2 and β-actin antibodies. 
 
As expected we saw positive NRF2 induction with MG132 and both CDDO and 
Sulforaphane in the wild-type K562 cells, and clone#5, but no induction in was seen 
in clone #4 and #6. The fact that neither a proteasome inhibitor can stabilise NRF2 
or that NRF2 can be induced by known activators indicate these cells were deficient 
in NRF2. 
 
Genomic DNA was extracted from these clones, Exon 4 amplified and the resulting 
PCR product purified and sequenced (Fig 5.21). We included an additional clone 
#8 as clone #5 appeared to still express NRF2. All clones were disrupted at or very 
near to the site at which the guide RNA is predicted to cleave the Exon 4 (3 bp 
downstream (3’ to) the PAM site). Clone #4 had insertion of a C. Clones #6 and #8 
had extensive deletion of Exon 4 starting near this site. The lack of uniformity in 
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5.2.10 Generation of NRF2 deficient THP-1 cells 
We next wished to see whether we could edit NRF2 in an AML cell line. The 
Lentiviral particles containing NRF2 guide #5 were used as for the K562 cells (see 
above). THP1 cells were transduced with two concentrations of LentiCRISPR 
NRF2 guide #5 for 72 hours, before being selected for with puromycin. DNA was 
extracted from these cells, NRF2 exon 4 was amplified before being denatured/ 
reannealed and a T7 endonuclease assay was carried out. The uncut gel showed a 
single PCR product in the correct size. Upon incubation with T7 endonuclease, a 
cleavage fragment was seen in both puromycin selected cells indicating cleavage 





Figure 5.22 Generation of NRF2-deficient THP1s cells THP-1 cells were 
transduced with two concentrations Lentiviral particles expressing NRF2 guide #5 
for 72 hours. Cells were selected with 6µg/ml puromycin as indicated. DNA was 
amplified and denatured/ re-annealed. T7 endonuclease assay was performed on un-
transfected and puromycin-selected cells as indicated 
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Like the K562 cells, single-clones of selected THP-1s were obtained by cloning the 
cells in Methylcellulose then transferring colonies to 96-well plates. Protein lysates 
were extracted and NRF2 detected by Western blot. We identified several clones 
(data not shown) that did not show any NRF2 expression, and 19 clones were 
passaged onwards. To confirm the results from the 96 well plate, the clones were 
once again treated with MG-132 and screened for NRF2/β actin expression by 
Western blot (Fig 5.23). 
 
NRF2 antibodies are notoriously poor and this was especially true for the THP-1 
cells. A band is present in untreated cells around the molecular weight we would 
expect to see NRF2 but following MG132 treatment upper bands are clearly visible 
which are not in the untreated sample. It appears that the lower band is non-specific. 
 
Whilst we identified several false negatives from the 96 well plate, we identified 
several clones with no detectable NRF2 expression including #1, #2, #10 and #16-
19. These clones were expanded for further investigation. 
 





Figure 5.23: Deriving an NRF2 edited clones from puromycin-selected THP-1 
cells Puromycin-selected THP-1 clones were single-cell cloned using semi-solid 
medium before expansion. Isolated clones were treated with MG-132 (10µM) for 
two hours to stabilise NRF2. Protein expression was detected by Western Blot using 
NRF2 or β-actin antibodies. * indicates a non-specific band 
 
Four of these clones (#1, #2, #10, and #19) were treated with MG-132 and the NRF2 
inducers CDDO-Me, and sulforaphane. Protein was extracted from these cells and 
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normalised and Western Blots were used to determine protein expression for NRF2 
and β-actin (Fig 5.24). 
 
As expected MG-132, CDDO-me and sulforaphane were able to induce NRF2 in 
the wild-type THP-1 cells, with CDDO-Me being the most potent. No NRF2 
expression was detected in any of the clones with any of the treatments indicating 
its expression is disrupted in the clones. 
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Figure 5.24: NRF2 inducers CDDO and Sulforaphane in NRF2-deficient THP-
1 cells. THP-1 clones (#1, #2, #10 and #19) were treated with MG-132 (10 µM) or 
the NRF2 inducers CDDO-Me (100 nM) and Sulforaphane (5 µM). Protein 
expression was detected by Western Blot using NRF2 and β-actin antibodies. * 
indicates non-specific band 
 
DNA was extracted from two of these clones and as with the K562 cells Exon 4 
was sequenced (Fig 5.25).  Clone #1 showed a large deletion starting just 4bp 3’ to 
the expected cleavage site. Clone #19 showed a small deletion starting 3bp 3’ to the 
expected cleavage site. As with the K562 cells, the modifications in the clones 
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5.3 Conclusions and Discussion   
In this Chapter we designed constructs with the aim of targeting and disrupting 
NRF2 and KEAP1 gene expression in AML cells. Whilst we predominately 
focussed on CRISPR-Cas9 (due to its simplicity) we also explored some additional 
gene-editing methods. All have their strengths and weaknesses. 
 
Guides targeting different exons in NRF2 and KEAP1 were designed and 
subsequently cloned into a LentiCRISPR plasmid that had an AML “friendly” 
SFFV promoter. HEK293T cells were used to validate all the initial experiments as 
they are highly transfectable.  
 
The editing ability of these guides were tested in HEK-293T cells and five 
successful guides were identified in NRF2, and two in KEAP1 (Figs 5.6, 5.7, 5.8 
and 5.14). In addition to transfecting these guides individually, we identified that 
CRISPR guides targeting the same exon can be used in tandem successfully with a 
high targeting efficiency. If the guides are spaced sufficiently far apart, a high 
proportion of cleavage shows the excision of bases between the two guide sites (as 
shown when KEAP1 guides #3 and 7 are co-transfected) (Fig 5.14). 
 
We initially tested our constructs in HEK-293 cells. NRF2 guides targeting exon 4 
were transfected and positively selected for with puromycin. While this created a 
highly selected population of edited HEK-293 cells, the exact mutation in exon 4 
can vary. For us to perform comparative studies, we required a homogeneous 
population of cells with the exact mutation being fully characterised. It was 
therefore necessary to derive an isogenic population from a single CRISPR clone. 
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We derived several HEK-293 clones containing disruptions to exon 4 of NRF2. 
Disrupted NRF2 clones of HCT-116 cells were made in a similar manner. To create 
NRF2 knockout leukaemia cell lines (K562 and THP-1), we transduced cells with 
an NRF2 guide #5 lentivirus. Similar to the HEK-293 cells, clonal populations were 
created from transduced K562 and THP1. The clonal mutations were confirmed 
through Sanger sequencing. 
 
CRISPR guides targeting KEAP1 was cloned into the Lentiviral SFFV plasmid and 
used to make clonal HEK-293 knockouts. We attempted to make KEAP1 edited 
HCT-116 cells, while we were able to develop a selected population of KEAP1 
edited HCT cells, we were unable to develop a clonal population of these cells. 
As well as Cas9 we also explored the use of alternate nucleases/editing 
methodologies TALENs and another CRISPR nuclease, Cpf-1. 
 
The only published studies on primary cells being manipulated and “returned” to 
patients is using TALENs. Both the Left- and Right-Hand TALEN is attached to 
one part of the bipartite Fok1 nuclease. This in part explains the reduction of off-
target effects compared to CRISPR as both 20 bp TALEN targeting sequences must 
occur within 20-30 bp of each other in order for Fok1 to dimerise and cause a 
double-strand break (Christian et al., 2010). Further specificity can be achieved 
using a heterodimerizing Fok1 (Miller et al., 2007), so in the unlikely event two 
Left- or Right-hand TALENs bind no cutting will occur (Cade et al., 2012). This 
specificity is their key advantage in a clinical setting. 
 
The TALENs we designed efficiently edited exon 4 in NRF2 (Fig 5.11). The design 
and construction however, is much more complicated than with CRISPR-Cas9 or -
Cpf-1. While “Golden-Gate” cloning using the Type II restriction enzymes makes 
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this much easier it still requires a few weeks to synthesise the final TALENs and 
they require at least an intermediate knowledge of molecular biology. The main 
issue lies with delivery. In vivo delivery generally requires the use of viruses. 
Introducing plasmids/proteins into certain cell types (such as AML and B-cell lines) 
also requires the use of viruses. Due to the nature of their structure (each RVD is 
contained within the Helix-Loop-Helix motif) TALENS (and Zinc Fingers contain 
many repeated sequences) this effectively rules out the use of viral methods of 
delivery. 
 
There have been attempts to reduce the off-target effect when using CRISPR and 
the initial studies mimicked the TALEN pairs and resulted in the use of a Cas9 
“nickase”. This enzyme has one of the active sites, either D10 in the HNH domain 
or H588 in the RuvC domain mutated to alanine. This renders Cas9 unable to create 
double- but only single-strand breaks (Cong et al., 2013). Cutting one strand of 
DNA results in the cell repairing the “nick” through the Base-Excision Repair 
pathway which is highly accurate, so no mutations will occur. If, however two 
“nicks” occur within 40-50bps a double-stand break will occur (Ran et al., 2013a). 
Later studies following the publication of structural information on Cas9 binding 
and mechanism have led to so called “enhanced” Cas9 nucleases with purported 
lower “off-target” such as eSpCas9 and SpCas9-HF1 (Kleinstiver et al., 2016, 
Slaymaker et al., 2016). 
 
The other current drawback for using CRISPR-Cas9 therapeutically is its size. At 
~4.2 kb (~150 kD) Cas9 is a large protein which makes it difficult to introduce 
efficiently into cells. While studies have tried to address this for example by using 
“split” Cas9 these proteins still have their issues (Zetsche et al., 2015b). The 
CRISPR system is very diverse and bacteria contain many CRISPR nucleases. 
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There is a tremendous push to find other Cas9-related nucleases that are smaller 
than SpCas9 or have differing specificities. One such from Staphylococcus aureus 
(SaCas9) is 300bp small than SpCas9 (115 kD) and has a longer PAM sequence 
NNGRRT which occurs less in genome, reducing the “off-target” effects. However, 
this also limits its list of targetable sites making it more of a complimentary tool 
(Ran et al., 2015). 
 
Cpf-1 is another such variant which, while only being slightly smaller than SpCas9, 
has some features that make it useful. Its PAM TTTN is T-rich meaning it can be 
used to target AT-rich genomic locations. The Tracer RNA is only 24 bp (compared 
to over 100 bp for Cas9 proteins) and perhaps more importantly its sgRNAs can be 
easily multiplexed without resorting to extra promoter or RNA splicing elements 
(Zetsche et al., 2017). We found that Cpf-1 could efficiently edit exon 4 in NRF2 
and when used as pairs was able to excise a piece of DNA from the exon (Fig 5.13). 
We were unable to try multiplexing these guides within one plasmid. But it would 
be envisaged that 3-4 of these guides including the TRACER RNA could be 
packaged into the same Lentiviral plasmid and only be around 300bp in total. 
 
The NGG PAM is fairly abundant in the genome but its efficiency is known to vary 
depending on the genomic location (for example in AT -rich regions). Its position 
may not always be optimal to edit a target gene while producing a guide sequence 
with low “off-target” effects. By engineering SpCas9 non-canonical PAM 
sequences (e.g. NAG and NGA) PAM specificity has been expanded to include 
NAG and NGA (Kleinstiver et al., 2015). 
 
In this study we attempted to overcome the problem of using a mixed CRISPR 
population by creating a clonal population of cells containing a single CRISPR 
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mutation. One problem we anticipate if undertaking comparison studies with these 
clones, is the lack of parental population for the individual clones. The clonal 
populations would therefore be compared against the wild-type cell line (which 
while similar, will inevitably contain a slightly different genetic makeup). If 
repeated we would aim to create and characterise the clonal populations first before 
editing them with CRISPR, thereby creating a more reliable method to determine 
the function of the mutated gene. 
 
Due to time constraints we have been unable to fully characterise NRF2 signalling 
in the edited leukaemic cells. We have shown no NRF2 protein was induced in these 
cells when stimulated with NRF2 activating compounds sulforaphane and CDDO 
(Fig 5.20 and 5.24). In the future we would like to characterise the expression of 
NRF2 target genes, in particular HO-1, NQO1 and GCLM. Whilst we expect no 
mRNA or protein change among the NRF2 targets, some minor modulation is to be 
expected due to the compounds being “dirty” and regulating other pathways in 
addition to NRF2. 
 
We would also like to do a more thorough investigation of downstream targets of 
NRF2 in particular to characterise the proteins binding to the promoters of certain 
NRF2-regulated genes. To do this we could like to perform an engineered DNA 
binding molecule mediated chromatin immunoprecipitation (enChiP). EnChip is a 
methodology that uses the binding ability of dCas9 to bind to a region of DNA, 
thereby creating an RNA/DNA complex. The dCas9 is tagged, which can be used 
to enrich the region of interest through chromatin immunoprecipitation. This can 
then be used for RNA, DNA or protein analysis. One study used enCHIP on a region 
of IRF-1 and mass spectrometry to identify all proteins that interacting with this 
locus (Fujita and Fujii, 2013).    
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6.1 Final Discussion 
6.1.1 NRF2 regulation of miR-125b and miR-29b 
The dysregulation of NRF2 results in chemotherapy-resistance and oncogenesis in 
several malignancies including AML. This work follows on from earlier 
observations in the laboratory which demonstrated AML cells exhibit constitutive 
NRF2 activation (Rushworth et al., 2012). In this study we aimed to investigate the 
function of NRF2 in AML, in particular, its ability to regulate miRNAs.  
 
We performed a miRNA array following treatment with an NRF2 activator or 
genetic perturbation of NRF2. The array identified several miRNAs that exhibited 
modulated expression in response to changes in NRF2. miRNAs were further 
validated through knockdown of NRF2 or KEAP-1 and a correlation was observed 
between NRF2 and miR-125b and miR-29b. NRF2 positively regulates miR-125b1 
and negatively regulates miR-29b1 in both AML cell lines and primary patient 
samples. A reporter assay demonstrated that this occurs through NRF2 binding to 
ARE sites in the promoter sequences of both miRNA.  
 
To understand the function these dysregulated miRNAs play in AML we directly 
modulated their levels using miRNA “mimics” and antagomiRs. Increasing or 
decreasing levels of miR-125b and miR-29b, resulted in only a slight increase in 
apoptosis respectively. However, simultaneously modulating levels of both miR-
125b and miR-29b resulted in a significant increase in apoptosis and increased 
sensitivity to front-line chemotherapy drugs such as Daunorubicin. This suggests 
NRF2 synergistically regulates both miRNAs to increase resistance to 
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chemotherapy and decrease sensitivity to apoptotic signalling. This is in part due to 
the repression of pro-apoptotic BAK and STAT3, while anti-apoptotic proteins such 
as AKT2 were induced. 
 
Of the 93 miRNAs tested we were only able to fully characterised miRs-125b and 
-29b. In the future it would be interesting to investigate the role the other NRF2 
regulated miRNA play in AML. For example miR-221 and -222 have been known 
to act as both oncomiRs and tumour suppressor miRs, with their exact role 
dependent on the malignancy involved (Garofalo et al., 2012). In breast and prostate 
cancer they act as oncomiRs by regulating ERα and the pro-apoptotic protein Bim 
(Di Leva et al., 2010, Tanaka et al., 2015). This results in increased proliferation 
and a reduction in apoptosis.  In erythroleukaemia they repress c-Kit expression, 
thereby reducing cell growth (Felli et al., 2005).  
 
It would be interesting to characterise the expression of NRF2-regulated miRNAs 
in different AML subtypes to identify any prognostic link. For example, 
dysregulated miR-125b expression is more highly associated with APL compared 
to other AML subtypes (Zhang et al., 2011a). The miRNAs we identified in AML 
would be compared to their expression in other malignancies to examine whether 
dysregulation is tissue specific or has global consequences to the disease 
progression as a whole. 
 
Despite significant research, chemotherapy agents such as daunorubicin and 
cytarabine still remain the predominant treatments used for AML (De Kouchkovsky 
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and Abdul-Hay, 2016). Kinase and Bcl-2 inhibitors are revolutionising the 
treatment of CML and CLL however these breakthroughs are not being transferred 
to AML (Kantarjian et al., 2012, Roberts et al., 2016). Haematopoietic stem cell 
transplantation (allogenic bone marrow transplant) remains the treatment option for 
many and the end of the line for clinical options if it fails.  
 
We have a good understanding of the underlying cytogenetics characterising AML, 
and the idea of targeted therapy, is becoming increasingly popular. The FLT3 
inhibitor Midostaurin is the only example of a new drug that has been approved for 
AML treatment in the last half century, but is suitable for only a subset of AML 
patients (Levis, 2017).  The hope is that more novel drugs will be developed and 
made currently available to treat all classes of AML.  
 
miRNAs predominately play a role in the “fine tuning” of gene expression, 
correcting their expression when dysregulated could provide a viable therapeutic 
option. Examples of miRNA-regulating agents (miR-mimics or antagomiRs) have 
shown promise, the most notable being an antisense oligonucleotide-based drug to 
treat Huntington’s disease (Zaghloul et al., 2017). A Phase 1/2a trial demonstrated 
that mutant Huntingtin protein levels could be reduced. Our data suggests this could 
be an avenue of interest in AML. 
 
6.1.2 Gene Editing NRF2  
Gene editing using site-directed nucleases (such as TALENS or CRISPR-Cas9) can 
be used to target specific regions of DNA leading to gene disruption. Due to their 
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“programmable” nature theoretically any area of the genome is targetable, and we 
wished to see whether we could use these targeted nucleases to disrupt NRF2 and 
KEAP1 in AML cells.  
 
We successfully validated a number of gene-editing methods targeting NRF2 in 
HEK-293T cells. Of these the CRISPR-Cas9 or CRISPR-Cpf1 were the easiest 
constructs to generate and multiple guides could easily be cloned and tested at one 
time. The TALEN pair did seem to be highly efficient in the HEK293Ts but was 
time-consuming to generate, however, this is currently the only gene-editing 
technology to date to be used therapeutically (Qasim et al., 2017). As our aim was 
to modify AML cell lines we would ultimately have to resort to using lentivirus to 
introduce the guides and Cas9 into the cells. TALENs cannot be packaged by 
lentiviruses due to the presence of many repeated sequences. 
 
We cloned CRISPR guides targeting Exons 1, 2 and 4 of NRF2 and observed 
editing in all these exons. However, guides targeting Exon 4 were used throughout 
this study as the genotyping primers were more robust.  
 
To test the methodology Exon 4 of NRF2 was targeted in HCT-116 colon cancer 
cells and in order to obtain “knock-out” cells, clonal populations were made from 
puromycin-selected cells. A total of 96 clones were screened per CRISPR guide, 
using Western Blot following treatment with MG-132. The clones which showed 
no NRF2 expression were further passaged and re-tested for NRF2 expression. 
Screening many clones by Western blot was time-consuming but the only other 
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method of verification would require genomic DNA extraction followed by the T7 
assay which could be prohibitively expensive. 
 
When validating guides targeting Exon 1 of Keap-1 and, also when using the Cpf-
1 plasmids as pairs we noticed the removal of the sequence in between the two 
guides. This was an interesting observation and suggests in future we could use 
guides as pairs and simply screen clones using agarose gels following a genotyping 
PCR. For this to work with Lentiviral plasmids the two guides would have to be 
clones within the same backbone. 
  
We were unable to directly transfect the plasmids into THP-1 cells. Although we 
have previously, successfully used nucleofection for AML lines we needed as high 
transfection efficiency as possible as the editing efficiency will always be low. We 
had to therefore package the Cas9 and guides into a lentivirus. 
  
Both the CML cell line K562 and the AML cells line THP-1 cells were transduced 
with lentiviral particles containing CRISPR targeting Exon 4 of NRF2.  
 
Positively-edited clones were selected by puromycin and clonal expansion of 
positive populations were obtained by plating cells in a Methylcellulose-based 
semi-solid medium. We tried cloning the cells by limiting dilution into 96-well 
plates but failed to obtain any clones growing out.  
 
Chapter 6: General Discussion 
189 
 
The “micro-environment” surrounding cells trapped in the semi-solid medium must 
allow them to divide and form colonies, which were identified by transmission light 
microscopy and could be picked using a pipette tip into 96 well plates. While this 
approach could at times be somewhat tedious it was the only reproducible way we 
could get clonal AML lines.  Expanded clones were treated with MG132 and NRF2 
was detected by Western blot post treatment with MG-132. As with the HCT116 
cells this was incredibly time-consuming and would benefit from a simplified 
genotyping approach to identify null cells. 
 
Several colonies negative for NRF2 expression were further expanded. They were 
subsequently treated with the NRF2 activating drugs CDDO and sulforaphane to 
assess any responsiveness and to confirm no NRF2 activity was present. We were 
successful in identifying positive NRF2 KD colonies which were absent in NRF2 
expression.   
 
6.1.3 Future work 
We successfully used CRISPR-Cas9 to generate NRF2-deficient AML and CML 
cell lines. Importantly, we were able to obtain single cell clones of these cells. This 
means we are now in a position to utilise our experience with both CRISPR and 
Lentiviral delivery in haematopoietic cell lines to further study NRF2 and other 
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Using NRF2-deficient AML cells to further explore the role NRF2 plays in 
miRNA regulation 
Given time constraints we were only able to briefly characterise these cells.  We 
would first analyse the expression of miR-125b1 and miR-29b1 in these cells to see 
if any mis-regulation supports our experimental hypotheses from Chapters 3 and 4. 
We would also like to analyse the expression of the miR-125b1/29b1 target genes 
and proteins, confirming the ones identified are indeed causing the anti-
apoptotic/pro-proliferative effects seen in the AML cell lines and patient samples.  
 
We are also able to “re-introduce” NRF2 into the deficient cells under the control 
of a Tet-On promoter which enables us to use Doxycycline to directly activate 
NRF2 in these cells. Although this is a non-physiological stimulus it is a “cleaner” 
method of activating NRF2 than drugs such as Sulforaphane and CDDO. 
 
Targeting miRNA “seed” regions  
We identified a number of ARE sites that NRF2 may use to regulate miR-125b1, 
and successfully modulated expression of miR-125b and miR-29b using miRNA 
mimics and antagomiRs. Clearly, we could use CRISPR to more precisely 
investigate the regulation of these miRNAs. Targeting a miRNA seed region with 
a guide RNA would effectively delete the miR from the cells. A more targeted 
promoter approach would be used to target individual ARE sites within the miRNA 
promoters in order to specifically identify those responsible for NRF2 regulation. 
Finally, by combining pairs of guides theoretically it would be possible to delete 
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specific seed regions from a given genomic location. All these approaches would 
give us a better insight into the role of both miRNAs in AML cells. 
 
Analysis of NRF2 target genes in AML 
NRF2 activation in AML is linked to resistance to commonly used chemotherapy 
drugs. It would be interesting to further characterise the NRF2-deficient versus 
parental cells to ascertain if any of the changes in gene expression can account for 
this. Although the cells we produced are clonal, they are not isogenic (as they were 
not derived from a single clone). So, it would be of use to generate clonal lines from 
untransfected AML cell lines prior to modifying them. The rationale behind 
performing editing in this way, would be to ensure an identical genetic background 
between the parental and “edited” clones.  
 
The clones could then be characterised before further comparative studies are 
carried out such as ChIP Seq or RNA Seq which can be used to characterise all 
binding sites and mRNA influenced by “knocking-out” NRF2. Other members of 
the laboratory have successfully used CRISPR to endogenously tag NRF2 and it 
would be interesting to use these plasmids in some of the AML cell lines as it would 
greatly simplify any ChIP-Seq methodologies. This would allow us to identify 
novel NRF2-targets and categorise the genes that are affected by NRF2 and 
responsible for chemoresistance.  
 
We have also noticed the NRF2-deficient THP-1 clones tend to grow at a slower 
rate than the wild-type cells (data not shown), this may be due to clonal variation 
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or due to NRF2-dependent changes in their metabolomic profiles. As previously 
discussed, NRF2 has been shown to regulate various cancer metabolism genes (in 
particular the phosphate pentose pathway (PPP) and NADPH synthesis) (Mitsuishi 
et al., 2012b). We would like to investigate NRF2’s role in regulating metabolism 
genes in AML, while we would focus on the PPP pathway we would also like to 
see if any additional metabolomic pathways are under the influence of NRF2 
regulation. 
 
Crosstalk of NRF2 and other transcription factors 
As previously discussed, despite AML cells being characterised by constitutive 
activation of NRF2, there is no mutation disrupting the NRF2/KEAP1 binding sites. 
Instead NRF2 is dysregulated due to additional upstream signalling pathways such 
as NF-κB (Rushworth et al., 2012). However, it is likely that NRF2 is regulated by 
additional upstream signalling.  
 
In order to identify upstream signalling factors we intend to use the technique 
enChIP (Fujita and Fujii, 2013). enChIP uses a catalytically inactive Cas9 (dCas9) 
which retains the binding ability of Cas9 to DNA but prevents DNA cleavage. We 
have previously made dCas9n which targets Exon 4 of NRF2, however we intend 
to redesign the dCas9 to target Exon1, the construct would also contain a tag. The 
dCas9 would bind to the targeted region of NRF2 and this region of DNA is purified 
and immunoprecipitated through antibodies against the tag. This can then be 
combined using techniques such as mass spectrometry or RNA seq to identify 
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proteins or RNA sequences which associate with the region. This will give us a 
greater understanding of the upstream regulators of NRF2 transcription factor. 
 
Genome screening to identify NRF2 target genes 
To further study other associated downstream targets of NRF2, we could carry out 
a CRISPR screening library. This would allow us to screen a high number of 
functional processes through the designing panels of multiple sgRNA per gene of 
interest. These are transduced using a lentiviral vector and a selection drug would 
be used (for example daunorubicin or cytarabine). DNA would be extracted from 
the surviving cells, and using the sgRNA barcode for identification, next generation 
sequencing could be performed. The surviving cells would assumedly contain a 
mutation in a gene that provides a survival advantage to them. We would perform 
the screen on both parental THP-1 clones and those with edited NRF2, looking in 
particular at guides which aid cell survival in one drug-resistant situation, but not 
the other. 
 
Overall this study gives us a greater insight into the role of NRF2 in AML, and, in 
particular, its contribution to oncogenesis through the regulation of miRNAs. 
Furthermore, the tools developed in this study have the potential to greatly expand 
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NRF2-driven miR-125B1 and miR-29B1 transcriptional
regulation controls a novel anti-apoptotic miRNA
regulatory network for AML survival
NM Shah1,2, L Zaitseva1, KM Bowles1,3, DJ MacEwan2,4 and SA Rushworth*,1,4
Transcription factor NRF2 is an important regulator of oxidative stress. It is involved in cancer progression, and has abnormal
constitutive expression in acute myeloid leukaemia (AML). Posttranscriptional regulation by microRNAs (miRNAs) can affect the
malignant phenotype of AML cells. In this study, we identified and characterised NRF2-regulated miRNAs in AML. An miRNA array
identified miRNA expression level changes in response to NRF2 knockdown in AML cells. Further analysis of miRNAs
concomitantly regulated by knockdown of the NRF2 inhibitor KEAP1 revealed the major candidate NRF2-mediated miRNAs in AML.
We identified miR-125B to be upregulated and miR-29B to be downregulated by NRF2 in AML. Subsequent bioinformatic analysis
identified putative NRF2 binding sites upstream of the miR-125B1 coding region and downstream of the mir-29B1 coding region.
Chromatin immunoprecipitation analyses showed that NRF2 binds to these antioxidant response elements (AREs) located in the
5′ untranslated regions of miR-125B and miR-29B. Finally, primary AML samples transfected with anti-miR-125B antagomiR or
miR-29B mimic showed increased cell death responsiveness either alone or co-treated with standard AML chemotherapy.
In summary, we find that NRF2 regulation of miR-125B and miR-29B acts to promote leukaemic cell survival, and their manipulation
enhances AML responsiveness towards cytotoxic chemotherapeutics.
Cell Death and Differentiation (2015) 22, 654–664; doi:10.1038/cdd.2014.152; published online 17 October 2014
Acutemyeloid leukaemia (AML) is a biologically heterogenous
disorder that occurs as a consequence of a wide variety of
genetic abnormalities in haematopoietic progenitors that are
derived from the bone marrow.1 However, it is likely that AML
share various survival pathways downstream of the driver
mutations, making the existence of common survival path-
ways and therapeutic targets likely.2
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a
member of the Cap ‘n’Collar basic leucine zipper transcription
factor family that protects cells from reactive oxygen species
through the regulation of a number of cytoprotective genes
including heme oxygenase-1 (HO-1) and NAD(P)H dehydro-
genase quinone 1 (NQO1).3–5 In cancer, NRF2 activation is
pro-tumoural in a spectrum of malignancies through mutations
in NRF2 or its cytosolic inhibitor KEAP1.6–9 However, we have
previously shown that in human AML constitutive activation of
the NRF2 signalling pathway is not through somatic mutations
of NRF2/Keap1 but as a consequence of upstream constitu-
tive activation by NF-κB.10,11 In addition to contributing to the
malignant phenotype of AML, we also found that NRF2
contributes to intrinsic leukaemia cell resistance to standard
front-line chemotherapy agents.12,10
microRNAs (miRNAs) are short non-coding RNA mole-
cules, approximately 20–30 nucleotides in length, that can
posttranscriptionally regulate gene expression by binding to
the 3′ UTR of their target mRNA, thereby repressing gene
transcription.13 miRNA expression has shown to be dysregu-
lated in a range of cancers, and can act as tumour suppressor
miRs (by downregulating oncogenes) or oncomiRs (by
targeting tumour suppressors).14 miRNAs are being increas-
ingly studied with the expectation that modulation of their
expression can be harnessed to improve cancer therapy. A
recent study using chromatin immunoprecipitation sequen-
cing (ChIP-Seq) identified high-confidence ChIP-Seq peaks
for NRF2 binding in the vicinity of several miRNAs, suggesting
they could be regulated by NRF2.15
In the present study, we look to identify whether NRF2
regulates miRNA in human AML. Furthermore, we evaluate
whether NRF2-regulated miRNAs have functional importance
not only on the biology of the disease but also in the leukaemia
cell death to chemotherapy treatment.
Results
Lentiviral NRF2 knockdown alters miRNA expression.
NRF2 can regulate drug resistance in AML via the induction
of cytoprotective and detoxification genes.10,12 To assess
whether NRF2 regulates miRNA expression in AML, we used
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a commercially available OncomiR Cancer miRNA qRT-PCR
Array on THP-1 cells infected with an NRF2 lentiviral
knockdown (NRF2-KD) and a negative control knockdown
(NEG-KD). Figure 1a shows the change in expression of
miRNA in response to NRF2-KD compared with the control
infected with NEG-KD. We then treated THP-1 cells with the
NRF2 activator sulforaphane for 6 h for comparison.
Supplementary Table 1 shows the fold increase of miRNA
in response to both NRF-KD and sulforaphane treatment.
From these experiments, we identified miR-125B, miR-222,
miR-221 and miR-223 as potential miRNAs upregulated by
NRF2 and miR-29B and miR-154 as potential miRNAs
downregulated by NRF2. Figure 1c shows western blot
analysis of NRF2 and KEAP1 protein expression in THP-1
cells in response to NRF2-KD, KEAP1-KD and NEG-KD.
Increased NRF2 activity increases miR-125B and
decreases miR-29B expression in AML. We used a qRT-
PCR approach to validate the data from the lentiviral array
experiments.10 NRF2-KD results in THP-1 cells showing a
consistent decrease in miR-125B expression and increasing
miR-29B expression as well as smaller but not significant
fluctuations in miR-221, miR-222, miR-223 and miR-154
expression (Figure 1b). To further assess the role of NRF2 in
regulating miRNA, we increased the activity of NRF2 in
THP-1 cells by knockdown of the NRF2 inhibitor KEAP1.16
THP-1 were infected with KEAP1 lentiviral knockdown
(KEAP1-KD). QRT-PCR confirmed the downregulation of
KEAP1 and as a positive control, we showed that KEAP-KD
upregulated the NRF2 target gene HO-1. Moreover,
miR-125B expression showed a similar increase to HO-1
and miR-29B showed a significant decrease in response to
KEAP1-KD (Figure 1b). The expression of miR-221, miR-
-222, miR223 and miR-154 were not significantly changed in
response in NRF2-KD or KEAP1-KD to warrant its inclusion
in further experiments.
NRF2 regulates homologues miR-125B1 and miR-29B1
and miR-29A in human AML. Both miR-125B and miR-29B
exist as two homologues (Figure 2a). miR-125B1 (located on
chromosome 11) and miR-125B2 (located on chromosome
21), both contain identical seed sequences. Both homo-
logues lie in the region of regulatory miRNA clusters,
miR-100-let-7-a-2 and LINC00478, respectively. miR-29B
also exists as two homologues, miR-29B1 (located on
chromosome 7) and miR-29B2 (located on chromosome 1)
(Figure 2a).
The sequence of themiRNA seed region of bothmiR-125B1
and 2 is identical. Similarly, the seed sequence of miR-29B1 is
identical to that of miR-29B2. Therefore, we used primers
designed specifically for the immature miRNA sequences
(which does differ between themiRNA homologues) to identify
which miR-125B and miR-29B homologues were being
regulated by NRF2. QRT-PCR on lentiviral NRF2-KD THP-1
cells identified reduced expression of the immature
miR-125B1 and increased expression of the immature miR-
-29B1, but no change in the expression of immature
miR-125B2 and miR-29B2 sequence (Figures 2b and c). This
suggests that miR-125B1 and miR-29B1, but not miR-125B2
or miR-29B2, are regulated by NRF2.
To determine whether NRF2 specifically regulated
miR-125B1 and miR-29B1 or had a more general regulatory
effect on their clusters, we looked for a differential expression
on other miRNAs in each of the homologue regions in
response to NRF2-KD. Following NRF2 knockdown, however,
there was no difference in the expression of miR-100 and
let-7a-2 (miR-125B1 cluster; chromosome 11) or miR-99a and
let7c (miR-125B2 cluster; chromosome 21) (Figure 2b). This
implies that NRF2 does not regulate these clusters to control
miR-125B expression but instead binds to a miR-125B1-
specific regulatory region. Conversely, knockdown of NRF2
elevated miR-29B1 and miR-29A but had no effect on
















































































































Figure 1 miRNA profiling of AML cells in response lentiviral NRF2 knockdown. (a) THP-1 cells were transduced with NEG (NEG-KD)- and NRF2 (NRF2-KD)-targeted miRNA
lentiviral constructs. QRT-PCR analysis of 92 cancer-associated miRNAs in NRF2-KD THP-1 cells. Values represent change in qRT-PCR cycle threshold normalised to RNU6B
(ΔCT). Dashed line indicates no change in expression. A red circle indicates miR-125B, miR221, miR-223, miR222, miR29B and miR154. (b) QRT-PCR of miR-125B, miR221,
miR-223, miR222, miR29B, miR154, NRF2, KEAP1 and HO1 in THP-1 cells transduced with NEG-KD, NRF2-KD or KEAP1-KD. Values represent fold change in RNA expression
over NEG-KD control. (c) THP-1 were transduced with NEG-KD, NRF2-KD or KEAP1-KD before cells were analysed for NRF2 and KEAP1 using western blotting. Blots were
reprobed for β-actin to show sample loading. The numbers under the blots indicate densitometry analysis of the blots using Image J software, and the results are expressed as
fold change relative to the NEG-KD control
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a defined pattern of expression of the miR-125B1 and
miR-29B1 cluster in human AML. Moreover, results from
Figure 1b and Figures 2b and c show that changes in total
levels of miR-125B and miR-29B are similar to changes in
miR-125B1 and miR-29B1. The main reason for this similarity
is that constitutive levels of miR-125B2 and miR-29B2 are
much lower in AML than that of their homologue, thus changes
observed in total miR-125B and miR-29B reflect changes
observed in miR-125B1 and miR-29B1 levels.
NRF2 binds to ARE sites in the promoters of miR-125B1
and miR-29B1. NRF2 acts as a transcription factor by
binding to the antioxidant response element (ARE) region in
the promoter regions of its target genes.17 To analyse the
5′ miR-125B1 and miR-29B1 promoter sequence, we used
transcription factor analysis programmes (http://www.gene-
regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi
and www.genomatix.de/matinspector.html). These analyses
identified three potential ARE sites within the miR-125B1
promoter and two in the miR-29B1 promoter (Figure 3a).
To confirm whether NRF2 bound to ARE binding sites in the
miR-29B1 or the miR-125B1 promoter, a ChIP assay was
undertaken. Figure 3b shows the analysis using antibodies for
NRF2 and quantified against control IgG with specific primers
for ARE1-3 (promoter region of miR-125B1; chromosome 11)
and ARE4 and ARE5 (promoter region of miR-29B1; chromo-
some 7). Recruitment of NRF2 was markedly enhanced to
ARE5 in the miR-29B1 promoter and ARE3 in the miR-125B1
promoter. Next, we evaluated the recruitment of NRF2 to
ARE1-5 sites in THP-1 cells transfected with KEAP1 siRNA.
Figure 3c shows that there was increased recruitment of NRF2
to the ARE3 and ARE5 site, but not the other potential ARE
sites in THP-1 cells transfected with KEAP siRNA over control
siRNA. These observations confirmed that NRF2 specifically
binds the miR-29B1 ARE5 site and the miR-125B1 ARE3 site.
To establish whether NRF2 functionally controls miR-125B1
expression, the miR-125B1 promoter was cloned into a PGL4
luciferase plasmid and the putative ARE3 site was mutated
(Figure 3d). AML is a disease characterised by constitutive
activation of NRF2, therefore the luciferase vector PGL4 and
PGL4/p125B were transfected into THP-1 cells without prior
treatment of an NRF2 activator or repressor. We observed an
approximate eightfold increase in luciferase activity in the
PGL4/p125B plasmid in comparison with the control
(Figure 3e). Site-directed mutagenesis of the ARE3 site in
the miR-125B1 promoter corresponded with a significant
decrease in miR-125B1 promoter activity (Figure 3e). More-
over, when we co-transfected KEAP1 and NRF2 siRNA with
the p125B and p125BNRF2Mut plasmids, KEAP1 siRNA
induced significant increase in p125B promoter activity and
NRF2 siRNA inhibited p125B promoter activity. KEAP1 siRNA
and NRF2 siRNA had no effect on p125BNRF2Mut promoter
activity (Figure 3f). Similar experiments on the miR-29B1
promoter were technically not possible as the construct was
too big and would not clone into a luciferase reporter vector.
These results demonstrate that the ARE3 site in the promoter
of mir-125B1 is regulated by NRF2.
NRF2 regulates the expression of miR-125B1 and
miR-29B1 in primary human AML. As we have established
in AML that high NRF2 mRNA expression causes an
increase in NRF2 activity,10 and that miR-125B1 and
miR-29B1 are regulated by NRF2 in AML cell lines, we next
examined the expression of NRF2, mir-125B1 and miR-29B1
in primary human AML cells. NRF2 and miR-125B1 is
increased in AML compared with normal CD34+ haemato-
poietic stem cells (HSC), whereas miR-29B1 is decreased in
AML compared with normal CD34+ HSC (Figure 4a). As total
levels of miR-125B and miR-29B most likely determine their










































































































Figure 2 NRF2 regulates homologues miR-125B1 and miR-29B1 and miR-29A in human AML. (a) Schematic representation of the miRNA chromosomal positioning of
miR-125B (1 and 2) and miR-29B (1 and 2). (b) Total RNA was extracted from THP-1 transduced with NEG-KD and NRF2-KD and examined for miRNA expression including
immature miR-125B1, miR-125B2 RNA and HO-1 mRNA expression. (c) Total RNA was extracted from THP-1 transduced with NEG-KD and NRF2-KD and examined for
miR-29A and miR-29C expression including immature miR-29B1, miR-29B2 RNA and HO-1 mRNA expression
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miR-29B in AML. Supplementary Figure 2 shows that total
miR-125B is increased in AML compared with normal CD34+
HSC, whereas miR-29B is decreased in AML compared
with normal CD34+ HSC. Furthermore, there is a positive
correlation between NRF2 RNA expression and mir-125B1
RNA expression, with an inverse correlation between NRF2
RNA expression and miR-29B1 RNA expression in primary
AML cells (Figure 4b). To confirm that NRF2 regulates
miR-125B1 and miR-29B1 expression in primary human AML
cells, we used NRF2 siRNA to silence NRF2 RNA expression
in eight AML patient samples. NRF2 mRNA is significantly
knocked down in seven out of the eight AML samples of
which the majority also had significantly lower miR-125B1
expression (Figure 4c). Moreover, NRF2 siRNA in the AML
samples increased miR-29B1 expression (Figure 4c).
Together, these results show that knockdown of NRF2
regulates the expression of miR-125B1 and miR-29B1 in
primary human AML.
miR-125B antagomiR and miR-29B mimic increases AML
apoptosis and sensitivity to frontline chemotherapy
agents. Previous studies in AML have suggested that the
overexpression of miR-125B plays an oncogenic role by
































































































Figure 3 NRF2 binds to ARE sites in the promoters of miR-125B1 and miR-29B1. (a) Schematic presentation of ARE binding sequences in the 5′ region of miR-29B1 on
chromosome 7 and miR-125B1 on chromosome 11. (b) Chromatin immunoprecipitation (ChIP) analysis of the miR-29B1 and miR-125B1 promoter using antibodies against
NRF2 and normal rabbit IgG was used as a control. QRT-PCR was performed in triplicate on immunoprecipitated DNA and input DNA. Data presented as percent of input.
* indicates Po0.05 between the different treatment groups. (c) THP-1 cells were transfected with control siRNA and KEAP1 siRNA for 24 h and ChIP was performed. Real-time
PCR was performed in triplicate on immunoprecipitated DNA and input DNA. Data presented as percent of input. * indicates Po0.05 between the different treatment groups.
(d) Schematic representation of mutated miR-125B promoter sequence. (e) THP-1 cells were transiently transfected with 0.5 μg of each promoter construct including control
plasmid and pRL-TK for normalisation of transfection efficiency. Cell extracts were harvested and luciferase assays were performed. Values are the means± S.D., n= 4.
* indicates Po0.01 of deleted ARE against PGL4 control. (f) Control, KEAP1 and NRF2 siRNAwere transfected at the same time as p125b and p125bNRF2 MUTand incubated
for 48 h. Cell extracts were harvested and luciferase assays were performed. Values are the means± S.D., n= 4. * indicates Po0.01 of KEAP1 siRNA and NRF2 siRNA against
NEG siRNA control
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proliferation and represses apoptosis.18,19 To determine the
functional role of inhibiting miR-125B and overexpressing
miR-29B both alone and in-combination, we transfected
miR-125B antagomiR and miR-29B mimic into THP-1 cells
and analysed cells for apoptosis by annexin V/PI staining.
However, before we did this, we showed that the concentra-
tions of transfected miR-125B antagomiR and miR-29B
mimic used manipulated the miRNA levels comparable with
that observed in the NRF2-KD and KEAP1-KD THP-1 cells
(Supplementary Figure 1). THP-1 cells transfected with the
miR-125B antagomiR or miR-29B mimic showed a small but
significant increase in annexin V/PI staining in comparison
with the control transfection (Figure 5a). Moreover, when we
co-transfected miR-125B antagomir and miR-29B mimic, we
observed a synergistic increase in annexin V/PI staining in
comparison with the control (Figure 5a). Transfection of
miR-125B antagomir and miR29B mimic into THP-1 and
Kasumi-1 cells potentiated the cytotoxic effect of the frontline
AML chemotherapy agent daunorubicin (Supplementary
Table 2).
Next, we examined the effects of inhibiting miR-125B and
increasing miR-29B expression in primary AML cells in
comparison with non-malignant primary CD34+ HSC. In six
primary AML patient samples, inhibition of miR-125B or
increasing miR-29B showed a significant decrease in cell
viability (Figure 5b). Finally, we compared the viability of
primary AML patient cells that had normal NRF2 expression
(and thus normal miR-125B and miR-29B expression) with an
AML patient sample that had high NRF2 expression (and thus
high miR-125B and low miR-29B expression) after treatment
with daunorubicin (Figure 5c and Table 1 and Supplementary
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Figure 4 NRF2 regulates miR-29B1 and miR-125B1 in primary AML. (a) Total RNA was extracted from patient AML blasts (n= 18) and CD34+ HSC (n= 8). NRF2,
miR-29B1 and miR-125B1 RNA expression levels were measured using QRT-PCR. (b) Pearson’s correlation analysis between miR-125B1 or miR-29B1 and NRF2 mRNA
expression in human primary AML cells. (c) Control and NRF2 siRNA were transfected into primary blasts (n= 7) for 48 h and RNA extracted. RNA was analysed for NRF2,
miR-125B1 and miR-29B RNA expression. Values are the means±S.D., n= 3
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Figure 5 miR-125B antagomiR and miR-29B mimic induce apoptosis of AML cells and increases there sensitivity to AML chemotherapy. (a) THP-1 were transfected with
control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before cells were analysed for
apoptosis by PI/Annexin V staining. (b) AML blasts (n= 6) and CD34+ (n= 4) were transfected with control miRNA, miR-125B antagomiR and miR-29B mimic and miR-125B
antagomiR in combination with miR-29Bmimic for 24 h and then assessed for cell viability by Cell Titer-GLO. (c) AML blasts and CD34+ cells were transfected with control miRNA
(miR-mimic negative control and the anti-miR miRNA inhibitor negative control for single experiments and combined miR-mimic negative control and the anti-miR miRNA inhibitor
negative control in combined experiments), miR-125B antagomiR, miR-29B mimic and miR-125B antagomiR in combination with miR-29B mimic for 24 h before the addition of
increasing doses of daunorubicin for 48 h. Cells assessed for viability by Cell Titer-GLO. (d) AML#27 was transduced with NEG-KD and KEAP1-KD for 48 h before cells before the
addition of increasing doses of daunorubicin for 48 h before cells were analysed for KEAP1 using western blotting. Blots were reprobed for β-actin to show sample loading.
(e) AML#27 was transduced with NEG-KD and KEAP1-KD for 48 h before the addition of increasing doses of daunorubicin for 48 h. Cells were assessed for viability by Cell
Titer-GLO. (f) AML#27 was transduced with KEAP1-KD for 48 h before cells were transfected with control miRNA, miR-125B antagomiR, miR-29B mimic and miR-125B
antagomiR in combination with miR-29B mimic for 24 h followed by the addition of increasing doses of daunorubicin for 48 h. Cells were assessed for viability by Cell Titer-GLO
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miR-29B expression were much more sensitive to daunor-
ubicin than AML patient samples that had high NRF2
expression and thus high miR-125B and low miR-29B
expression. Moreover, when we transfected the primary AML
that had high NRF2 and high mir-125B and low miR29B with
miR-125B antagomiR together with miR-29B mimic, the result
was that sensitivity of these AML cells to daunorubicin was
increased to a level comparable with AML with normal NRF2
expression. Because AML#27 has low NRF2 expression over
normal CD34+ HSC (Table 1), which is more sensitive to
daunorubicin (Figure 5c), and miR-125B antagomiR together
with miR-29B mimic had no effect on resistance to daunor-
ubicin (Figure 5c), we examined the effect of KEAP1-KD on
AML#27 to determine if we could increase the activity of NRF2
and increase the chemoresistance of this sample. Figure 5d
showsKEAP1-KD in AML#27. Figure 5e shows that KEAP1-KD
AML#27 is more resistant to daunorubicin compared with
NEG-KD. However, when we transfected AML#27 KEAP1-KD
cells with control miRNA, miR-125B antagomiR, miR-29B
mimic and miR-125B antagomiR in combination with
miR-29B mimic, only the combination decreased resistance
to daunorubicin (Figure 5f). These results demonstrate
that inhibiting miR-125B and overexpressing miR-29B in
combination increases apoptosis of primary AML and also
increases sensitivity of AML cells to current frontline
chemotherapy.
miR-29B and miR-125B gene targets in human AML.
Studies have shown that a number of different targets exist
for both miR-29B and miR-125B in AML (Supplementary
Table 3).18,20–28 Here we examine the expression of genes
listed in Supplementary Table 3 for their response to
transfection of control miRNA, miR-125B antagomiR,
miR-29B mimic and miR-125B antagomiR in combination
with miR-29B mimic. Figure 6a shows that MYBL2, AKT2,
CDK4 and SP1 are inhibited by miR-29B mimic in THP-1
cells; we also observe that AKT2 and CDK4 are further
inhibited by the addition of miR-125B antagomiR. From the
miR-125B targets, Figure 6a shows that MAPK14, STAT3 and
BAK1 show an increase in mRNA in response to miR-125B
antagomiR. Next, we examined the protein expression of
AKT2, STAT3 and BAK1. Figure 6b shows a reduction in
AKT2 protein expression in response to miR-29B mimic and
miR-125B antagomiR in combination with miR-29B mimic.
STAT3 showed a slight increase in response to miR-29B
mimic and miR-125B antagomiR in combination with
miR-29B mimic. BAK1 showed an increase in response to
miR-125B antagomir and miR-125B antagomiR in combina-
tion with miR-29B mimic.
Finally, we wanted to determine whether NRF2 deregulation
in AML affects miRNA levels to such an extent that expression
of their target genes is changed as a consequence. Figure 6c
shows a change in expression of AKT2, STAT3 and BAK1 but
not MCL1 mRNA in response to NRF2-KD or KEAP1-KD
compared with NEG-KD. Figure 6d shows changes in AKT2
and BAK1 protein expression in response to NRF2-KD and an
increase in response to KEAP1-KD. Together, these results
link the two major observations of this study; first, that NRF2
Table 1 AML patient sample information, NRF2 RNA expression and relative miR-125B1 and miR-29B1 RNA expression levels
Number Age Gender WHO diagnosis Cytogenetics % Blasts Fold NRF2 mRNA
over CD34+
Fold RNA over CD34+
miR-125B1 miR-29B1
AML#1 49 M AML with maturation Normal 80 3.35 6.57 0.04
AML#2 39 M AML with maturation Normal 65* 6.89 12.33 0.11
AML#3 64 M AML with RUNX1-RUNX1T1 t(8;21) 85 1.26 1.09 1.01
AML#4 92 F AML with myelodysplasia related changes Not available 70* 1.23 1.70 0.20
AML#5 82 F AML with MDSrelated changes Deletion 13 85 3.39 3.20 0.07
AML#6 46 F AML with maturation +4,+8, t(9;22) 70* 4.99 12.51 0.10
AML#7 66 F AML with maturation t(2;12) 65* 1.23 5.22 0.27
AML#8 78 M AML with MDS related changes Not available 85 4.19 9.85 0.01
AML#9 57 M AML without maturation Not available 95 4.35 4.59 0.09
AML#10 27 M AML with RUNX1-RUNX1T1 t(8;21) 60* 4.99 10.93 0.08
AML#11 25 M AML with maturation Normal 50* 4.81 6.63 0.37
AML#12 61 M Relapsed AML without maturation Not available 95 1.96 1.07 0.71
AML#13 28 F Acute Monoblastic and Monocytic Leukaemia Normal 90 4.68 6.52 0.33
AML#14 31 F AML without maturation Trisomy 8 75* 2.73 6.37 0.03
AML#15 84 M Acute meyloid leukaemia, NOS Not available 70* 3.99 2.43 0.24
AML#16 53 M AML with t(6;9)(p23;q34);DEK-NUP214 t(6;9) 65* 3.25 9.13 0.24
AML#17 51 F AML with maturation Normal 40* 4.54 3.45 0.02
AML#18 47 M Acute myeloid leukaemia without maturation Not available 90 4.20 2.07 1.33
AML#19 77 F AML with maturation Normal 70* 2.78 7.70 0.21
AML#20 62 M AML with maturation Complex 55* 2.96 2.67 0.59
AML#21 70 M AML with minimal differentiation Normal 95 2.01 1.98 0.64
AML#22 65 F AML with maturation Normal 40* 1.44 2.75 0.24
AML#23 77 M Therapy related AML Complex 70* 3.24 3.10 0.24
AML#24 40 F AML with minimal differentiation Normal 90 1.77 3.23 1.09
AML#25 70 M AML without maturation Complex 95 3.18 6.54 0.42
AML#26 91 F AML NOS Not available 75* 1.08 1.63 0.97
AML#27 59 F AMLwith t(8;21)(q22;q22); RUNX1-RUNX1T1 t(8;21) 85 1.17 1.44 0.53
This table defines the nature of the AML disease including WHO diagnosis and cytogenetics. NRF2, miR125B1 and miR-29B1 RNA expression levels over CD34+
control cells
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directly regulates miR-125B and miR-29B expression.
Second, that miR-125B and miR-29B synergistically influence
AML survival and chemoresistance, possibly via deregulation
of target genes such as AKT2, STAT3 or BAK1.
Discussion
Our understanding of the role of non-coding RNAmolecules in
diseases such as cancer is presently in its infancy. To date,
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Figure 6 miR-125B antagomiR and miR-29B mimic gene targets in AML cells. (a) THP-1 were transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B
mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before cells were analysed for target gene expression using QRT-PCR. (b) THP-1 cells
were transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before
cells were analysed for AKT2, STAT3 and BAK1 using western blotting. Blots were reprobed for β-actin to show sample loading. (c) QRT-PCR of mRNA for AKT2, STAT3, BAK1
and MCL1 in THP-1 cells transduced with NEG-KD, NRF2-KD or KEAP1-KD. Values represent fold change in RNA expression over NEG-KD control. (d) THP-1 cells were
transduced with NEG-KD, NRF2-KD or KEAP1-KD before cells were analysed for AKT2, STAT3 and BAK1 protein expression using western blotting. Blots were reprobed for
β-actin to show sample loading. The numbers under the blots indicate densitometry analysis of the blots using Image J software, and the results are expressed as fold change
relative to the negative control
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biology through the regulation of both tumour suppressors and
oncogenes. Less is known, however, about the upstream
control of miRNA expression in cancer and the biological
processes that control miRNA expression. In AML, the
differential expression of a number of miRNAs has been
reported to be associated with the malignant phenotype but as
yet the upstream mechanisms by which this is controlled are
yet to be described.29–32 As we have previously identified
NRF2 as an important regulator of cell survival in AML, the aim
of the present study was to investigate the ability of NRF2 to
affect miRNA expression and furthermore define the function
of these miRNAs in human AML both in a resting state and in
response to front-line chemotherapeutic agents.
Through gene expression data and multiple transcription
factor binding assays, we found that NRF2 upregulates
mir-125B1 and downregulates miR-29B1 though binding to
specific ARE sites in the miR-125B1 and miR-29B1 regulatory
regions. Furthermore, we observed that by decreasing the
expression of miR-125B and increasing the expression of
miR-29B, the cells becomemore sensitive to apoptotic stimuli.
These findings are in keeping with previous observations that
miR-29B and miR-125B regulate the expression of multiple
survival pathways in AML. The global repression of miR-125B
targets and elevation of miR-29B targets genes would aid the
uncontrolled proliferative phenotype of AML. Therefore, in
Figures 6a and b, we analyse the targets of miR-29B and
miR-125B in AML cells transfected with corresponding mimic
and antagomir, both alone and in combination. We observe
changes in a number of genes including AKT2, CDK4,
MAPK14, STAT3, BCL2 and BAK1. Interestingly, AKT2 and
CDK4 are targets of miR-29B only; however, when we
co-transfect miR-125B antagomir and miR-29B mimic, we do
observe a further reduction over miR-29B mimic only. There
are no miR-125B sites within these two genes suggesting that
the combined observations are due to off-target effects.
Together, the cumulative repression of miR-29B and
the overexpression of miR-125B significantly contribute to
leukaemia cell proliferation within the bone marrow niche.
Transcription factors are generally structured in context of
networks. In AML, miR-29B downregulation has been found to
be associated with high C-MYC levels aswell as high SP1 and
NF-κB.33,34 Furthermore, NF-κB, JUN and C-MYC have been
linked to increased NRF2 activity in human cancer (including
AML)10,35 and NRF2 has been shown to transcriptionally
regulate miR-125B in kidney epithelia cells in response to
cisplatin-induced toxicity.36 Taken together, it is likely that
NRF2 has a central role in the complex network regulating
miR-29B and miR-125B in human AML.
We also highlight that other miRNAs may be regulated by
NRF2. The array data shown as Supplementary Table 1 show
that somemiRNAs are downregulated in response toNRF2-KD
and increased in response to sulforaphane. This list includes
miR-222, miR221, miR-223 miR-23a, miR-195 and miR-196a.
Of particular interest from this group is miR-222, miR-221 and
miR223,which have been shown to behighly expressed inAML
compared with other leukaemias.37 Moreover, we also noted
that high NRF2 activity caused a decrease in the expression of
miRNAs, which includes miR-154, miR146a and miR-181B. All
these miRNAs have been shown to be of interest in AML with
miR-146a being shown to have low expression in AML, which
correlates with high expression of its target gene CXCR4,38
which in a separate study has been shown to be regulated by
NRF2 in human HSC.39 Consequently in human AML, NRF2
not only regulates key genes involved in the reaction to
oxidative stress but also regulates miRNAs that appear to have
a broader impact on gene expression and regulation.
In summary, here we report the first description of upstream
miRNA regulation by NRF2 in a human cancer and its
downstream cyto-protective consequences. In doing so, we
not only provide novel mechanistic insight into the pro-
tumoural consequences of the constitutive NRF2 expression
in AML, but we also propose that targeting the NRF2
regulation of these miRNA (or the miRNA directly) would be
a biologically plausible therapeutic strategy to increase the
effectiveness of chemotherapy in human AML.
Materials and Methods
Materials. The AML-derived cell lines were obtained from the European
Collection of Cell Cultures where they are authenticated by DNA fingerprinting. In
the laboratory, they are used at low passage number for a maximum of 6 months
post-resuscitation, testing regularly for Mycoplasma infection. All primers were
purchased from Invitrogen (Paisley, UK). AKT2, STAT3 and BAK1 antibodies were
purchased from Cell Signalling Technology (Cambridge, MA, USA). NRF2 and
KEAP1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO,
USA), unless indicated. To assess whether NRF2 regulates miRNA expression in
AML, we used commercially available OncomiR collection Cancer miRNA
qRT-PCR Array (SBI, Mountain View, CA, USA).
Primary AML cell culture. AML cells were obtained from patients' bone
marrow or blood following informed consent and under approval from the UK
National Research Ethics Service (LRECref07/H0310/146). For primary cell
isolation, heparinised blood was collected from volunteers and human peripheral
blood mononuclear cells isolated by Histopaque (Sigma-Aldrich, Dorset, UK) density
gradient centrifugation. AML samples that were less than 80% blasts were purified
using the CD34-positive selection kit (Miltenyi Biotec, Auburn, CA, USA) (denoted
by * in Table 1). Cell type was confirmed by microscopy and flow cytometry. We
obtained haematopoietic CD34+ cells from two sources, Stem Cell Technologies
(Manchester, UK) and volunteers. Positive selection of CD34+ cells were isolated
from peripheral blood mononuclear cells using a CD34-positive selection kit
(Miltenyi Biotec). For all CD34+ experiments, at least three different donors were
used to obtain the results presented in this paper. Cell type was confirmed by
microscopy and flow cytometry.
RNA extraction and real time PCR (RT-PCR). Total mRNA extraction
was carried out using mirVana miRNA isolation kit (Ambion, Paisley, UK) and
reverse transcribed using the miRscript II RT kit (Qiagen, Manchester, UK). All
mature miRNA were normalised to RNU6B and immature miRNA and mRNA were
normailsed to GAPDH for qRT-PCR as described previously.40 qRT-PCR was
carried out using SYBR green technology (Qiagen). The samples were preamplified
at 95 °C for 2 min, after which was amplified for 45 cycles at 95 °C for 15 s, 60 °C
for 10 s and 72 °C for 10 s. The qRT-PCR was performed on the LightCycler480
(Roche, Burgess Hill, UK).
Virus construction and infection. Lentiviruses containing miRNA
sequence miRNA-Nrf2 (5′-TTAATGAGTTCACTGTCAACT-3′), miRNA-KEAP1
(5′-GTTTTGGCCACTGACTGAC-3′) and miR-NEG were constructed and
produced as described previously.41 For transduction, THP-1 cells and AML
blasts cells were plated onto 12-well plates (5 × 104 cells/well) and infected with
lentiviruses (multiplicity of infection of 15) with 8 μg/ml Polybrene (Sigma, Dorset,
UK). Transduced cells were analyzed by flow cytometry (Accuri, BD Biosciences,
Oxford, UK), real-time PCR (Roche) and western blotting.
Transfections. AML transfections were carried out with 2 × 106 cells using the
Amaxa Nucleofactor Kit II (Cambridge, UK). Control miR, miR-29B mimic and
miR-125B antagomiR, control siRNA, KEAP1 and NRF2 siRNA were purchased
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from Invitrogen were transfected in at a concentration of 45 nm. For control miR, the
miR-mimic negative control and the anti-miR miRNA inhibitor negative control for
single experiments and combined miR-mimic negative control and the anti-miR
miRNA inhibitor negative control in combined experiments were used. For all gene
expression experiments, the cells were incubated for 24 h post transfection before
RNA extraction. For the cell viability assays, AML cells were incubated for 48 h post
transfection. For reporter assays, 0.5 μg of PGL4 reporter and pRL-TK control
constructs were co-transfected into THP-1. Transfected cells were incubated for 24 h
before the indicated treatments. For reporter assay, cells were treated with Dual-
Luciferase reporter assay system (Promega, Southampton, UK).
Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and western blot analyses were performed as described previously. Briefly, whole
cell lysates as well as nuclear and cytosolic were extracted and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis separation was performed.42 Protein was
transferred to nitrocellulose and western blot analysis performed with the indicated
antisera according to their manufacturer’s guidelines.
Cloning of miR-125B promoter construct. To generate the p125B
promoter construct containing ARE3, a DNA fragment containing 2.6 kb of the
human 125b promoter region was amplified from genomic DNA with PCR
and specific primers: 5′-TGAGAGGAGCGCAACAATG-3′ reverse primer and
5′-AGAAAGGCCACCAAGATTCAC-3′ forward primer. The fragment was cloned
into the PGL4.11 basic plasmid (Promega). To generate mutated NRF2 construct
(p125B NRF2 MUT) the sense PCR primer used was 5′-GCTGTG
GCTGtTTTGTtATTCTCTTTGACTAG-3′. This mutation was introduced with the
QuikChange XL Site-Directed Mutagenesis Kit (Agilent, Stockport, UK).
Cell viability and apoptosis assays. THP-1, Kasumi-1, primary CD34+
HSC and primary AML cells were transfected with control miR (miR-mimic negative
control and the anti-miR miRNA inhibitor negative control for single experiments and
combined miR-mimic negative control and the anti-miR miRNA inhibitor negative
control in combined experiments), miR-29B mimic and miR-125B antagomiR and
combined miR-29B mimic and miR-125B antagomiR for 24 h. THP-1 cells were
analysed for apoptosis using PI/Annexin V staining. THP-1, Kasumi-1, primary
CD34+ HSC and primary AML transfected cells were treated with different
concentrations of chemotherapy agents and incubated for 48 h; then, viable cells
were measured with Cell-Titre GLO (Promega).
Chromatin immunoprecipitation assay. THP-1 cells were transfected
with control siRNA or KEAP1 siRNA 24 h before the cells were fixed with 1%
formaldehyde in medium for 10 min at room temperature. The sonication conditions
were optimised to determine generation of DNA fragments between 300 and 600
base pairs in length. Chromatin was immunoprecipitated with IgG, anti-NRF2
(Cell Signalling). The association of NRF2 was measured by RT-PCR on
immunoprecipitated chromatin using primers spanning the ARE sites described in
Figure 3a and Supplementary Table 4.
Statistical analyses. Student’s t test was performed to assess statistical
significance from controls. Results with Po0.05 were considered statistically
significant (*). Results represent the mean± S.D. of three independent experiments.
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Supplementary Table 1 - Shah et al
miRNA Sequence (5’ to 3’)
miRNA fold 
expression in NRF2-







miR-200b TAATACTGCCTGGTAATGATGAC 0.2432 0.2031
miR-125b TCCCTGAGACCCTAACTTGTGA 0.2912 3.6553
miR-222 AGCTACATCTGGCTACTGGGTCTC 0.2994 1.2386
miR-221 AGCTACATTGTCTGCTGGGTTTC 0.3896 0.9266
miR-15b TAGCAGCACATCATGGTTTACA 0.3926 0.0487
miR-1224 GTGAGGACTCGGGAGGTGG 0.4005 0.8942
miR-30a TGTAAACATCCTCGACTGGAAG 0.4175 0.8933
miR-25 CATTGCACTTGTCTCGGTCTGA 0.4204 1.6240
miR-223 TGTCAGTTTGTCAAATACCCC 0.4293 1.7291
miR-200c TAATACTGCCGGGTAATGATGG 0.4353 0.5743
miR-18a TAAGGTGCATCTAGTGCAGATA 0.4931 0.5946
miR-23a ATCACATTGCCAGGGATTTCC 0.5035 1.2478
miR-27a+b TTCACAGTGGCTAAGTTCCGC 0.5070 0.6969
mir-301 CAGTGCAATAGTATTGTCAAAGC 0.5249 0.1768
miR-24 TGGCTCAGTTCAGCAGGAACAG 0.5359 1.0404
miR-195 TAGCAGCACAGAAATATTGGC 0.6029 0.5471
miR-196a TAGGTAGTTTCATGTTGTTGG 0.6242 1.3318
miR-20a TAAAGTGCTTATAGTGCAGGTAG 0.6329 0.8645
miR-95 TTCAACGGGTATTTATTGAGCA 0.6462 0.9727
miR-30b TGTAAACATCCTACACTCAGCT 0.6552 0.9794
miR-134 TGTGACTGGTTGACCAGAGGG 0.6643 1.1578
miR-17 CAAAGTGCTTACAGTGCAGGTAGT 0.7220 0.6783
miR-133a TTGGTCCCCTTCAACCAGCTGT 0.7270 3.2193
miR-214 ACAGCAGGCACAGACAGGCAG 0.7631 0.6783
miR-183 TATGGCACTGGTAGAATTCACTG 0.7721 0.6507
miR-141 TAACACTGTCTGGTAAAGATGG 0.7792 0.6373
miR-185 TGGAGAGAAAGGCAGTTC 0.7871 1.1183
miR-103 AGCAGCATTGTACAGGGCTATGA 0.7900 2.0681
miR-34a TGGCAGTGTCTTAGCTGGTTGT 0.7900 1.1385
miR-7 TGGAAGACTAGTGATTTTGTTG 0.8012 2.8879
miR-186 CAAAGAATTCTCCTTTTGGGCTT 0.8039 1.5911
miR-22 AAGCTGCCAGTTGAAGAACTGT 0.8293 1.1975
miR-203 GTGAAATGTTTAGGACCACTAG 0.8586 0.1331
miR-15a TAGCAGCACATAATGGTTTGTG 0.8586 2.3134
miR-107 AGCAGCATTGTACAGGGCTATCA 0.8766 4.5948
let-7-family TGAGGTAGTAGGTTGTATAGTT 0.9005 11.1579
miR-191 CAACGGAATCCCAAAAGCAGCT 0.9126 0.7684
miR-197 TTCACCACCTTCTCCACCCAGC 0.9330 1.9588
miR-21 TAGCTTATCAGACTGATGTTGA 0.9353 2.5669
miR-16 TAGCAGCACGTAAATATTGGCG 0.9395 1.1019
miR-125a-5p TCCCTGAGACCCTTTAACCTGTG 0.9461 1.2592
miR-149 TCTGGCTCCGTGTCTTCACTCC 0.9466 0.4931
miR-106b TAAAGTGCTGACAGTGCAGAT 0.9495 0.8888
miR-219 TGATTGTCCAAACGCAATTCT 0.9526 0.4863
miR-150 TCTCCCAACCCTTGTACCAGTG 0.9527 0.3737
miR-194 TGTAACAGCAACTCCATGTGGA 0.9659 0.9395
miR-17* ACTGCAGTGAAGGCACTTGT 0.9859 0.9727
miRNA Sequence (5’ to 3’)
miRNA fold expression in 
NRF2-KD compared to 
NEG-KD
miRNA fold expression in 
sulf 5μM treated compared 
to untreated
miR-34b CAATCACTAACTCCACTGCCAT 1.0129 0.2872
miR-181a AACATTCAACGCTGTCGGTGAGT 1.0329 0.3463
miR-151 ACTAGACTGAAGCTCCTTGAGG 1.0353 0.4444
miR-205 TCCTTCATTCCACCGGAGTCTG 1.0535 0.6878
miR-101 TACAGTACTGTGATAACTGAAG 1.0674 0.2774
miR-188-5p CATCCCTTGCATGGTGGAGGG 1.0709 1.3755
miR-181c AACATTCAACCTGTCGGTGAGT 1.0727 1.1975
miR-142-3p TGTAGTGTTTCCTACTTTATGGA 1.0732 0.2045
miR-122 TGGAGTGTGACAATGGTGTTTGT 1.0792 0.0802
miR-373 GAAGTGCTTCGATTTTGGGGTGT 1.0831 1.3219
miR-140 AGTGGTTTTACCCTATGGTAG 1.0958 0.1250
miR-9 TCTTTGGTTATCTAGCTGTATGA 1.1383 1.1810
miR-128 TCACAGTGAACCGGTCTCTTTC 1.1487 0.9303
miR-296 AGGGCCCCCCCTCAATCCTGT 1.1810 0.9395
miR-26a TTCAAGTAATCCAGGATAGGC 1.1892 1.0987
miR-192 CTGACCTATGAATTGACAGCC 1.2086 1.5801
miR-144 TACAGTATAGATGATGTACT 1.2544 1.0987
miR-143 TGAGATGAAGCACTGTAGCTCA 1.2570 0.0708
miR-193b AACTGGCCCTCAAAGTCCCGCT 1.2689 0.4617
miR-19a+b TGTGCAAATCTATGCAAAACTGA 1.2863 0.4133
miR-106a AAAAGTGCTTACAGTGCAGGTAGC 1.3021 0.5946
miR-92a TATTGCACTTGTCCCGGCCTG 1.3287 1.9810
miR-181d AACATTCATTGTTGTCGGTGGGTT 1.3471 1.6021
miR-155 TTAATGCTAATCGTGATAGGGG 1.3660 0.4730
miR-29a TAGCACCATCTGAAATCGGTTA 1.4142 0.3415
miR-93 AAAGTGCTGTTCGTGCAGGTAG 1.4271 0.8645
miR-202 AGAGGTATAGGGCATGGGAAAA 1.4641 0.7120
miR-181b AACATTCATTGCTGTCGGTGGG 1.4641 0.7919
miR-146a TGAGAACTGAATTCCATGGGTT 1.4871 0.5548
miR-372 AAAGTGCTGCGACATTTGAGCGT 1.5602 1.4241
miR-200a TAACACTGTCTGGTAACGATGT 1.7532 2.4453
miR-154 TAGGTTATCCGTGTTGCCTTCG 1.7570 0.6690
miR-132 TAACAGTCTACAGCCATGGTCG 1.8921 1.9811
miR-29b TAGCACCATTTGAAATCAGTGTT 2.1435 0.3660
Supplementary table 1 (continued) - Shah et al
Supplementary Table 1. miRNA profiling of AML cells in response lentiviral NRF2
knockdown and treatment with the NRF2 activator sulforaphane. THP-1 cells were either
transduced with NEG (NEG-KD) and NRF2 (NRF2-KD) targeted miRNA lentiviral constructs or with
sulforaphane (5µM) for 8 hours. QRTPCR analysis of 92 cancer-associated miRNAs in treated
cells were evaluated. Values represent fold increase over control conditions normalized to RNU6B
(ΔCT).
IC50 daunorubicin [μM]
THP-1 Kasumi1 CD34+ AML#25 AML#27
negative control 0.276 0.092 0.207 0.293 0.037
α125B 0.221 0.077 0.186 0.219 0.036
29B mimic 0.153 0.085 0.187 0.152 0.034
α125B + 29B mimic 0.123 0.066 0.157 0.106 0.033
Supplementary Table 2 - Shah et al
Supplementary Table 2. miR-125B antagomiR and miR-29B mimic increases
AML sensitivity to chemotherapy. THP-1, Kasumi-1, primary CD34+ HSC,
AML#25 and AML#27 were transfected with control miRNA, miR-125B
antagomiR, miR-29B mimic and miR-125B antagomiR in combination with miR-
29B mimic for 24 h before the addition of increasing doses of daunorubicin for 48
h. Cells assessed for viability by Cell Titer-GLO. Table shows the IC50 values for
all cells types in response to daunorubicin
Supplementary Table 3 - Shah et al






TGFB1 Trabecular meshwork 42
PIK3R1 Cholangiocarcinoma 28
CDK4 Mantle cell lymphoma 25
SP1 AML 24
miR-125B targets
CBFβ AML subtype-APL 39
KLF13 Haematopoietic stem cells 22






CDK6 Mantle cell lymphoma 25
BCL2 Hepatacellular carcinoma 20
MCL1 Hepatacellular carcinoma 20
BAK1 AML/Breast Cancer 21
Supplementary Figure 3. Targets for miR-29B and miR-125B
miRNA Sites position ARE sequence 5'-3' oligos for ChIP analysis
miR-125B1 ARE1 40923-40933 ATGACTCAGTG For - ATGTTTCCAAACCAGGCTGA    Rev - CTAACACTGCAGGCTCACCA
miR-125B1 ARE2 4537-4548 TGATCTCAGCA For - CAGAGCCAGCTGTCAATGAA   Rev - CCAGAATGGGAGAAATGGAG
miR-125B1 ARE3 1357-1368 GCTTTGTCATT For - GTTGAGGCCTCTCCAGTGTC   Rev - GCCACCAAAAATGAAAGGAA
miR-29B1 ARE4 16788-16799 AGCTGAGTCAC For - TCAAGGTGCAGGATCTTTCC   Rev - GTCTACCTTGGATGGCCTCA 
miR-29B1 ARE5 7647-7658 TGCTGAGTCAT For - CACATCTGGGCAACATCATC   Rev - CTCCAAGGGGGTGTCCTTAT
Supplementary Figure 4. Locations and sequences of putative ARE elements.
Primers used in ChIP analysis.
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Supplementary Figure 1. Expression analysis of miRNA levels after
transfection with miR-29B mimic and miR-125B antagomir. THP-1
were transfected with control miRNA, miR-125B antagomiR (α125B),
miR-29B mimic (29B mimic) and miR-125B antagomiR in combination
with miR-29B mimic for 48 h. Also THP-1 cells were transduced with
NEG (NEG-KD) and NRF2 (NRF2-KD) targeted miRNA lentiviral
constructs for 72 hours. QRTPCR analysis of miR-29B and miR-125B












































































































































Supplementary Figure 2. miR-29B and miR-125B in primary
AML. Total RNA was extracted from patient AML blasts (n=18) and
CD34+ HSC (n=8), miR-125B (A) and miR-29B (B) RNA expression
levels were measured using QRTPCR and compared to miR-125B1
and miR-29B respectively from figure 4 A.
Supplementary Figure 2 - Shah et al
